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Abstract 
Osteoarthritis is a common, multifactorial disease, characterised by the progressive 
loss of articular cartilage from synovial joints. It has a major genetic component that is 
polygenic in nature. The aim of my thesis was to explore functional effects of several 
osteoarthritis susceptibility loci. 
I have carried out functional studies on five genes in total, covering three osteoarthritis 
susceptibility loci, including GDF5, MICAL3 and CHST11. I used protein, gene and allelic 
expression analyses. 
 Firstly, I assessed whether human chondrocytes would respond in a predictable 
manner to GDF5. Reduced expression of GDF5 (chromosome 20q11.22) correlates with 
an increased risk for osteoarthritis and I assessed what effect providing exogenous 
GDF5 to chondrocytes had on expression of target genes. I observed that chondrocytes 
responded to exogenous GDF5 in a highly discordant manner. Secondly, I carried out 
gene and allelic expression analyses on MICAL3 (chromosome 22q11.21), to 
investigate if the association to osteoarthritis at this locus is mediated by an influence 
on gene expression.  I observed allelic expression imbalance (AEI) at this locus, 
however, this did not correlate with genotype at the associated polymorphism in the 
human joint tissues investigated. I then focused on the susceptibility locus at CHST11 
(chromosome 12q23.3). AEI was common at this gene, although a correlation with 
genotype at the associated polymorphism was not observed in the human joint tissues 
investigated. I carried out sequence analysis of CHST11 in osteoarthritic patients to 
identify rare amino acid coding variants, and found no evidence for any accounting for 
disease susceptibility. I explored the role of CHST11 in mesenchymal stem cells during 
chondrogenesis and observed that CHST11 knockdown leads to gene expression 
changes in chondrocyte marker genes and a reduction in cartilage extracellular matrix 
synthesis.  
My studies highlight the complexity in performing functional studies to identify and 
characterise the causal polymorphisms influencing osteoarthritis susceptibility.  
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Chapter 1: General introduction 
1.1 Background to osteoarthritis 
Osteoarthritis (OA) is the most common form of arthritis and is the leading cause of 
disability in adults (Guccione et al., 1994). OA is characterised by the progressive loss 
of articular cartilage, which is a smooth protective layer covering the ends of 
articulating joints. In addition to cartilage breakdown, OA is characterised by the 
abnormal formation of new bone (osteophytes), subchondral bone thickening 
(sclerosis) and synovial proliferation and inflammation (Figure 1.1). Other components 
of the joint also undergo changes in structure and function, including the ligaments, 
tendons, capsule and synovial joint lining (Wieland et al., 2005). OA can affect any joint 
in the body, however the joints that are most affected are the hands, knees, hips and 
spine. 
 
Figure 1.1: Normal knee joint compared to an osteoarthritic knee joint. 
Degeneration of cartilage, osteophyte formation, subchondral bone 
sclerosis and synovial inflammation are observed in OA. Adapted from 
Wieland et al., 2005. 
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1.1.1 Defining OA 
The commonly used standard for defining the presence of hand, hip or knee OA is the 
Kellgren and Lawrence (KL) grade. This is a radiographic grading system which scores 
the severity of OA on a scale of 0 to 4, with definite radiographic OA being defined as a 
KL grade of or greater than 2 (Kellgren and Lawrence, 1963).  The scoring system is 
based on the degree of the osteophyte formation, joint space narrowing and bone 
sclerosis. OA can be described in a joint specific manner (hand, hip or knee OA) or if 
several joints are affected, it can be described as generalised OA.  
1.1.2 Incidence and prevalence of OA 
The risk of developing symptomatic knee OA is reported to be 40% for men and 47% 
for women, with an elevated risk in obese individuals (Murphy et al., 2008). The 
incidence of hand, hip and knee OA is estimated at 100, 88 and 240 cases per 100,000 
person-years respectively (Oliveria et al., 1995).  
The prevalence of moderate to severe radiographic hand, hip and knee OA is reported 
to be 4.4 million, 210,000 and 0.5 million individuals in the UK, respectively (Arthritis 
Research Campaign, 2002; Arthritis and Musculoskeletal Alliance, 2004). 
1.1.3 Treatment of OA 
Pharmacological intervention 
There is currently no cure for OA, therefore pharmacological management of OA 
involves the control of symptoms such as pain and function of the joints. Analgesics 
such as paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs) are 
commonly used to relieve pain in hand, knee and hip OA (Jordan et al., 2003; Zhang et 
al., 2010). Furthermore, corticosteroid and hyaluronic acid administration to intra-
articular joints is widely used in the management of knee OA, which acts to reduce 
pain and inflammation at the joints (Arroll and Goodyear-Smith, 2004; Bannuru et al., 
2009). In addition, nutritional supplements including glucosamine, chondroitin 
sulphate and vitamins are less commonly used for the management of OA (Vlad et al., 
2007; Vallières and du Souich, 2010; Wandel et al., 2010). 
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Non-pharmacological intervention 
Non-pharmacological approaches are used in combination with pharmacological 
intervention in the treatment of OA. These include educating patients in disease 
management, exercise, weight reduction and diet, as well as providing patients with 
physical aids such as orthoses (braces), insoles and walking aids (Heuts et al., 2004).  
Surgical intervention 
Surgery in OA is considered at the end stage of the disease, after failure of other non-
surgical therapies. Total joint replacement or arthroplasty is currently regarded as the 
most cost-effective, successful and effective treatment of OA (Ethgen et al., 2004; 
Hawker et al., 2009). This procedure eliminates pain and disability in end stage OA and 
can restore the function of the impaired joints to near-normal. However, joint 
replacement surgery can fail due to aseptic loosening and particle-induced osteolysis 
(Colizza et al., 1995; Delaunay et al., 2010; Huber et al., 2010). This is a consequence of 
the degradation of the orthopaedic implant, resulting in bone loss. Therefore, newer 
designs utilising alternative materials and bearings such as ceramic and metal-on-
metal bearings are being introduced to reduce wear (Delaunay et al., 2010). 
Other non-arthroplasty procedures include osteomy, arthroscopic debridement and 
arthrodesis. Osteomy is used to correct alignment in anatomic abnormalities of the hip 
or knee, mostly in younger patients (Coventry, 1979). Arthroscopic debridement is 
used to remove osteophytes in hip and knee OA, and arthrodesis or fusion is most 
frequently used to rescue failed joint replacements (Insall, 1967; Callaghan et al., 1985; 
Conway et al., 2004).  
Cell-based approaches 
The development of cellular therapies to repair articular cartilage in OA is an emerging 
area of research. These approaches are aimed at younger patients, and aim to culture 
new articular chondrocytes to replace the damaged cartilage (Khan et al., 2010; 
Roberts et al., 2011). If successful, these procedures may reduce pain, disability and 
enhance function in patients and may delay the need for joint replacement.  
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Autologous chondrocyte implantation (ACI) is currently used in clinical practice, where 
chondrocytes harvested from knee articular cartilage are cultured ex vivo and then re-
implanted into damaged areas of the articular surface (Brittberg et al., 1994; Giannoni 
et al., 2005; Minas and Bryant, 2005). However, this approach is limited by the size of 
the cartilage biopsy required to obtain a sufficient number of cells (Oldershaw, 2012). 
Therefore, mesenchymal stem cells (MSCs) isolated from bone marrow or synovium 
have been considered as an alternative cell source. MSCs can be isolated from 
different tissue types including bone marrow, synovium, synovial fluid, adipose tissue, 
skeletal muscle, placenta, and umbilical cord (Oldershaw, 2012). These cells can be 
expanded ex vivo to obtain high cell numbers, which can overcome the limitations 
faced by ACI (Hardingham et al., 2006; Khan et al., 2009). Under appropriate 
conditions, MSCs can be differentiated into chondrocytes, osteoblasts and adipocytes 
in vitro (Dominici et al., 2006), and such a technique is described by (Murdoch et al., 
2007) for chondrogenic differentiation using Transwell culture (Murdoch et al., 2007). 
1.2 The normal structure and function of the synovial joint 
Synovial joints are composed of articular cartilage, subchondral bone, joint capsule, 
synovial fluid, synovium, ligaments and tendons, with knee joints containing a pair of 
menisci and a fatpad. All tissues of the joint have a highly specialised structure and 
function, and coordinate smooth pain-free movements, contributing to the ultimate 
function of the joint system.  
1.2.1 Articular cartilage 
Articular cartilage is a smooth frictionless surface with a thickness of approximately 3 
mm in humans that covers the edges of skeletal bones, and acts as a gliding surface to 
dissipate the shearing and compressive stresses applied across the articulating joints 
(Wieland et al., 2005).  
Articular cartilage has no blood or nerve supply and the only type of cell present within 
this tissue is called the chondrocyte. These cells are responsible for the synthesis, 
secretion and maintenance of the extracellular matrix (ECM), composed of fibrillar and 
non-fibrillar components. The fibrillar matrix consists of a network rich in type II 
collagen, and other minor collagens including collagen type IX, XI and XVI. The non-
fibrillar matrix components include proteoglycans such as aggrecan, decorin, biglycan 
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and fibromodulin (Goldring, 2006). The major proteoglycan, aggrecan, is made up of a 
core protein with three globular domains (G1, G2 and G3; Poole, 2005). G1 domain is 
bound non-covalently to hyaluronic acid (HA), and is stabilised by link protein. These 
then bind non-covalently to the collagenous network (Figure 1.2; Poole, 2005). Many 
glycosaminoglycan (GAG) chains consisting of keratan sulphate (KS) and chondroitin 
sulphate (CS) are present between the G2 and G3 domains of aggrecan. These GAGs 
are rich in carboxyl and sulphate groups that attract water molecules, thereby creating 
a swelling pressure, which is restricted heavily by the collagenous network (Poole, 
2005). Water is the major constituent of articular cartilage and occupies approximately 
70% of the tissue, hence water retention is very important for the function of articular 
cartilage (Allan, 1998; Knudson and Knudson, 2001). Water is expelled under 
compression to uphold mechanical loads and during unloading, the tissue is 
rehydrated and tissue elasticity is restored. Therefore, proteoglycans together with the 
collagenous network acts to withstand tensile and shear forces within the tissue and 
maintains the structural integrity of cartilage (Poole, 2005). In addition to collagens 
and proteoglycans, other structural proteins which help maintain the structure and 
function of the ECM include matrilin-3, cartilage oligomeric matrix protein (COMP) and 
fibronectin (Reginato and Olsen, 2002). 
The articular cartilage is divided into four zones characterised by the shape of the 
chondrocytes and the arrangement of the matrix fibrils (Figure 1.3; Aigner et al., 
2006a). The superficial zone chondrocytes are small and round in appearance and the 
collagen fibrils are very thin and are arranged in parallel to the surface. Furthermore, 
the collagen content is greatest in this zone, due to the greater shear forces of 
articulation exerted on the surface. The middle zone chondrocytes are larger in size 
and the collagen fibrils are thicker and are arranged in random (Aigner and McKenna, 
2002). The deep zone chondrocytes are arranged in perpendicular columns and the 
collagen content is the lowest in this zone (Salter, 1998). However, the aggrecan 
content is at the highest in this zone and is the lowest in the superficial zone (Poole, 
2005). The collagen fibrils in the deep zone are arranged vertically, and extend through 
the tidemark, which is the boundary between articular cartilage and the calcified 
cartilage, into the calcified zone.  The collagen fibrils in the calcified zone are arranged 
perpendicularly to the subchondral bone, and penetrate into it, anchoring the calcified 
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zone to the underlying bone, thereby forming a strong bond which can help resist 
shear forces of articulation (Aigner and McKenna, 2002; Salter, 1998). The ECM in the 
calcified zone is partly calcified and contains type X collagen, a marker of hypertrophy.  
 
Figure 1.2: Components of the cartilage extracellular matrix 
Aggrecan molecules (shown in blue) are bound to hyaluronan (HA), which then interact with 
type II collagen fibrils to form the cartilage extracellular matrix, to maintain its structural 
integrity. Keratan sulphate (KS) and chondroitin sulphate (CS) are present on aggrecan 
molecules in between the G2 and G3 globular domains. Adapted from Poole (2005). 
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Figure 1.3: Four different zones of normal adult articular cartilage 
The chondrocytes within each zone are illustrated in blue. The boxes shaded in grey show 
the arrangement of the type II collagen fibrils in the superficial, middle and deep zones. 
Adapted from Poole (2005). 
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1.2.2 Subchondral bone 
The subchondral bone lies beneath the calcified cartilage, thereby providing support to 
the cartilage, and consists of the subchondral plate and the cancellous bone, which lies 
beneath the plate. The cancellous bone contains trabeculae, which are arranged in 
different directions to distribute the stresses and help with shock absorption (Burr, 
2004). The bone is comprised of a collagenous matrix rich in type I collagen fibrils and 
mineral crystals made of calcium hydroxyapatite (Wehrli, 2007). The bone contains 
two types of cells, which are important in bone turnover and remodelling. Osteoclasts 
are involved in the resorption of old bone and osteoblasts are responsible for the 
deposition of new bone (Wehrli, 2007). The subchondral bone is also highly vascular 
and neural, and blood vessels and nerve fibres are contained in structures called 
Haversian canals that run parallel to the cartilage surface. 
1.2.3 The joint capsule, synovium and synovial fluid 
The joint capsule is a fibrous tissue that is attached to the distal end of the bone, and 
contains blood vessels, lymphatic vessels and nerve fibres. It also contributes to the 
movement of the joint and provides mechanical stability. The inside of the capsule is 
lined by the synovium, which is approximately three cells deep (Aigner and McKenna, 
2002). The synovium consists of two cell types. Type A synovial cells line the joint 
cavity and are involved in endocytosis of bacteria and viruses, thereby maintaining an 
aseptic environment within the joint-space. Type B synovial cells are fibroblast-like 
cells that synthesise and secrete two key components of synovial fluid: lubricin, a 
lubricant important for the articulation of the joints, and hyaluronic acid, which is 
important in maintaining the viscosity of the synovial fluid (Allan, 1998).  The synovial 
fluid provides low friction between articulating surfaces by coating the joint surfaces. It 
also provides nutrition to the joint by acting as a medium through which nutrients and 
oxygen can diffuse from the synovium to the cartilage (Aigner et al., 2006a).  
1.2.4 Meniscus 
The meniscus is a fibrocartilaginous tissue composed mainly of type I collagen fibrils. 
The pair of menisci in the knee joint is attached to the joint capsule and act as shock 
absorbers and distribute the intra-articular load within the joint to help with stability 
(Makris et al., 2011).  
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1.2.5 Tendons and ligaments 
Tendons and ligaments play an important role in the movement and stability of the 
joint. Tendons attach muscle to bone and ligaments attach bone to bone and are 
predominantly composed of type I collagen fibrils, which help resist tensile stress (Woo 
SL-Y et al., 1992).  
1.2.6 Fatpad 
The infrapatellar fatpad of the knee is a fibrous tissue composed of adipocytes. It 
protects exposed articular surfaces by adapting to the changing contours of 
articulating surfaces during joint movement and also assists in the distribution of 
synovial fluid within the joint (Resnick, 1995; Vahlensieck et al., 2002). 
1.3 Synovial joint and articular cartilage formation 
Joint development starts with the formation of mesenchymal condensations, mediated 
by cell adhesion molecules including Cadherins and N-CAM, and the appearance of an 
interzone, which determines the future site of joint formation (Pacifici et al., 2005). 
The interzone contains closely packed fibroblast-like cells that show a more flattened 
shape. In humans, these cells form a layer that is two to three cells in thickness (Figure 
1.4; Archer et al., 2003). GDF5, which encodes growth and differentiation factor-5 is 
expressed in these cells and is believed to promote joint function and mediate the 
differentiation of interzone cells into chondrocytes (Francis-West et al., 1999a; Merino 
et al., 1999a; Storm and Kingsley, 1999). Also, noggin and chordin, which are GDF5 
antagonists, are also expressed in the interzone cells in order to regulate the pace and 
degree of chondrocyte differentiation during joint development (Brunet et al., 1998; 
Francis-West et al., 1999b). Wnt-14 is another molecule important for the formation of 
joints, and is believed to act upstream of GDF5, playing a role in maintaining the 
mesenchymal character of interzone cells by preventing chondrogenesis (Hartman and 
Tabin, 2000; Archer et al., 2003). 
Once the joint site is specified by the formation of the interzone, the opposing sides of 
the synovial joint physically separate to form a synovial cavity (Figure 1.4).  Several 
mechanisms have been proposed to explain this phenomenon including apoptosis, 
mechanical factors, interzone degradation by enzymatic activities, and the differential 
growth and matrix synthesis of the opposing sides of the cavity (Archer et al., 2003).  It 
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is now believed that hyaluronan (HA) synthesis and accumulation mediated by 
embryonic limb movement lead to the loss of tissue integrity in the interzone, thus 
initiating the formation of a fluid-filled cavity (Dowthwaite et al., 1998). 
Subsequently, as the synovial space cavitation progresses, the opposite sides of the 
joints begin the process of morphogenesis leading to the maturation of the joint, 
forming articular cartilage and the synovial cavity enveloped by the joint capsule.  
The cells of the outer layers of the interzone differentiate into chondrocytes, forming 
the articular cartilage. The transcription factor ERG plays a vital role in this process by 
imposing a stable and immature chondrocyte phenotype, preventing endochondral 
ossification and in the induction of differentiation of immature chondrocytes to 
permanent articular chondrocytes (Iwamoto et al., 2000). Immature chondrocytes 
express collagen types I, III and V, which are replaced by collagen types II, IX and XI and 
aggrecan as the cells differentiate into articular chondrocytes (Archer et al., 2003). 
Endochondral ossification starts during joint formation in the embryo and continues 
after birth in cartilaginous growth plates in long bones, which is required for bone 
growth (Kronenberg, 2003). Hypertrophic chondrocytes which undergo endochondral 
ossification do not express type II collagen and express high levels of type X collagen, 
MMP13, VEGF and RUNX2. The hypertrophic zone undergoes matrix remodelling, 
chondrocyte apoptosis and vascular invasion, thus replacing nonvascular cartilage 
tissue with highly vascularised bone (Kronenberg, 2003).     
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Figure 1.4: Major steps involved in synovial joint formation 
The joint site is determined in the mesenchyme condensations, forming an interzone. 
Subsequently, joint cavitation occurs to physically dissociate the opposite sides of the 
synovial joint. The cells adjacent to the interzone start to differentiate into chondrocytes. 
Joint morphogenesis occurs and leads to joint maturation with the formation of articular 
cartilage, synovial cavity and the joint capsule. Adapted from Pacifici et al., 2005.  
1.4 Pathology of OA 
The imbalance between the mechanical stresses applied within a joint, mainly at load 
bearing sites, and the functional ability of the cartilage to manage these stresses can 
account for the development of OA. The cellular response to damage can bring about 
degenerative and reparative structural changes in the joint tissues, which can lead to 
joint failure.   It is still unclear which tissue of the joint harbours the most damage in 
OA as all tissues of the joint, including cartilage, subchondral bone, menisci, synovium 
and ligaments show pathological changes in the early stages of OA (Lohmander, 2000).  
Also, the sequence of degradative events that undergo during OA is unknown, for 
example, both the cartilage and the subchondral bone can show damage 
concomitantly, or follow or precede damage in one tissue (Dieppe and Lohmander, 
2005). 
1.4.1 Articular cartilage 
The loss of the protective function of articular cartilage results in terminal joint failure, 
therefore a range of abnormal changes in cartilage is observed in OA.  
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The loss of articular cartilage is a result of the depletion and destruction of the ECM. In 
early stages of OA, the type II collagen network is disrupted either by direct physical 
stresses or by the action of collagenases, mainly matrix metalloproteinase-13 (MMP13; 
(Wu et al., 2002). This is accompanied by proteoglycan loss, initially in the superficial 
zone, and then in deeper zones as the disease progresses, due to the increased 
expression and activity of ADAMTS (a disintegrin and metalloproteinase with a 
thrombospondin motif) aggrecanases (Song et al., 2007). As a result, the cartilage 
swells due to increased water content and a reduction in the tensile strength and 
stiffness of the ECM ensues.   
OA cartilage shows fibrillations, fissures and erosions, and therefore appears 
discoloured and rough, with a fragmented surface (Aigner et al., 2006a). Fibrillations 
are surface discontinuities that result from the loss of type II collagen fibrils and 
proteoglycans from the cartilage surface. As the fibrillations extend from the 
superficial zone to deeper zones, they appear as vertical cracks or fissures. With time, 
as more and more cartilage tissue is lost, erosions appear and eventually the 
subchondral bone is exposed (Lorenz and Richter, 2006). Furthermore, vascular 
invasion from the subchondral bone contributes to further cartilage thinning. This 
occurs as capillaries penetrate the calcified zone, resulting in the duplication or 
multiplication of the tidemark, thereby blurring the boundary between calcified and 
uncalcified cartilage (Lane and Bullough, 1980; Revell et al., 1990). 
As the ECM is depleted, the chondrocytes are exposed to abnormal extracellular 
stimuli such as increased amounts of growth factors and cytokines (Aigner et al., 
2007). In response, chondrocytes undergo cell proliferation or cell death, mainly 
through apoptosis. Increase in cell proliferation can be an attempt to repair damaged 
cartilage, and can be observed microscopically by the increased amounts of small 
chondrocyte aggregates. These are seen initially in the superficial zone at early stages 
of OA, and then in deeper zones as OA progresses (Goldring and Goldring, 2010). Thin 
superficial pannus-like tissue can be observed in some OA cartilage, as an attempt to 
replace the damaged cartilage with a fibrocartilage, containing an abnormal 
arrangement of collagen fibrils. Loss of chondrocytes due to apoptosis, which can be 
seen under the microscope as areas of empty chondrocyte lacunae, further 
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contributes to the loss of ECM, cartilage structure and regulation of tissue homeostasis 
(Blanco et al., 1998; Kühn et al., 2004). 
1.4.2 Subchondral bone 
Changes seen in subchondral bone in OA include sclerosis, osteophyte formation, cyst 
formation and osteonecrosis. 
Subchondral bone sclerosis is the thickening of the subchondral plate and the 
cancellous bone, resulting from an imbalance between bone synthesis and resorption 
(Lajeunesse and Reboul, 2003; Buckland-Wright, 2004).   In late stage OA, increased 
bone thickening is seen in areas where there is a significant reduction in the protective 
layer of cartilage, suggesting that a change in mechanical forces may result in bone 
remodelling (Goldring and Goldring, 2010). However, it is also reported that bone 
remodelling occurs in early stages of OA, perhaps contributing to cartilage loss as a 
result of the alteration of biomechanical properties of the remodelled bone (Hutton et 
al., 1986; Buckland-Wright et al., 1991). An increase in the number of trabeculae in the 
cancellous bone and a decrease in the separation between trabeculae are also seen in 
OA (Buckland-Wright, 2004). Although this increases the mineral content and volume 
of cancellous bone, this also renders the bone mechanically weak due to the irregular 
arrangement of trabeculae. 
Osteophytes are newly synthesised bony projections seen at joint margins. These are 
believed to be formed from periosteal or perichondrial stem cells, which are 
differentiated into chondrocytes, thus, mature osteophytes are capped with hyaline 
and fibrocartilage tissue (van der Kraan and van den Berg, 2007; Goldring and 
Goldring, 2010). Some evidence suggests that osteophyte formation is a consequence 
of a reparative response to protect cartilage, however, others have reported that 
osteophyte formation leads to cartilage loss (Wieland et al., 2005; Goldring and 
Goldring, 2010).  
Subchondral bone cysts are seen mainly in regions with severe cartilage loss, which 
appear as fluid filled sacs protruding from the joint. These are perhaps formed as a 
consequence of synovial fluid flowing into the subchondral bone under high pressure 
(Landells, 1953; Freund, 1940).  
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Osteonecrosis is seen at articular surfaces in severe OA, where the subchondral bone is 
exposed. Loss of articular cartilage results in an increased load and pressure being 
applied on the subchondral bone, leading to subchondral plate fracture. This can cause 
vascular occlusion, thereby obstructing blood flow to the subchondral bone which is 
then weakened and can collapse under normal mechanical stresses (Kiaer et al., 1990).  
1.4.3 Synovium 
Although OA is not regarded as an inflammatory condition, synovial inflammation 
(synovitis) is commonly seen in OA patients (Wieland et al., 2005; Aigner et al., 2006a). 
When the ECM is degraded in OA, the breakdown products including chondroitin 
sulphate peptides, proteoglycan fragments and type II collagen peptides are infiltrated 
into the synovial fluid (Aigner et al., 2006a). This can result in synovial hyperplasia, 
where the normal flat synovium changes into a more villous structure. The abnormal 
synovium is seen close to areas with severe cartilage loss, and is thought to secrete 
catabolic molecules such as MMPs, resulting in more ECM breakdown (Wieland et al., 
2005; Aigner et al., 2006a). 
1.4.4 Joint capsule, meniscus and ligaments 
Abnormalities in other tissues of the joint in OA are less well characterised compared 
to articular cartilage, subchondral bone and synovium, but nonetheless exhibit 
extensive changes.  
The joint capsule undergoes thickening and fibrosis in OA, leading to a shortened 
capsule. This can result in more mechanical forces being applied on the articular 
cartilage, which can disrupt the ECM (Aigner et al., 2006a). 
In OA, meniscal tears, fibrillations and fissures are frequently observed (Noble and 
Hamblen, 1975; Englund et al., 2009). In addition, calcification within the meniscus is 
also seen in late stage OA (Noble and Hamblen, 1975; Sun et al., 2010).  
It has been reported that ligaments show thickening and fissuring in OA at the site 
where they attach to bone. 
1.5 Effect on joint homeostasis during the pathogenesis of OA 
Joint homeostasis is crucial in maintaining the structure and function of the joint and 
involves maintaining a careful balance between anabolic and catabolic activities. The 
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damage caused by continuous mechanical stress and catabolic enzymatic action in 
cartilage is counteracted by the anabolic activities of articular chondrocytes. In healthy 
cartilage, the anabolic and catabolic processes are maintained in equilibrium by 
chondrocytes. In OA, joint homeostasis is disturbed and this balance is tipped towards 
catabolism, leading to cartilage degradation (Aigner et al., 2006b). The balance 
between anabolism and catabolism is tightly regulated by a network of anabolic and 
catabolic factors including cytokines, growth factors, enzymes, transcription factors 
and other mediators whose expression levels are affected during the progression of 
OA. 
1.5.1 Cytokines 
Inflammatory cytokines play a catabolic role during the progression of OA and these 
include interleukins (IL) and tumour necrosis factor–α (TNF-α). IL-1β levels are 
increased during OA and is found in synovial fluid in OA joints (Schlaak et al., 1996). 
TNF-α acts in synergy with IL-1β and this leads to an increase in MMP13 levels, which 
promote the breakdown of the ECM (Saklatvala, 1986; Lefebvre et al., 1990). 
Chondrocytes synthesise more prostaglandin E and bone morphogenetic protein-2 
(BMP2) in response to an increase in catabolic cytokines, which increase type II 
collagen expression, as an attempt to compensate for the loss of ECM (Goldring et al., 
1996; Fukui et al., 2003). 
1.5.2 Growth factors 
Transforming Growth Factor-β (TGF-β) is a potent regulator of chondrocyte 
proliferation and differentiation. The effects of TGF-β are mediated through TGF-β 
type I receptor and TGF-β type II receptor, which upon ligand binding, phosphorylate 
and activate Smad 2 and Smad 3 (Wrana et al., 1994; Heldin et al., 1997). These form a 
complex with Smad 4, which then translocates into the nucleus to regulate gene 
expression of COL2A1 and ACAN (Edwards et al., 1987; Izumi et al., 1992). Therefore, 
TGF-β can counteract the effects induced by IL-1β in OA. The expression of both TGF-β 
receptors and Smad 2 are down regulated in OA, resulting in a reduction in response to 
this growth factor, leading to a reduction in anabolism in OA chondrocytes (Blaney 
Davidson et al., 2005).  
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Bone morphogenetic proteins (BMPs) are members of the TGF-β superfamily and have 
roles in cell proliferation, differentiation, apoptosis and tissue homeostasis (Hogan, 
1996). The most well characterised BMPs in articular cartilage are BMP2, BMP4, BMP7 
and GDF5 (also known as BMP14). In OA, both BMP2 and GDF5 are upregulated, 
perhaps as an attempt to repair damaged cartilage (Karlsson et al., 2010; Xu et al., 
2012). Exogenous BMP2, BMP7 and GDF5 have been shown to have anabolic effects in 
chondrocytes including increased proteoglycan synthesis, measured by sulphate 
incorporation assays (Chubinskaya et al., 2008).  
Insulin-like growth factor-1 (IGF1) is another growth factor essential for normal 
cartilage homeostasis, and has roles in promoting ECM synthesis and inhibiting matrix 
degradation (Luyten et al., 1988; Trippel et al., 1989). Both IGF1 and its receptor are 
elevated in OA chondrocytes (Middleton et al., 1996). However, the levels of IGF 
binding protein-3 is also elevated in OA, which interferes with IGF1 ligand receptor 
interaction, thereby reducing the ability of chondrocytes to respond to IGF1, despite 
its high expression in OA (Chevalier and Tyler, 1996; Eviatar et al., 2003).  
Fibroblast growth factor-2 (FGF2) is elevated in OA and was initially thought to have 
anabolic roles in cartilage, due to its effects on increased cell proliferation (Orito et al., 
2003; Hiraide et al., 2005; Chen et al., 2006). However, more recent evidence suggests 
that FGF2 is responsible for the increase of the ratio of type I collagen to type II 
collagen, producing more fibrous cartilage tissue (Muddasani et al., 2007; Im et al., 
2008). It is also reported that FGF2 can counteract the effects mediated by IGF1 and 
BMP7 and can also induce MMP13 expression (Loeser et al., 2005; Muddasani et al., 
2007; Im et al., 2008).  FGF18 in contrast has anabolic roles in chondrocytes and 
promotes ECM biosynthesis (Ellsworth et al., 2002; Moore et al., 2005). FGF18 also 
inhibits noggin, a BMP antagonist, hence facilitating anabolism in chondrocytes, 
whereas FGF2 induces its expression (Reinhold et al., 2004; Li et al., 2008). 
1.5.3 Enzymes 
MMP1 and MMP13, whose products are responsible for the breakdown of type II 
collagen in the cartilage ECM, are upregulated in OA (Karlsson et al., 2010). This is a 
consequence of the activation of NF-κB and AP1 pathways by the catabolic cytokines 
including IL-1β and TNF-α, which are produced at high levels in OA chondrocytes 
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(Brenner et al., 1989; Conca et al., 1989). MMP1 and MMP13 cleave the triple helical 
structure of type II collagen fibrils, making them susceptible for further degradation by 
MMP9 (Hashimoto et al., 2008). 
ADAMTS4 and ADAMTS5 are the major aggrecanases responsible for aggrecan 
breakdown in OA. ADAMTS4 has been shown to be regulated by IL-1 and TNF-α, whose 
upregulation in OA can in turn upregulate ADAMTS4 (Bondeson et al., 2006; Ahmad et 
al., 2009). Also, ADAMTS5 gene expression is upregulated in OA, thus leading to 
increased ECM breakdown in OA (Karlsson et al., 2010). 
1.5.4 Transcription factors 
Sex determining region-Y box-9 (SOX9) is a transcription factor crucial for 
mesenchymal chondrogenesis in embryonic development and regulates gene 
expression of COL2A1, which encodes the α-1 chain of type II collagen and ACAN, 
which encodes aggrecan (Sekiya et al., 2000; Stokes et al., 2001). It has been reported 
that IL-1β and TNF-α, which are upregulated in OA activate NF-κB signalling. This leads 
to the inhibition of SOX9 binding to the COL2A1 enhancer, to exert their catabolic 
effects in OA (Murakami et al., 2000; Sitcheran et al., 2003). NF-κB signalling is also 
involved in the induction of MMP1, MMP9 and MMP13 expression, which contribute 
to the breakdown of type II collagen (Yan et al., 2001; Vincenti and Brinckerhoff, 2002). 
AP1 is another transcription factor involved in cartilage homeostasis and most MMPs 
contain AP-1 binding sites in their promoters. AP1 is activated by TGF-β, FGF2 and TNF-
α, which are upregulated in OA, thereby further increasing levels of collagenases in OA 
cartilage (Yan and Boyd, 2007). 
1.5.5 Other mediators 
Nitric oxide (NO) is produced by OA chondrocytes and is an inflammatory catabolic 
mediator (Abramson, 2008). Mechanical factors and increased levels of IL-1β and TNF-
α in OA chondrocytes lead to the overproduction of inducible nitric oxide synthase 
(iNOS) (Goldring and Berenbaum, 2004). This results in high levels of NO, which has 
shown to mediate a range of catabolic effects in chondrocytes including MMP 
activation, reduction in matrix biosynthesis, chondrocyte apoptosis and activation of 
the NF-κB pathway, further leading to cartilage degradation (Taskiran et al., 1994; 
Häuselmann et al., 1998; Sasaki et al., 1998).  
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IL-1β and TNF-α also induce prostaglandin E synthase and cyclo-oxygenase-2 (COX2), 
which are responsible for the production of prostaglandin E2, an important mediator 
of inflammation and pain in OA (Thorén and Jakobsson, 2000).  
1.6 Risk factors of OA 
Several risk factors affect the development and progression of OA including advancing 
age, sex, obesity and genetic predisposition. Over time, these factors can initiate and 
promote abnormal biochemical alterations in joints, which may contribute to the 
characteristic features associated with OA, resulting in pain, disability and poor quality 
of life. 
1.6.1 Age 
Age is the major risk factor for OA and estimates show that 60-90% of adults over the 
age of 65 and over 30% of adults aged between 45 and 64 years are affected with OA, 
whilst it is rare before the age of 40 (WHO Scientific Group, 2003). Several factors 
associated with age can induce mechanical stress on the joint cartilage, such as altered 
gait, changes in proprioception, muscle weakness and changes in body mass. Also, 
chondrocytes in the articular cartilage, which are responsible for the production and 
maintenance of the cartilaginous matrix, show an age-related reduction in response to 
anabolic growth factors and synthesise less extracellular matrix components such as 
proteoglycans (Martin and Buckwalter, 2002). This suggests that the ability of 
chondrocytes to maintain and repair the tissue is decreased with age, leading to age-
related changes in morphology of the articular cartilage. Furthermore, aged cartilage 
shows increased expression of pro-apoptotic genes, including Fas, FasL, BCL2 and 
CASP8, which may promote apoptosis of chondrocytes (Kim et al., 2000; Allen et al., 
2004). This will lower cartilage matrix protein synthesis, such that the chondrocytes 
lose the ability to repair damaged tissue and this further increases tissue degradation, 
resulting in the loss of articular cartilage and hence leading to OA.  
1.6.2 Sex 
Sex is another risk factor correlated with OA, which is supported by the significant 
increase in the risk for OA prevalence in the knee and hand in females compared to 
males in a meta-analysis performed by Srikanth et al. (2005). The authors also 
reported a significantly higher incidence of knee and hip OA in females compared to 
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males, whilst post-menopausal females present with more severe knee OA.  Although 
the cause for this is poorly understood, evidence suggests that this may be an effect of 
menopause, hence oestrogen deficiency in earlier life may play a role (Wluka et al., 
2000). It is reported that articular chondrocytes express oestrogen receptors, which 
once activated can promote proteoglycan synthesis, supporting the theory that 
oestrogen deficiency post-menopause can lead to OA in women (Richmond et al., 
2000). However, there is as yet no strong evidence for this correlation, as data from 
clinical trials regarding effects of oestrogen replacement therapy in OA have been 
conflicting (Nevitt et al., 2001; Hanna et al., 2004). A review of various studies that 
compared magnetic resonance imaging (MRI) features of OA with sex shows that 
women have thinner and more reduced volume of knee cartilage compared to men, 
possibly from early childhood (Maleki-Fischbach and Jordan, 2010), which can account 
for the higher prevalence of OA in women. However, it is unclear if the rate of cartilage 
degradation is higher in women than that in men.  
1.6.3 Obesity 
Obesity is identified as a risk factor for knee OA, as an increase in mechanical forces 
experienced by this joint type can accelerate the degenerative process (Anderson and 
Felson, 1988). A positive correlation has been made between high body mass index 
(BMI) and elevated risk for knee OA (Marks and Allegrante, 2002). Furthermore, a 
meta-analysis showed that individuals who were obese (BMI above 30) had a 2.96 fold 
higher risk of developing knee OA and those who were overweight (BMI of 25-30) 
showed a 2.18 fold higher risk of developing knee OA compared to those with a normal 
BMI (BMI less than 25; Blagojevic et al., 2010). In addition, most obese patients show 
varus knee deformities, where the distal part of the leg below the knee is deviated 
inwards, resulting in an increased strain on the knee, contributing to the rapid 
degeneration of the joint (Leach et al., 1973).  Although this can contribute to OA, it 
has been shown that an increase in BMI increases risk for knee OA regardless of knee 
alignment, hence other mechanisms may be involved (Niu et al., 2009). Obesity is also 
associated with hand OA, further supporting the notion that obesity mediates risk for 
OA, but not only through mechanical effects (Sayer et al., 2003; Haara et al., 2004). It is 
hypothesised that obesity may confer an increased risk for OA through metabolic or 
inflammatory mediators that act on joint tissues (Manek et al., 2003; Garstang and 
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Stitik, 2006). As opposed to knee OA, hip OA is not strongly correlated with obesity, 
although it has been reported that high BMI increases risk for hip replacement due to 
OA in women (Karlson et al., 2003; Sharma et al., 2006).  
1.6.4 Genetics 
A genetic predisposition is another important risk factor for OA, evidence for which 
comes from numerous epidemiological studies. Early family studies by Stecher (1941) 
showed that the risk of developing hand OA was two to three times elevated in 
mothers and sisters of patients. A link between genetics and OA was also shown in a 
study by Kellgren et al. (1963) where the occurrence of generalised nodal OA was 
found to be twice as frequent in first degree relatives (parents, siblings and offspring) 
compared to controls. However, family studies provided limited information as 
gathering family history from patients was unreliable, and there were difficulties in 
matching individuals with respect to age, especially since OA is strongly age-related. 
Also, shared family environment may also contribute to risk for OA, which was difficult 
to control, thus making it hard to make comparisons between studies (Spector and 
MacGregor, 2004).  
Twin studies are a more robust method to separate the effects of genetic factors and 
the shared environmental factors as they naturally control for age. Twin studies 
compare the concordance rates of the trait of interest between monozygotic (MZ) 
twins, who share 100% of their genes at birth, with dizygotic (DZ) twins, who share on 
average 50% of their genes. A lower concordance in DZ twins implies the existence of 
genetic effects on the trait, whilst an incomplete concordance in MZ twins implies the 
existence of non-genetic, environmental effects on the trait. Heritability, which is the 
proportion of the causation of the trait that has a genetic basis, can then be 
determined. The heritability of radiographic OA of the hand and knee in women was 
estimated to be in the order of 39% to 65%, independent of known environment or 
demographic confounding factors, in a twin study performed using 130 MZ and 120 DZ 
female twins aged between 48 to 69 years (Spector et al., 1996).  Another twin study 
performed by the same group estimated the heritability for hip OA in women to be 
60% (MacGregor et al., 2000).  
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Genetic susceptibility in OA is thought to be transmitted in a complex, non-Mendelian 
manner, as OA is a multifactorial and heterogeneous disease and genetic differences 
can be seen between sexes, joint sites and disease characteristics (Spector and 
MacGregor, 2004; Loughlin, 2001; Peach et al., 2005). Therefore, genetics can account 
for approximately 50% of the variation seen in disease susceptibility at a population 
level (Spector and MacGregor, 2004).  
1.7 Studies to identify alleles implicated in OA 
As OA has been shown to be heritable, it is of interest to identify the genes that are 
responsible for disease susceptibility. Multiple studies have been carried out to 
determine susceptibility loci associated with OA through candidate gene studies, 
genome-wide linkage studies and genome-wide association scans. 
1.7.1 Candidate gene studies 
Candidate gene studies were initially an attractive method to identify OA susceptibility 
genes, by taking a hypothesis-driven approach. These studies examined a panel of 
genes that have shown association in a related disease or which encode a protein that 
plays a vital role in the pathogenesis of a particular disease (Newman and Wallis, 
2002). In early OA candidate gene studies, genes that harbour mutations in rare 
inherited monogenic diseases in which individuals often present symptoms of early 
onset, severe secondary OA were selected (Loughlin, 2001; Reginato and Olsen, 2002). 
Examples include chondrodysplasias, often caused by mutations in genes encoding 
ECM components of cartilage including COL2A1, which encodes the α1 chain of type II 
collagen, COL9A1, encoding the α1 chain of type IX collagen, COL11A2, encoding the 
α2 chain of type XI collagen), COMP, encoding cartilage oligomeric matrix protein, and 
ACAN, which encodes aggrecan (Olsen, 1995; Reginato and Olsen, 2002; Peach et al., 
2005). However, these studies were limited by small sample size and yielded negative 
or inconclusive data. This may indicate that these genes have not undergone 
mutational events to predispose individuals to primary OA or even if mutated, the 
effect of these polymorphisms can only influence a small proportion of OA heritability 
(Jakkula et al., 2005). A weakness in this approach is that these studies depend on 
prior knowledge of the target, so only a few genes have been analysed, thus many 
important genes may have been over-looked.  
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Other candidate gene studies have looked at genes whose products are involved in 
pathologic changes in OA bone, such as sclerosis and higher mineral density (Loughlin, 
2003; Peach et al., 2005). VDR, which encodes the vitamin D receptor, and ESR1, which 
encodes the oestrogen receptor-α, have been assessed as they are shown to be 
involved in the regulation of bone mass and bone density (Loughlin, 2001; Bandrés et 
al., 2005). Studies have shown an association between mutations in VDR and knee 
(Keen et al., 1997; Uitterlinden et al., 1997; Uitterlinden et al., 2000), spine (Jones et 
al., 1998; Videman et al., 1998) and hand OA (Solovieva et al., 2006), although this was 
not replicated in other studies where hip, knee and hand OA were assessed (Aerssens 
et al., 1998; Huang et al., 2000; Loughlin et al., 2000). Similar discordant results were 
observed with ESR1, where association to knee OA was reported (Bergink et al., 2003; 
Jin et al., 2004), however this was not replicated in other knee or hip OA studies 
(Loughlin et al., 2000; Fytili et al., 2005).  These discrepancies can arise from utilising a 
small sample size, which can produce false positive or false negative signals, as well as 
variations in study cohorts such as sex, ethnicity, age and joint site analysed (Loughlin, 
2001; Solovieva et al., 2006).  
Two compelling OA associations have been identified by a Japanese group through 
candidate gene studies in ASPN, which encodes asporin (Kizawa et al., 2005), and in 
GDF5 (Miyamoto et al., 2007). The protein products of these two genes are involved in 
signal transduction during cartilage development (Loughlin, 2005b). ASPN was selected 
as a candidate based on the role of its protein product, which is a member of the 
family of small leucine-rich proteoglycans (SLRPs), in binding to TGF-β (Kizawa et al., 
2005). A variable tandem repeat sequence in ASPN showed association to hip and knee 
OA. A subsequent study by this group identified an association of the single nucleotide 
polymorphism (SNP) rs143383 in GDF5 with hip and knee OA in Japanese and Chinese 
populations (Miyamoto et al., 2007). The same SNP was then shown to be associated 
with knee OA in European populations (Chapman et al., 2008). This was the first clear 
example of an OA susceptibility gene affecting different ethnic groups.  
1.7.2 Genome-wide linkage studies 
As candidate gene studies rely on prior knowledge of the disease process, they are 
prone to ignoring novel disease pathways (Peach et al., 2005). Genome-wide linkage 
scans examine affected families for the co-segregation of various markers and defined 
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OA phenotypes. However, these studies have limitations. For example, due to the late 
onset of OA, it can be difficult to study the parents of the affected individuals. To 
overcome this, studies utilise affected sibling pairs instead (ASPs; Loughlin, 2002).  
Several OA linkage scans on patients affected by hip, knee or hand OA have been 
performed in small families of affected relatives collected in the UK, Finland, Iceland 
and the USA (Loughlin, 2003). These studies have mapped susceptibility loci to 
chromosomes 2, 4, 6, 7, 11, 16, 19 and the X chromosome (Moskowitz et al., 2007). 
Although no susceptibility genes have been identified by linkage alone, candidate gene 
studies within regions that showed linkage have yielded moderately supportive 
evidence for several OA associated genes. Examples of these include IL1RN 
(interleukin-1 receptor antagonist; Meulenbelt et al., 2004), MATN3 (matrilin 3; 
Stefánsson et al., 2003), FRZB (frizzled-related protein 3; Loughlin et al., 2004) and 
BMP5 (bone morphogenetic protein 5; Southam et al., 2004).   
1.7.3 Genome-wide association scans 
Linkage scans have yielded susceptibility regions which can contain a large number of 
genes, making it cumbersome to find causal loci (Loughlin, 2005a). Genome-wide 
association scans (GWASs) have emerged as an attractive method to identify disease 
susceptibility loci. This has become possible owing to the completion of the human 
genome project and the cost-effective high throughput genotyping arrays (Barrett and 
Cardon, 2006; Pe'er et al., 2006). Also, genomic databases such as HapMap can be 
utilised to select a number of tag SNPs which is estimated to be 300,000 to 600,000 to 
cover the entire genome, instead of studying 10 million common SNPs (International 
HapMap Project, 2013). GWASs are typically performed on large (over 2000 
individuals) cohorts of cases and controls who are unrelated to each other and drawn 
from the same population (Barrett and Cardon, 2006; Chanock et al., 2007). They 
provide quite narrow, refined genomic intervals to be examined further, compared to 
linkage scans, hence are higher in resolution. A particular allele, if associated with 
disease, will be observed more frequently than expected in affected individuals (cases) 
than in controls. 
Although GWASs are able to identify susceptibility loci, they can generate false 
positives due to multiple testing and population stratification. Therefore, high 
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resolution studies with broad coverage of the genome, a large sample size and several 
replication studies are needed to be performed to eliminate false positives and to 
increase reliability (Reynard and Loughlin, 2013). There have been three GWASs 
reported in OA that combined these requirements. They are the Rotterdam study, 
Tokyo study and arcOGEN (arthritis research campaign osteoarthritis genetics) study.  
The Rotterdam study identified a locus on chromosome 7q22 that harbours six genes 
(PRKAR2B, HBP1, COG5, GPR22, DUS4L, BCAP29), which showed association to knee 
OA in Dutch Caucasians (Kerkhof et al., 2010). None of these genes had been 
previously implicated in OA, therefore were not obvious OA candidates. The Tokyo 
study identified a locus that maps to the HLA locus on chromosome 6p, in knee OA in 
Japanese populations (Nakajima et al., 2010). 
The arcOGEN study was conducted in two stages using cases and controls from the UK 
and tested 550,000 polymorphisms (Reynard and Loughlin, 2013). All cases of OA 
showed radiographic evidence and over 80% had undergone joint replacement 
surgery, and had therefore reached a severe clinical end point of OA. The first stage of 
arcOGEN studied 3177 cases and 4894 controls and identified three association signals, 
although none reached genome-wide significance of P≤5.0x10-8 (Panoutsopoulou et al., 
2011). These signals mapped to MICAL3 in hip and/or knee OA, to C6orf130 in knee OA 
and to COL11A1 in hip OA. The second stage of the arcOGEN study employed 7410 
cases and 11, 009 controls, and identified eight compelling signals, of which five 
surpassed genome-wide significance (Table 1.1, Zeggini et al., 2012). Of interest, 
RUNX2 (chromosome 6p), PTHLH (chromosome 12p) and CHST11 (chromosome 12q) 
can be regarded as plausible candidates for OA susceptibility due to their roles in 
cartilage biology. RUNX2 and PTHLH encode runt-related transcription factor-2 and 
parathyroid hormone-related protein, respectively, and are involved in endochondral 
ossification (Kronenberg, 2006; Komori, 2010; Wysolmerski, 2012). CHST11 encodes 
carbohydrate sulfotransferase-11, which catalyses the transfer of sulphate groups to 
chondroitin, a constituent of the GAG chains of cartilage proteoglycans (Okuda et al., 
2000). The majority of the arcOGEN signals however do not contain obvious OA 
candidates. Most of the arcOGEN signals emerged after stratification by sex and joint 
type (Reynard and Loughlin, 2013). For example, the signal on chromosome 6p was 
associated only in male OA cases whilst several others were associated only in female 
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OA. Furthermore, some signals were associated only in knee OA (chromosome 3q) and 
some only in hip OA (chromosomes 6q, 9q, 12p and 12q; Table 1.1). These 
observations further highlight that OA is a multifactorial disorder and that its genetic 
predisposition operates in a sex-specific and joint-specific manner.  
SNP Chromosome Nearest genes Strata P-value 
rs11177/rs6976 3p GNL3/GLT8D1 TJR 7.24 x 10
-11
 
rs12107036 3q TP63 TKR-female 6.71 x 10
-8
 
rs10948172 6p SUPT3H, RUNX2 Male 7.92 x 10
-8
 
rs9350591 6q FILIP1 Hip 2.42 x 10
-9
 
rs4836732 9q ASTN2 THR-female 6.11 x 10
-10
 
rs10492367 12p KLHDC5, PTHLH Hip 1.48 x 10
-8
 
rs835487 12q CHST11 THR 1.64 x 10
-8
 
rs8044769 16q FTO Female 6.85 x 10
-8
 
Table 1.1: The eight signals from the arcOGEN GWAS. 
TJR, Total joint replacement; TKR, total knee replacement; THR, total hip replacement 
Adapted from Zeggini et al. (2012). 
1.8 Measuring functional effects of polymorphisms 
Polymorphisms in susceptibility loci can influence the variation in disease susceptibility 
and the response to therapies. Therefore, it is important to identify and characterise 
susceptibility loci further, in order to increase the understanding of the underlying 
mechanisms involved in the development and progression of the disease under 
investigation.  
DNA polymorphisms can give rise to phenotypic differences by altering the coding 
sequence of a protein coding gene, by interrupting the regulation of gene expression, 
by causing differential mRNA splicing or by affecting translation. Polymorphisms in 
regulatory elements that cause gene expression changes account for a majority of 
phenotypic diversity observed within and among species (Wang and Sadée, 2006). 
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Gene expression levels are under control by cis and trans acting regulators. It is 
believed that an average individual is heterozygous at functional cis regulatory sites in 
more than 40% of all genes (Rockman and Wray, 2002). The effect of cis regulatory 
elements can be context specific, such that they may cause an increase in expression 
of one allele relative to the other in one tissue type, but can cause repression or may 
not show any effect in another tissue type (Koch et al., 2006).  Cis variants regulate 
target gene expression either by affecting the transcription level of a gene or by 
influencing the stability of the mRNA.  
It is possible to measure the overall expression of a particular gene using quantitative 
methods such as real time polymerase chain reaction (PCR) and stratify gene 
expression by the genotype at a polymorphism which has shown association in the 
disease under investigation. This will detect if a change in the expression of this gene is 
mediated or marked by the associated variant and can quantify cis and trans effects 
acting at this locus. However, this method is subject to generating false negative 
results due to the natural fluctuation in gene expression observed among individuals. 
It has been challenging to quantify effects caused by cis-acting factors alone, due to 
the inability to distinguish these from gene expression variance caused by trans-acting 
factors. As a solution, the relative expression of each allele of a gene of interest can be 
measured to determine the proportion of cis acting regulation that influences gene 
expression (Yan et al., 2002). This can be carried out by allelic expression imbalance 
(AEI) studies that measure expression of one allele relative to the other at a 
heterozygous locus in a transcribed region of a gene. This method assumes that in the 
absence of cis-acting polymorphisms, the level of expression from one allele should 
equal that of the other in the same tissue type, as both alleles are exposed to the same 
environmental as well as trans acting factors (Wang and Sadée, 2006). On the other 
hand, if an individual shows AEI, this individual may be heterozygous for a cis 
regulatory polymorphism which affects transcription, mRNA stability, splicing or 
translational efficiency of the target gene. Such allelic expression imbalances are 
measured by determining the amount of mRNA molecules relative to the amount of 
genomic DNA molecules for each allele in the same tissue. Each allele acts as an 
internal control for the other as it measures allelic variation within an individual, thus 
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eliminating effects caused by environmental and trans-acting factors, tissue quality 
and preparation (Wilkins et al., 2007).  
Several techniques can be used to detect AEI, including real-time allele-specific PCR or 
primer extension assays such as Sequenom iPLEX assays. In these methods, the region 
surrounding the polymorphism is first amplified using genomic and complementary 
DNA (cDNA) as templates. 
The real-time PCR method uses TaqMan probes designed for the two different alleles 
which are differentially labelled with a fluorescent dye. During the PCR, a different 
fluorophore will be emitted for each allele, which will allow the differentiation 
between the two alleles. The increase in emission can be measured for each allele, 
which will enable the quantification of one allele relative to the other in cDNA and 
genomic DNA.  
Primer extension assays use an extension primer designed to anneal immediately 
adjacent to the polymorphic locus in the amplified template. The extension reaction 
mix contains dideoxynucleotide (ddNTP) terminators so that during the extension, the 
primers are extended by a single base complementary to the allele present. Sequenom 
iPLEX assays use mass modified ddNTP terminators. The products are run on the 
Sequenom MassARRAY analyzer which uses MALDI-TOF mass spectrometry, enabling 
the detection of the mass of the extended primer which determines the sequence 
amplified. Therefore, the amount of each allele present at the polymorphic site can be 
quantified. The Sequenom assays can be multiplexed to allow the analysis of up to 40 
SNPs (Gabriel et al., 2009). In order to measure AEI using these methods, a ratio is 
calculated between the amounts of each allele at a locus in cDNA, which is then 
normalised against that calculated for genomic DNA from the same sample.  
 
 
 
 
 
 
28 
 1.9 Aims 
The overall aim of my thesis is to explore the functional effects of OA susceptibility 
loci.  
1.9.1 Aim 1: Investigation of the effect of exogenous growth factor GDF5 on 
primary chondrocytes 
As noted earlier, a SNP in the 5’UTR of GDF5 (rs143383, C/T) was reported as being 
associated with OA in Japanese and Chinese (Miyamoto et al., 2007) and European 
(Chapman et al., 2008) populations. Functional studies carried out on this SNP showed 
that there was up to 27% reduced transcription from the T allele relative to the C allele 
in OA patients heterozygous at this locus (Southam et al., 2007). These findings suggest 
that a slight reduction in GDF5 expression increases the risk for OA. My aim was to 
determine if this deficit could be attenuated by the application of exogenous GDF5 
protein. I have assessed what effect exogenous GDF5 will have on primary OA 
chondrocyte gene expression. 
1.9.2 Aim 2: Allelic expression analysis of the osteoarthritis susceptibility locus 
that maps to MICAL3 
The first stage of the arcOGEN study produced evidence of an association of the SNP 
rs2277831 to primary hip and/or knee OA, with a P-value of 2.3x10-5 and an odds ratio 
of 1.07 for allele G (Panoutsopoulou et al., 2011). rs2277831 is an A/G transition 
located within an intron of the gene MICAL3, which maps to chromosome 22q11.21. 
The association interval marked by rs2277831 encompasses two additional genes, 
BCL2L13 and BID. My aim was to explore whether the OA association to rs2277831 is 
mediated by an influence on MICAL3, BCL2L13 or BID expression. 
1.9.3 Aim 3: Assessing whether the OA associated locus mapping to 
chromosome 12q23.3 mediates its effect by influencing the expression of 
CHST11 
The arcOGEN study reported a SNP rs835487 (G/A) on chromosome 12q23.3 as being 
associated with hip OA, with an odds ratio of 1.13 for allele G and a P-value of 1.64 x 
10-8 (Zeggini et al., 2012). The SNP is located within intron 2 of CHST11, which encodes 
carbohydrate sulfotransferase-11. As discussed earlier, this enzyme catalyses the 
transfer of sulphate groups to chondroitin, to form chondroitin-4 sulphate. This is a 
major constituent of the GAG chains in the cartilage ECM. Its role in cartilage biology 
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combined with previous reports that showed an upregulation of CHST11 in knee and 
hip OA (Karlsson et al., 2010; Xu et al., 2012), make it an attractive candidate for OA 
susceptibility. My aim was to study CHST11 as an OA susceptibility locus by the use of 
total and allelic expression analyses to determine if the association to rs835487 is 
mediated by a change in CHST11 expression. 
1.9.4 Aim 4: Search for rare variants in the coding region of CHST11 
There are no common coding variants in CHST11 recorded in online public databases, 
which are based on population samples. The aim of this chapter was to search for rare 
penetrant variants that can account for OA susceptibility. I therefore sequenced 192 
male and female hip OA patients to look for rare variants in the coding exons of 
CHST11. 
1.9.5 Aim 5: The role of CHST11 in chondrocyte differentiation 
The critical role of CHST11 during skeletal development has been demonstrated 
previously in mice and zebrafish, where knockout mice showed severe 
chondrodysplasias whilst the knockout zebrafish showed multiple embryonic 
morphological defects including a ventrally bent trunk and a curled tail (Klüppel et al., 
2005;  Mizumoto et al., 2009; CL Hammond, personal communication, 18th July 2012). 
My aim was to study the role of CHST11 during chondrogenesis by using iliac crest 
derived mesenchymal stem cells from young donors. CHST11 mRNA and CHST11 
protein were knocked-down in these cells and the cells were then differentiated into 
chondrocytes using Transwell culture (Murdoch et al., 2007). Gene expression of a 
panel of maker genes for various metabolic processes in chondrocytes were analysed 
in the knocked-down cells compared to control cells. The GAG content and the wet 
mass were also compared to assess the role of CHST11 in chondrocyte matrix 
synthesis. 
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Chapter 2: Materials and methods 
2.1 Tissue collection and grinding 
See Appendix 1 for ethics statement. Cartilage, fatpad, meniscus, synovium, 
osteophyte and cancellous bone were collected from OA patients that had undergone 
joint replacement surgery. Cartilage tissue from neck-of-femur fracture (NOF) patients 
was collected as healthy controls. The tissues were removed from the joint on the 
same day as the surgery using a scalpel blade, washed in Phosphate Buffered Saline 
(PBS; Lonza, Slough, UK) and stored at -80 °C. Prior to tissue grinding, all surfaces, 
forceps, grinding vials and balls were cleaned with RNase-Zap (Ambion, Life 
Technologies, Paisley, UK) and 70% ethanol made up with diethylpyrocarbonate 
(DEPC)-treated water (Invitrogen, Life Technologies, Paisley, UK). The tissue to be 
ground was placed on dry ice and transferred to a grinding vial with a grinding ball. The 
vials were cooled in liquid nitrogen, clamped to a Mixer Mill MM200 (Retsch, 
Castleford, UK) and oscillated at a frequency of 20 Hz for 90 seconds. The cycles were 
repeated until the tissue was powderised, cooling the vials in liquid nitrogen between 
every cycle. The ground tissue was stored at -80 °C for nucleic acid extraction. 
2.2 Nucleic acid extraction from ground joint tissue 
DNA and RNA were extracted from ground cartilage using E.Z.N.A DNA/RNA isolation 
kit (VWR International, Lutterworth, UK). The tissue samples were kept on dry ice and 
0.25 g of tissue were transferred to eppendorf tubes, four tubes per sample (1 g in 
total). One tube was to be used for DNA extraction and the remaining three for RNA. 
GTC lysis buffer was prepared by adding 20 μl of β-mercaptoethanol per 1 ml of buffer 
and 700 μl of this was added to each sample. The mixture was vortexed thoroughly to 
homogenise and centrifuged at 11700 rpm for 5 minutes. The supernatant from one of 
the tubes was transferred to a HiBind DNA column placed in a 2 ml collection tube. The 
supernatants from the remaining three tubes were transferred to 700 μl of chilled 70% 
DEPC-treated ethanol and 750 μl of the mix was transferred to RNA columns placed in 
2 ml collection tubes. The tubes were centrifuged at 10300 rpm for 1 minute. The flow 
through from the RNA columns was discarded. The flow through from the DNA column 
was added to the remaining supernatant/ethanol mix equally. The mix was transferred 
to the RNA columns, which were centrifuged at 10300 rpm for 1 minute, and the flow 
through was discarded. To the RNA columns, 500 μl of RNA Wash Buffer I was added 
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and centrifuged at 11700 rpm for 1 minute, and the flow through was discarded. Next, 
500 μl of RNA Wash Buffer II was added to RNA columns and 500 μl of Buffer HB was 
added to DNA columns. The columns were centrifuged at 11700 rpm for 1 minute and 
the flow through was discarded. A further 500 μl of RNA Wash Buffer II was added to 
RNA columns and 700 μl of DNA Wash Buffer was added to the DNA column. The tubes 
were centrifuged at 11700 rpm for 1 minute. The collection tubes were discarded and 
were replaced with fresh collection tubes. The tubes were centrifuged at 13000 rpm 
for 2 minutes to dry the columns. The columns were transferred to fresh 1.5 ml tubes 
and 50 μl of DEPC water was added to RNA columns and 50 μl of Elution Buffer was 
added to the DNA column. The tubes were centrifuged at 11700 rpm for 1 minute, and 
the elution was repeated. The eluted RNAs were combined and labelled. The RNA 
columns were transferred to fresh 1.5 ml tubes and were washed twice with 50 μl of 
DEPC water by centrifuging at 11700 rpm for 1 minute to obtain any remaining DNA. 
This was combined with the eluate from the DNA column.  
One microlitre of the sample was used to quantify the nucleic acid using a NanoDrop 
1000 spectrophotometer. Three microlitres of RNaseOUT RNase inhibitor (Invitrogen) 
were added to RNA samples which were then centrifuged in a DNA 120 SpeedVac 
system (Thermo Scientific, Epsom, UK) along with the DNA samples. The DNA and RNA 
pellets were resuspended in DEPC water and made to 50 ng/ml and 250 ng/ml 
respectively. DNA samples were stored at -20 °C and RNA samples at -80 °C until 
further use. 
2.3 Complementary DNA (cDNA) synthesis  
RNA extracted from cells and patient tissue was reverse transcribed to synthesise 
cDNA. RNase-free pipettes and tubes were used throughout to ensure that the RNA 
did not degrade. To remove genomic DNA (gDNA) contamination, 4 μl of 250 ng/μl 
RNA was incubated at 37 °C for 30 minutes with 1 μl of Turbo DNase (2 units; Ambion), 
1 μl of DNase buffer (10X; Ambion) and 4 μl of DEPC-treated water (Invitrogen). This 
was then heated to 75 °C for 10 minutes with 1.8 μl of 100 mM 
Ethylenediaminetetraacetic acid (EDTA; Sigma-Aldrich, Poole, UK) to inactivate the 
DNase.  
The reverse transcription (RT) of RNA was carried out using the SuperScript First-
Strand Synthesis System for RT-PCR (Invitrogen). The DNase treated RNA was 
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incubated at 65 °C for 5 minutes with 1 μl of random primers (50 ng/μl), 1 μl of 10 mM 
dNTP mix (10 mM each of dATP, dCTP, dGTP and dTTP) and 2 μl of DEPC water. A DEPC 
water blank with no RNA was also used as a negative control. The reaction mix was 
then left on ice for at least 1 minute followed by incubation at 25 °C for 1 minute with 
4 μl of 5X Reaction buffer (250 mM Tris-HCL pH 8.3, 375 mM KCl, 15 mM MgCl2), 4 μl 
of MgCl2 (25 mM), 2 μl of DTT (0.1 mM) and 1 μl of RNaseOUT RNase inhibitor (40 U/μl; 
Invitrogen). SuperScript II RT enzyme (200 U/μl; Invitrogen) was diluted four times 
using DEPC water and 1 μl (50 U) of this was added to the reaction and mixed by 
pipetting. The RT reaction was carried out by incubating at 25 °C for 10 minutes, 42 °C 
for 50 minutes and 70 °C for 15 minutes. Finally, 1 μl of RNaseH (5 U/μl; New England 
Biolabs, Hitchin, UK) was added and the reaction mixture was incubated at 37 °C for 20 
minutes.  
The synthesised cDNA and the DEPC water blank were PCR amplified using primers 
that amplify cDNA and gDNA producing different sized PCR products, to distinguish 
cDNA products from any products resulting from residual gDNA contamination 
(forward primer 5'TCGAAGAGTGAACCAGCCTT3' and reverse primer 
5'GAAGGCCAGGAATTGCACCATCC3' which target HBP1) . The PCR products were 
electrophoresed through a 2% (weight/volume) agarose gel containing 1 μl of ethidium 
bromide (10 mg/ml) per 100 ml of agarose and were visualised under UV light using a 
G:BOX gel doc system (Syngene, Cambridge, UK). Only cDNA samples that produced 
the appropriate bands specific for cDNA (152 bp in size), and not for gDNA or the DEPC 
water blank, were taken forward for subsequent analysis. These cDNA samples were 
stored at -20°C until further use. 
2.4 Polymerase Chain Reaction (PCR) 
Genomic DNA and cDNA from cell lines and patient tissues were amplified in a 15 μl 
reaction using 1 μl of template DNA (50ng/μl) or 0.5 μl of cDNA synthesised from 1 μg 
of RNA. The PCR was first optimised using different MgCl2 concentrations (ranged 
between 1 and 3 mM) and annealing temperatures (ranged between 55 °C and 70 °C). 
The reaction contained 0.075 μl of 100 μM forward and reverse primers (Sigma), 0.375 
μl of 10 mM dNTPs (Bioline, London, UK), 1.5 μl of 10X PCR buffer (500 mM KCl, 100 
mM Tris-HCl pH 8.3; Applied Biosystems, Life Technologies, Paisley, UK), 0.6 -1.8 μl of 
25 mM MgCl2 (final concentration of 1-3 mM; Applied Biosystems), 0.08 μl of AmpliTaq 
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Gold DNA polymerase (5 U/μl, Applied Biosystems) and was made up to 15 μl with 
water (Sigma). The PCR cycle conditions were  94 °C for 14 minutes, followed by 35 
cycles of 94 °C for 30 seconds, 55 °C to 70 °C for 30 seconds and 72 °C for 30 seconds 
and 72 °C for 5 minutes. Five microlitres of PCR product mixed with loading dye was 
electrophoresed through a 2% agarose gel containing ethidium bromide and was 
visualised under UV light to ensure the PCR amplification was successful. 
2.5 SW1353 cell culture 
Cell culture was carried out under sterile conditions at all times. A cryovial containing 
one million SW1353 human chondrosarcoma cells was removed from liquid nitrogen 
storage and thawed rapidly for 30 seconds in a 37 °C water bath. The cells in the vial 
were diluted in 1 ml of pre-warmed Dulbecco's Modified Eagle Medium: Nutrient 
Mixture F-12 (DMEM / F-12; Gibco, Life Technologies, Paisley, UK) supplemented with 
10% FBS (Gibco), 2 mM glutamine (Sigma), 100 U/ml penicillin and 100 μg/ml 
streptomycin mix (Sigma). The cells were then resuspended in 10 ml of complete 
media and transferred to a 75 cm2 cell culture flask (VWR) and placed in a cell culture 
incubator maintained at 37 °C with 0.5% CO2. The media was changed 24 hours after 
resurrection and the cells were passaged 1 in 3 when they reached 80% confluence. 
This was achieved by removing the media, washing cells with PBS and incubating the 
flask containing the cells with 1 ml of 0.05% trypsin (Gibco) at 37 °C for 5 minutes. The 
cells were resuspended in 4 ml of complete media to inactivate the trypsin and 
pelleted at 1100 rpm for 5 minutes. The media was removed and the cell pellet was 
resuspended in 30 ml of complete media and 10 ml was transferred to a fresh 75 cm2 
cell culture flask.  
2.6 Bacterial cell transformation with Smad 1/5/8 reporter vector 
The experiments were carried out under sterile conditions. Smad 1/5/8 binding 
elements were cloned to a pGL3 basic vector (Promega) which was a kind gift from Dr. 
Mark Birch. One vial of chemically competent MACH bacterial cells (Invitrogen, cat no. 
C8620-03) was removed from -80 °C and was allowed to defrost on ice. Two microlitres 
of vector DNA was added to the cells and the vial was left on ice for 20 minutes. The 
cells were heat shocked at 42 °C for 30 seconds and placed immediately on ice for 2 
minutes. The vial was incubated at  37 °C at 200 rpm for one hour with 200 μl of Super 
Optimal broth with Catobolite repression (S.O.C) medium (Invitrogen Cat no. 15544-
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034). Eighty microlitres of cells were spread on Lysogeny Broth (LB) agar (Sigma) plates 
containing Ampicillin (Sigma) using a sterile glass spreader. The plates were incubated 
at 37 °C overnight to allow colonies to grow. One positive colony of cells was picked 
with a sterile autoclaved filter tip and the tip was ejected into 3 ml of LB broth 
containing 3 μl of Ampicillin in a 15 ml tube. The tube was incubated at 37 °C at 200 
rpm overnight. Two hundred microlitres of bacterial culture was mixed with 200 μl of 
glycerol and stored at -80 °C. 
2.7 Plasmid DNA purification using MiniPrep 
QIAGEN Plasmid Mini Kit (QIAGEN, Crawley, UK) was used to purify plasmid DNA. 
Briefly, 1.5 ml of overnight bacterial culture was centrifuged at 7500 rpm for 3 minutes 
to pellet the bacteria. LB supernatant was removed and the pellet was resuspended in 
100 μl of Buffer P1+RNase A. Two hundred microlitres of Buffer P2 was added to the 
tube and inverted several times and the cells were allowed to lyse for 2 minutes. The 
lysate was mixed with 150 μl of Buffer P3 and centrifuged at 13000 rpm for 5 minutes. 
The supernatant was then transferred to a fresh tube and centrifuged at 13000 rpm for 
2 minutes. This supernatant was transferred to a fresh tube containing 1 ml of 100% 
ethanol, and stored at -80 °C for 15 minutes. The tube was centrifuged at 13000 rpm 
for 5 minutes to pellet the DNA. The supernatant was removed and the DNA pellet was 
allowed to air dry for 15 minutes and resuspended in 40 μl of DEPC-treated water 
(Invitrogen) and stored at -20 °C.  
2.8 Plasmid DNA purification using MaxiPrep 
QIAGEN plasmid maxi kit was used to purify DNA. Ten microlitres of the glycerol stock 
of a bacterial culture was incubated in 250 ml of LB containing 250 μl of Ampicillin at 
37 °C at 200 rpm for 4 hours. The cultures were centrifuged at 6000 x g for 15 minutes 
at 4 °C. The supernatant was removed and the bacterial pellet was resuspended first in 
10 ml of Buffer P1, then in 10 ml of Buffer P2 and incubated at room temperature for 5 
minutes to allow the cells to lyse. The lysate was mixed with 10 ml of chilled Buffer P3 
and incubated on ice for 20 minutes. The lysate was centrifuged at 4 °C at 20,000 x g 
for 30 minutes. The supernatant containing plasmid DNA was centrifuged at 4 °C at 
20,000 x g for 15 minutes. A QIAGEN-tip 500 was equilibrated by applying 10 ml of 
Buffer QBT and the column was allowed to empty by gravity flow. The supernatant was 
applied to the QIAGEN-tip and was allowed to enter the resin by gravity flow. The 
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QIAGEN-tip was washed with 30 ml of Buffer QC. The DNA was eluted with 15 ml of 
Buffer QF. The DNA was precipitated by centrifugation with 10.5 ml of isoproponol at 4 
°C at 15,000 x g for 30 minutes. The supernatant was removed and the pellet was air 
dried for 10 minutes and resuspended in 500 μl of water (Sigma) and transferred to a 2 
ml screw cap tube. The DNA was washed with 1.25 ml of 100% ethanol and centrifuged 
for 10 minutes at full speed. The supernatant was removed and the pellet was air dried 
for 10 minutes. The DNA was resuspended in 300 μl of water and stored at -20 °C. 
2.9 Transfection of SW1353 cells with Smad 1/5/8 luciferase reporter vector 
SW1353 cells were seeded at 17, 500 cells/well in 48-well cell culture plates (VWR) in 
300 μl of media containing 10% FBS. The cells were cultured to 80% confluence, which 
took 48 hours. Cells were co-transfected with 15 ng of Renilla vector DNA (Promega, 
Southampton, UK) as an internal control and 500 ng of basic pGL3-Smad 1/5/8 vector 
DNA or basic pGL3 empty vector DNA (Promega) using ExGen 500 in vitro transfection 
reagent (Fermentas, Thermo Scientific, Epsom, UK). A master mix was prepared with 
25.35 μl of 0.9% NaCl, 2.5 μl of 200 ng/μl DNA and 0.5 μl of 30 ng/μl Renilla DNA. The 
mix was vortexed briefly and 1.65 μl of ExGen 500 was added and vortexed for 10 
seconds. The mix was incubated at room temperature for 10 minutes. The media was 
aspirated from the wells and 30 μl of the DNA and ExGen 500 mix was added to each 
well. The wells were filled with 270 μl of complete media and the cells were incubated 
at 37 °C for 24 hours. 
2.10 Cartilage digestion and chondrocyte culture  
Articular cartilage was obtained from knee or hip OA patients and neck-of-femur 
fracture patients after their surgery. The cartilage was removed from the joint using a 
scalpel and then cut finely. The cartilage was digested by incubating with 1mg/ml 
hyaluronidase (type I-S from bovine testes; Sigma) in PBS at 37 °C for 15 minutes, then 
with 2.5 mg/ml trypsin (type III, from porcine pancreas; Sigma) in PBS at 37 °C for 30 
minutes. The supernatant was removed and the cartilage was washed with complete 
DMEM (Gibco) supplemented with 10% FBS (Gibco), 2 mM  glutamine (Sigma) , 100 
U/ml penicillin, 100 μg/ml streptomycin (Sigma) and 50 U/ml nyastatin (Sigma) to 
inactivate the trypsin. The cartilage was then incubated with 2.5 mg/ml bacterial 
collagenase (type I from Clostridium histolyticum; Sigma) in complete DMEM at 35 °C 
overnight. The supernatant was removed and centrifuged at 1100 rpm for 10 minutes 
 
 
36 
to collect the cells. The cell pellet was washed with PBS and resuspended in complete 
DMEM culture media. A cell count was obtained using a haemocytometer.  
2.11 Stimulation of cells with exogenous growth factors (GDF5, TGF-β1, IL-1α 
and OSM) 
2.11.1 Monolayer culture with exogenous growth factors post transfection 
Twenty four hours after transfection, the media was aspirated off and the cells were 
washed with PBS. The cells were incubated in 150 μl of serum-free media at 37 °C 
overnight. The cells were stimulated with four different recombinant GDF5 proteins 
(mouse GDF5, human wild type GDF5 and two variants, A and B) at 10 ng/ml, 30 ng/ml, 
100 ng/ml and 300 ng/ml. Recombinant mouse GDF5 protein (R&D Systems, Abingdon, 
UK) was diluted serially from a stock concentration of 150 μg/ml and recombinant 
human GDF5 and variants A and B (Biopharm GmbH, Heidelberg, Germany) from a 
stock concentration of 1000 μg/ml. Recombinant human TGF-β1 (5 ng/ml; R&D 
Systems) and BMP2 (100ng/ml; R&D Systems) were also used as positive  controls. The 
proteins were diluted in 150 μl of serum-free media at double the concentration 
required and added to 150 μl of media already in the wells to give the correct final 
concentration. The experiment was performed in four replicates. The plates were 
incubated at 37 °C and lysed at 6 hours, 12 hours, 24 hours and 48 hours post 
stimulation. 
2.11.2 Monolayer culture for western blot analysis 
Chondrocytes from two OA patients were seeded at 350,000 cells/well in four 6-well 
cell culture plates (VWR) in 2 ml of serum positive DMEM culture media. Cells from 
each plate were isolated at four different time points after stimulation (15 minutes, 30 
minutes, 1 hour and 2 hours). The cells were cultured at 37 °C until 80% confluent, 
which took 10-12 days. Chondrocytes were replenished with fresh complete media 
after three days when the cells had adhered to the bottom of the wells and again 
every two days.  
The cells were then serum-starved by removing the media from the wells, washing the 
cells with PBS and adding 1 ml of serum-free DMEM culture media (supplemented with 
2 mM glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin and 50 U/ml nyastatin). 
The plates were incubated at 37 °C overnight.  
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The cells were stimulated with GDF5 protein at 100 ng/ml in 2 ml of serum free media. 
At appropriate time points, the cells were lysed for protein extraction. 
2.11.3 Monolayer culture for gene expression analysis 
Chondrocytes extracted from a total of 20 OA patients were seeded at 10,000 
cells/well in four 96-well cell culture plates (VWR). The volume in each well was made 
to 200 μl with serum positive complete DMEM culture media. Four plates were 
prepared to enable the cells to be isolated at four different time points; 6 hours, 12 
hours, 24 hours and 48 hours. The cells were cultured at 37 °C with 0.5% CO2 until 80% 
confluent, which took 10 to 12 days. The chondrocyte medium was changed after 
three days when the cells had adhered to the bottom of the wells and again every two 
days.  
The culture media was removed from the wells, the cells were washed with PBS and 
cultured in 100 μl of serum-free DMEM culture media at 37 °C overnight. 
Six wells in 6, 12, 24 and 48 hour plates were cultured with 100 ng/ml GDF5 protein by 
preparing a solution of 200 ng/ml of GDF5 with serum-free DMEM media and adding 
100 μl of this to the 100 μl of serum-free media already in the wells. The untreated 
control wells (6 wells in each plate) received 100 μl of serum-free media instead of 
GDF5.  
Three wells in the 24 hour plate were treated with IL-1α (0.05 ng/ml) and recombinant 
oncostatin M (OSM) (10 ng/ml) as positive controls for the assay. IL-1α was a gift from 
Dr Keith Ray (GlaxoSmithKline, Stevenage, UK) and recombinant OSM was a gift from 
Dr Amit Patel (Newcastle University, UK).  Six wells in the 48 hour plate were treated 
with recombinant human TGF-β1 (5 ng/ml; R&D Systems) as positive controls. 
The plates were incubated at 37 °C. At appropriate time points, the cells were lysed for 
RNA extraction. 
2.12 Luciferase activity reading 
The dual-Luciferase Reporter assay system (Promega) was used to measure luciferase 
activity in the transfected cells. The media was aspirated off and the cells were washed 
in PBS. At each time point, 65 μl of 1X Passive Lysis Buffer (PLB; Promega) was added 
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to each well. The plates were incubated at room temperature for 20 minutes on a 
rocker, and stored at -20 °C overnight. 
The plates were defrosted and 20 μl of lysate was transferred to a luminometer plate. 
The plate was placed in a Microlumat Plus luminometer (Berthold Technologies, Bad 
Wildbad, Germany) and 50 μl of Luciferase Assay Reagent II (LAR II; Promega) was 
added to each well and firefly luciferase activity was measured on the instrument. 
Next, 50 μl of Stop and Glo Reagent (Promega) was added to each well and Renilla 
luciferase activity was measured as an internal control, which served as the baseline 
response. The firefly luciferase reading was normalised to the Renilla luciferase 
reading, by dividing the former by the latter, to account for differences in cell viability 
and transfection efficiency.  
2.13 Protein extraction 
At specific time points, media was removed from 6-well plates and the cells were 
washed with PBS. One millilitre of fresh PBS was added to the cells on ice and a cell 
scraper was used to lift the cells off the wells. The cells in PBS were transferred to a 1.5 
ml eppendorf tube and centrifuged at 4 °C, at 13000 rpm for 5 minutes to obtain a cell 
pellet. The supernatant was removed and the cells were resuspended in 30 μl of 
protein lysis buffer (50 mM Tris, 10% v/v glycerol, 50 mM NaF, 1 mM EGTA, 1 mM 
EDTA, 10 mM glycerol phosphate, 1% v/v Triton X-100, 1x complete inhibitor cocktail, 
1 µM microcystin-LR and 1mM Na3VO4) and left on ice for 20 minutes. The tubes were 
centrifuged at 13000 rpm for 10 minutes at 4 °C. The supernatant containing whole cell 
protein was transferred to a fresh 1.5 ml eppendorf and was stored at -80 °C until 
further use. 
2.14 Protein quantification using Bradford assay 
To enable equal loading in western blot gels, the amount of whole cell protein was 
quantified. A protein standard curve was made using Bovine Serum Albumin (BSA; 
Thermo Scientific). A stock concentration of 2 mg/ml was diluted with protein lysis 
buffer to achieve concentrations ranging from 0 to 1.5 mg/ml BSA as shown in Table 
2.1.  
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Required concentration for 
standard curve (mg/ml) 
BSA (2 mg/ml) in µl Lysis buffer (µl) 
0  0 50.0 
0.1  2.5 47.5 
0.25  6.25 43.75 
0.5 12.5 37.5 
0.75 18.75 31.25 
1.0 25 25.0 
1.25 31.25 18.75 
1.5 37.5 12.5 
Table 2.1: BSA standard curve for protein quantification 
 
The proteins to be measured were diluted 1 in 10 using protein lysis buffer. Twenty 
microlitres of samples were loaded onto a 96-well microtiter plate in duplicate. Three 
hundred microlitres of Bradford Ultra (Expedeon, Harsdon, UK) was added to samples 
and the absorbance at 595 nm was measured using a microplate reader (Tecan, 
Reading, UK). The absorbance values were used to plot a BSA standard curve, which 
was used to then calculate the concentration of the test samples. 
2.15 Western blot 
2.15.1 Gel preparation 
A separating gel and a stacking gel were made up fresh for each experiment. First, the 
glass plates (Bio-Rad Laboratories, Hemel Hempstead, UK) were cleaned with 100% 
ethanol and were assembled on a glass holder. A 12% separating gel was made as 
follows: 
 3.6 ml of 40% bis-acrylamide (NBS biologicals, Huntigdon, UK) 
 3 ml of lower buffer (1.5 M Tris, 0.4% w/v SDS; Sigma), pH 8.8 
 5.4 ml of distilled water 
 60 μl of 10% ammonium persulphate (Sigma) 
 20 μl of N, N, N’, N’-tetramethylethylenediamine (TEMED; Sigma)  
Six millilitres of separating gel were pipetted through the glass plates and 1 ml of 
isoproponol was added to the top to avoid evaporation. The gel was allowed to set for 
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half an hour. Once the gel was set, the isoproponol was poured off and a 4.5% stacking 
gel was made up as follows: 
 1.35 ml of 40% bis-acrylamide  
 3 ml of upper buffer (0.5 M Tris, 0.4% w/v SDS), pH 6.8 
 7.65 ml of distilled water 
 60 μl of 10% ammonium persulphate 
 20 μl TEMED 
 Three millilitres of stacking gel was pipetted through the glass plates on to the top of 
the separating gel, and a comb was applied. The gel was allowed to set for 15 minutes, 
the comb was removed and the wells were washed with distilled water. The glass 
plates containing the gel in between were removed from the holder and were 
assembled in a gel tank (Bio-Rad). Ten times running buffer (5.86 g glycine, 20 g of SDS, 
60.6 g of Tris base in 2 l of water, pH 8) was diluted in distilled water to make up 1X 
running buffer, which was poured into the gel tank ensuring the glass plates were fully 
covered.  
2.15.2 Sample preparation 
For western blot analysis of anti-phospo Smad 1/5/8 antibody, 10 µg of sample was 
mixed with 4 μl of 5X laemmli sample buffer (0.1M Tris-HCL, 0.35M SDS, 20% (v/v) 
glycerol, 0.01% (v/v) bromophenol blue, 5% (v/v) β-mercaptoethanol) and made up to 
20 μl with water. Thirty micrograms of protein in 6 µl of 5X laemmli sample buffer was 
made up to 30 µl with water for western blot analysis of anti-CHST11 antibody. The 
samples were boiled at 95 °C for 5 minutes to denature the proteins. 
2.15.3 Running the gel 
The samples were loaded onto the gel and 4 μl of pre-stained page ruler ladder 
(Fermentas) was loaded at the end of the gel, which was run at 100 V. 
2.15.4 Transfer of proteins to PVDF membrane 
Four pieces of blotting paper (10x7 cm) were soaked in transfer buffer (5.86 g of 
glycine, 0.65 g SDS, 11.62 g Tris in 400 ml of 100% methanol) for 5 minutes. Whatman 
Westran Polyvinylidene Fluoride (PVDF; GE Healthcare, Amersham, UK) membrane 
(9x6 cm) was soaked in 100% methanol for 3 minutes.  Once the gel had finished 
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running, the stacking gel was removed and the separating gel was soaked in transfer 
buffer for 3 minutes. A complex was assembled on a semi-dry transfer machine with 
two pieces of blotting paper, the PVDF membrane, the gel, followed by two more 
pieces of blotting paper. Air bubbles were removed with a roller. The proteins were 
transferred at 100 mA for 1 hour. 
2.15.5 Blocking 
Once the transfer was complete, the membrane was blocked in 5% milk, made up with 
1 g of dried milk powder (Marvel) in 20 ml of Tris Buffered Saline/Tween-20 (TBS/T; 
12.1 g of Tris, 90 g of NaCl and 10 ml of 10X Tween-20 in 1 l of distilled water, pH 7.4) 
for 30 minutes (for anti-pSmad 1/5/8 and anti-β-actin antibodies) or in 5% BSA for 1 
hour (for anti-CHST11 antibody).   
2.15.6 Detection 
Anti-phospho-Smad1 (Ser463/465)/ Smad5 (Ser463/465)/ Smad8 (Ser426/428; rabbit 
polyclonal; Cell Signalling, cat no. 9511) and anti-CHST11 (mouse monoclonal; Abcam, 
cat no. ab57225) antibodies were used at 1 in 2000 dilution in 5% BSA and 0.02% 
sodium azide. Anti-β-actin (Sigma, cat no. A5316) antibody was used at 1 in 10000 
dilution in 5% milk and was used as a loading control. The membrane was incubated 
with the primary antibody at 4 °C overnight on a rocker.  
The membrane was then washed with TBS/T for 20 minutes on a rocker, changing the 
buffer every 5 minutes. The membrane was incubated for 1 hour at room temperature 
on a rocker with the corresponding secondary antibody. Either polyclonal goat anti-
rabbit IgG (0.25 g/l; Dako, Ely, UK) or polyclonal goat anti-mouse antibody (1 g/l; Dako) 
were used at 1 in 2000 or 1 in 10000 dilution respectively in 5% milk. Both antibodies 
were linked to horseradish peroxidise (HRP). The membranes were washed with TBS/T 
for 30 minutes.  
Enhanced chemiluminescent (ECL; GE Healthcare, Amersham, UK) reagent, which acts 
as a substrate for HRP, was used for visualisation of the proteins using a G: BOX gel doc 
system (Syngene). ECL was used for membranes incubated with anti-β-actin and ECL 
advanced was used for membranes incubated with anti-pSmad 1/5/8 and anti-CHST11 
due to the low abundance of these proteins. The membranes were exposed 5 times at 
20 second intervals to obtain 5 digital images. 
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2.15.7 Stripping membrane 
After the use of anti-CHST11 antibody, the membrane had to be stripped before 
incubation with anti-β-actin, since both antibodies were raised in mouse. The 
membrane was incubated in mild stripping buffer (15 g of glycine, 1 g of SDS, 10 ml of 
Tween-20 in 1 l of distilled water, pH 2.2) at room temperature for 40 minutes. The 
buffer was replaced after 20 minutes. The membrane was incubated with PBS for 20 
minutes and then with TBS/T for 10 minutes at room temperature. The membrane was 
blocked with 5% milk for 30 minutes.  
2.16 Cell lysis and reverse transcription of cell lysates 
At appropriate time points, the media was removed from the cells in 96-well plates 
and the cells were washed with PBS. Thirty microlitres of Cells-to-cDNA II Cell Lysis 
Buffer (Ambion) was added to each well on ice and the suspension was transferred to 
a fresh 96-well PCR plate. The plates were heated to 75 °C for 15 minutes. The plates 
were then stored at -80 °C until all time points were reached. 
One microlitre of RNase free DNase I (0.1 U; Qiagen) was added to each well and 
incubated at 37 °C for 15 minutes and 75 °C for 5 minutes. Eight microlitres of this mix 
was transferred to a fresh microtitre plate and incubated at 70 °C for 5 minutes with 1 
μl of random primers (0.2 μg/μl; Invitrogen) and 3 μl of 10 mM dNTP mix (2.5 mM each 
of dATP, dCTP, dGTP and dTTP; Invitrogen). This mix was then subjected to reverse 
transcription by adding 4 μl of 5X RT buffer (Invitrogen), 0.5 μl of MMLV reverse 
transcriptase (200 U/μl; Invitrogen), 2 μl of DTT (0.1 M; Invitrogen) and 1.5 μl of water. 
The cycle conditions were 37 °C for 50 minutes and 75 °C for 15 minutes. Finally, 30 μl 
of water was added to the wells to give a final volume of 50 μl in each well. The plates 
were stored at -20 °C until further use. 
2.17 Gene expression analysis using real time quantitative PCR 
The TaqMan primers and probes listed in Table 2.2 were used to analyse gene 
expression changes in a panel of selected genes. Some TaqMan assays used 
commercially available primer-probe mixes (IDT, Glasgow, UK) or a combination of PCR 
primers (Sigma) and custom designed probes (IDT). The gene expression was measured 
relative to the housekeeping genes GAPDH, HPRT1 and 18S.  
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Gene Forward primer (5'-3') Reverse primer (5'-3') Probe (5'-3') 
GAPDH ACATCGCTCAGACACCATG TGTAGTTGAGGTCAATGAAGGG AAGGTCGGAGTCAACGGATTTGGTC 
HPRT1 TGCTGAGGATTTGGAAAGGG ACAGAGGGCTACAATGTGATG AGGACTGAACGTCTTGCTCGAGATG 
18s CGAATGGCTCATTAAATCAGTTATGG TATTAGCTCTAGAATTACCACAGTTATCC TCCTTTGGTCGCTCGCTCCTCTCCC 
BCL2L13 AGGTATGTCACGCCAAACTG GGAATGTACACTGGAGACCAC TCGTAGCAAAACCAGAGGCACCA 
BID ATTAACCAGAACCTACGCACC TGACCACATCGAGCTTTAGC CAGAAATGGGATGGACTGAACGGACA 
MICAL3 GAACAAAGTGAAGTACATGGCG TGGCAGAAGTAGCATGTGTC ATCGGCATACGGAGACAGGGC 
BMPR-II GGCTGACTGGAAATAGACTGG CACAGTCCCTCAAGTTCACAG CCTCGCTTATGGCTGCATTATCTTCCTC 
BMPR-IA ACAAAGTTCTGGTAGTGGGTC CATCCATACTTCTCCATATCGGC ATTCAGATGGTCCGGCAAGTTGGT 
BMPR-IB CTGCACAGAAAGGAACGAATG AGGACCAAGAGCAAACTACAG TGGAGGCAGTGTAGGGTGTAGGT 
MMP13 AAATTATGGAGGAGATGCCCATT TCCTTGGAGTGGTCAAGACCTAA CTACAACTTGTTTCTTGTTGCTGCGCATGA 
MMP1 AAGATGAAAGGTGGACCAACAATT CCAAGAGAATGGCCGAGTTC CAGAGAGTACAACTTACATCGTGTTGCGGCTC 
TIMP1 TTCTGCAATTCCGACCTCG TCATAACGCTGGTATAAGGTGG TTGACTTCTGGTGTCCCCACGAAC 
COL2A1 ACCTTCATGGCGTCCAAG AACCAGATTGAGAGCATCCG AGACCTGAAACTCTGCCACCCTG 
SOX9 CTGGTACTTGTAATCCGGGTG ACTTGCACAACGCCGAG TCTGGAGACTTCTGAACGAGAGCGA 
ACAN TGTGGGACTGAAGTTCTTGG AGCGAGTTGTCATGGTCTG CTGGGTTTTCGTGACTCTGAGGGT 
CHST11 TGCTTGGGATCCTTTATCCTG GCTGGATTGGGTTGTAGAGTTC AATCCCTTTGGTGTGGACATCTGCT 
COL10A1 CAAGGCACCATCTCCAGG TGGGCATTTGGTATCGTTCAG ACTCCCAGCACGCAGAATCCAT 
BGLAP CAGCGAGGTAGTGAAGAGAC TGAAAGCCGATGTGGTCAG TCCCAGCCATTGATACAGGTAGCG 
COL1A1 CCCCTGGAAAGAATGGAGATG TCCAAACCACTGAAACCTCTG TTCCGGGCA ATCCTCGAGCA 
ADAMTS4 CTGGGTATGGCTGATGTGG TGGCTTGGAGTTGTCATGG TTCACTGCTGCTCATGAACTGGGT 
ADAMTS5 CAAGTGCGGAGTATGTGGAG GTCTTTGGCTTTGAACTGTCG TTTATGTGGGTTGCCCCTTCAGGA 
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IHH ATGAAGGCAAGATCGCTCG GATAGCCAGCGAGTTCAGG TCAAGGACGAGGAGAACACAGGC 
RUNX2 AATGGTTAATCTCCGCAGGTC TGTTTGATGCCATAGTCCCTC CTGTTGGTCTCGGTGGCTGGTAG 
 Table 2.2: Primer and probe sequences for TaqMan assays used for real time quantitative PCR. 
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Two and a half microlitres of the reverse transcribed lysate or cDNA corresponding to 
6.25 ng of RNA were mixed with 7.5 μl of assay master mix in wells of a 96 well optical 
realtime-PCR plate. The reaction components for each assay are shown in Table 2.3.  
The reactions were then run on either an ABI PRISM 7900HT Standard or Fast Real 
Time PCR System, under the following cycle conditions: 50 °C for 2 minutes, 95 °C for 
10 minutes and 40 cycles of 95 °C for 15 seconds and 60 °C for 1 minute for a standard 
run or 95 °C for 20 seconds and 40 cycles of 95 °C for 1 second and 60 °C for 20 
seconds for a fast run. 
 
18S, MMP1 and MMP13 Assays with primer-probe mix 
TGE                    5 μl 
Forward primer   0.2 μl 
Reverse primer   0.2 μl 
Probe                  0.4 μl 
Water                  2 μl 
TGE/TFU                 5 μl 
Primer probe mix     1 μl 
Water                       1.5 μl 
Table 2.3: Reaction mix for TaqMan assays. TGE: TaqMan 
Gene Expression Master Mix (Applied Biosystems), TFU: 
TaqMan Fast Universal PCR Master Mix (Applied 
Biosystems) 
 
The relative expression for each gene was analysed using the comparative cycle 
threshold (Ct) method using SDS 2.3 software (Applied Biosystems).  
Ct values for each target gene were normalised to the mean Ct value of the reference 
genes. Normalised Ct values were calculated using the following formula: 
Normalised Ct = 2
-(target assay Ct – reference assay Ct) 
2.18 Qualitative gene expression analysis 
Complimentary DNA synthesised from joint tissue RNA were assessed for gene 
expression using primers shown in Table 2.4 and Table 2.5. The PCR products were 
electrophoresed through a 2% agarose gel and visualised following ethidium bromide 
staining on a gel doc system.  
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Gene Forward primer (5'-3') Reverse primer (5'-3') 
BCL2L13 GGAATTGACAAGACGTGGTC GCTTTCTGTGTGCCAACTCTGG 
BID AGACATCATCCGGAATATTGC AGACATCATCCGGAATATTGC 
MICAL3 CTTTCCAGGAGCTCTGTGAC CCAGTAAGGATAAGTCGATG 
MICAL3 (2) GTGGACTCTGGAAAGCACAG CAGCTTGGCATTCAGTTCCTC 
CHST11 GGAATCCCTTTGGTGTGGAC CAGTAGATGAGCTCGTGGTCC 
 Table 2.4: PCR primer sequences used to detect gene expression in joint tissues 
 
Ensembl 
transcript ID* 
Forward primer (5'-3') Reverse primer (5'-3') 
ENST00000303694 CTATTTCCAAAGTATGTTGCACC CAGTAGATGAGCTCGTGGTCC 
ENST00000549260 CTATTTCCAAATCATGCGGAGG CAGTAGATGAGCTCGTGGTCC 
ENST00000549016 GTGTTCATAGCAGCATGAGTCACG CAGTAGATGAGCTCGTGGTCC 
ENST00000546689 CTATTTCCAAATCATGCGGAGG GGTAAAATGCCAGGCTGTG 
ENST00000547956 CTATTTCCAAAGTATGTTGCACC GGTAAAATGCCAGGCTGTG 
 Table 2.5: PCR primer sequences used to detect expression of different 
transcript isoforms of CHST11 in joint tissues 
* http://www.ensembl.org 
2.19 Database searching for polymorphisms  
HapMap genome browser (http://hapmap.ncbi.nlm.nih.gov/) was used to query the 
genotype frequency and linkage disequilibrium (LD) database to search for 
polymorphisms on chromosome 22q11.21 and 12q23.3 that have been genotyped in 
the CEU population (individuals of European ancestry). Transcribed polymorphisms in 
BCL2L13, MICAL3, BID and CHST11 with high minor allele frequency (greater than 15%) 
in the population were selected using the National Centre for Biotechnology 
Information (NCBI) variation database (dbSNP; 
http://www.ncbi.nlm.nih.gov/projects/SNP/).  
2.20 Restriction Fragment Length Polymorphism (RFLP) Analysis 
Genomic DNA was PCR amplified using primers designed to target the region 
surrounding the SNP of interest. The primer sequences used for each SNP are shown in 
Table 2.6. 
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The PCR products were then incubated with 5μl of a digestion mixture containing the 
corresponding restriction enzyme (5 U; New England Biolabs), 2 μl of the 
recommended buffer (10X; New England Biolabs), 0.2 μl of BSA (100X; New England 
Biolabs) where required and water (Table 2.6). Digestion reactions were incubated for 
3 hours at the optimum temperature for the corresponding restriction enzyme.  
The digested products were electrophoresed through a 2% agarose gel containing 
ethidium bromide. The genotype of each sample was determined by analysing the 
sizes of the digestion products. 
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SNP Forward primer (5'-3') Reverse primer (5'-3') 
Restriction 
Enzyme 
Digestion 
conditions 
rs4488761 GCTTGTCCTTCGTTTCTAGG CAGGATCCATTGCAATCTGC AluI NEB 4, 37 °C 
rs2587100 GGTTTCTCAGCCTTGGCACTAGT CTCTCGCTAAAGCAGTGGGTCTCAATAGGGGATGTTCACA BstNI NEB 2, BSA, 60 °C 
rs9967 CCACTTGTGAGTGCAACTG CCTAGCAAGAGACCCATAGAAC BstNI NEB 2, BSA, 60 °C 
rs11538 CCTTGTGCTGGCATCAGAG CCTACCCTAGAGACATGG Tsp5091 NEB 1, 65 °C 
rs2277831 GGATCACCTATGAAGAAAGAC CAGGGATGGACAGCTAGTGG MslI NEB 4, 37 °C 
rs5992854 GTCGGCCTTCTTCTTCTTGTC GCTCTTTCACTTCATCCGAG BstNI NEB 2, BSA, 60 °C 
rs11917 CCTCAAGCTCACTCCCAAGACCTG CAGGAGAGGATTAGCTGTGC HincII NEB 3, BSA, 37 °C 
rs1057721 TCAGCTATGGCTCTTGGGGTAAGGTGGGAG
GTAAGCTGGATTG 
CATAGTTCGGATCCTGAATGG PstI NEB 3, BSA, 37 °C 
rs4819639 GGTCATGAAAGTGGGACAGGT CCGTGGTCTTGTTTTGGGTTC AluI NEB 4, 37 °C 
rs835487 GGAGTGAGCCAGAACAGATAAG CTCTGCTGGACCAAATTCACG KpnI NEB 1, BSA, 37 °C 
rs835488 TGAATTTGGTCCAGCAGAGTCTGG GAGCCGGATCAGTATCTAGCAAAACC HaeIII NEB 4,37 °C 
rs864454 GCTTCTTAGCACCACCTAAGG GGTTGGCTCTACTGGCTAGACTCCCTCCTAAAGACAAAACCCCATTA AseI NEB 3, 37 °C 
rs835489 GCACCCCTCATAGGGTCATATAGG GCTGACGTCCCAACGCAGTGTGTTCTGTGTTGCCA NcoI NEB 3, 37 °C 
rs835490 CTGGAGATTAGCTGTGTTGTGC GGTTCCAAAGAGAACAGTTCG SmaI NEB 4, 25 °C 
rs1164760 GCTATTTGGAGAGCTTTGCTTG CTCTCTGACCTCGTTTACTGC MspI NEB 4, 37 °C 
rs2463018 GGTGAGACTCGTACACTTGG CTAGCTGTAAGAGGGATGTGG BCCI NEB 1, BSA, 37 °C 
rs2453155 GCATATCTGAGGTCTTCAAGG TTTGAGCCTGAGGAGTAGG NcoI NEB 3, 37 °C 
CHST11 
novel variant 
CTCTCAAACACTGCTGTCCTGCACC GCTTTTCAAGCGGTGGTTGATTTCTGGGATGCTGTACTGGTTCAGGGT HinfI NEB 4, 37 °C 
Table 2.6: RFLP assays used for genotyping
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2.21 Allelic Expression Imbalance (AEI) analysis using Sequenom iPLEX 
assays 
Sequenom assays were designed using the online ‘MySequenom Genotyping Tools’ 
(https://www.mysequenom.com/Tools).  A 300 bp sequence surrounding each SNP 
was imported into the software, which then designs appropriate multiplexed assays. 
The software validates all primers in the multiplex by aligning them against each other 
to check for cross-hybridisation. All PCR primers contain a 10 bp tag (ACGTTGGATG) 
which helps to standardise the primers so that they work more efficiently in a 
multiplex. The extension primers are designed to anneal immediately adjacent to the 
polymorphic site and to differ in mass from each other. Table 2.7 lists the assays 
designed for six transcript SNPs and the OA-associated SNP rs2277831 from 
chromosome 22q11.21, which were in two multiplex groups. 
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Multi
plex 
SNP Forward primer (5'-3') Reverse primer (5'-3') Mass of 
extension primer 
Extension primer sequence (5'-3') 
1 rs4488761 ACGTTGGATGTCTCCA
ACTGTGACCACTTC 
ACGTTGGATGCTTTCTG
TGTGCCAACTCTG 
5127.3 TTACCTGTGTCACTGTC 
1 rs2587100 ACGTTGGATGCCCAGA
GATGACAAACGAAA 
ACGTTGGATGAAGCAG
TGGGTCTCAATAGG 
5443.6 GACATTGCCAAATGTCCC 
1 rs2277831 ACGTTGGATGTGAAGA
AAGACAATGCCAGG 
ACGTTGGATGGAAGAA
GAAAAGACTGGAGC 
6126 AAAGACTGGAGCCATTCCTG 
1 rs11917 ACGTTGGATGTGGTGT
GTTTCTTTGTGAG 
ACGTTGGATGAAGCAC
GACAACTTGGTTT 
7032.6 TGTGTAACTTTGTTTTTGCCGTT 
2 rs9967 ACGTTGGATGAACTCT
GGCTAGAGAGACAC 
ACGTTGGATGGGCTGA
AGAGACCTCAGAAG 
5277.5 AAGGCAGGAGGATAACC 
2 rs1057721 ACGTTGGATGGCTTTT
TAGTGGAGCAAGAG 
ACGTTGGATGACACATC
ACCGTCAGCTATG 
5659.7 GGGAGGTAAGCTGGATTG 
2 rs4819639 ACGTTGGATGATGTCC
CATCACGGTGCAG 
ACGTTGGATGATTCTGC
GTCCTGTTCCCTG 
6194.1 AGACAGGAGAGCAGCCACAG 
 Table 2.7: Sequenom assays designed to the seven SNPs from chr22q11.21. The assays were grouped in two multiplexes. 
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Prior to the experiment, an extension primer mix was prepared by sorting the primers 
into four groups based on their mass. This is necessary because the primers with the 
highest mass generate a lower peak intensity compared to primers with a lower mass. 
Hence, the extension primers are adjusted by concentration to ensure that they 
generate peaks with equal intensity. Therefore the concentrations were doubled in 
high and low mass primers in four groups, such that the first group of lower mass 
primers are mixed at 7 μM, the second at 9.33 μM, the third at 11.66 μM and the 
highest mass group at 14 μM. The extension primer mixes prepared for the two plexes 
are shown in Table 2.8. 
A 
SNP 
Mass of 
extension 
primer (Da) 
Concentration 
in cocktail (μM) 
Volume in 
cocktail (μl) 
rs4488761 5127.3 7.00 8.75 
rs2587100 5443.6 9.33 11.66 
rs2277831 6126 11.66 14.58 
rs11917 7032.6 14 17.50 
  
Water 322.51 
  
Total 375 
 
B 
SNP 
Mass of 
extension 
primer (Da) 
Concentration in 
cocktail (μM) 
Volume in 
cocktail (μl) 
rs9967 5277.5 7.00 8.75 
rs1057721 5659.7 9.33 11.66 
rs4819639 6194.1 11.66 14.58 
  
Water 340.01 
  
Total 375 
 
Table 2.8: Extension primer mix prepared for multiplex 1(A) and 
2(B). Primers with lowest mass were used at 7 μM and those 
with the highest mass were used at 14 μM. 
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Patients who were heterozygous for one or more of the six transcript SNPs were 
selected for AEI analysis. The gDNA and cDNA were amplified in four replicates using 
the Sequenom primers listed in Table 2.7 in multiplex. A multiplex PCR primer mix was 
prepared by adding 0.075 μl of each forward and reverse primer at a 100 mM stock 
concentration to give a final concentration of 0.5 mM for each primer in a 15 μl PCR 
reaction. This was added to 0.75 μl of 10 mM dNTP mix, 1.875 μl of 10X PCR buffer 
(500 mM KCl, 100 mM Tris-HCl pH 8.3), 1.2 μl of 25 mM MgCl2 and 0.2 μl of AmpliTaq 
Gold DNA polymerase (5 U/μl, Applied Biosystems). The reaction volume was made to 
14.5 μl by the addition of H2O. Twenty nanograms of genomic DNA and 0.5 μl of cDNA 
synthesised from 1 μg of RNA were added to the reaction mix. The PCR conditions 
were; 94 °C for 14 minutes, 35 cycles of 94 °C for 30 seconds, 57 °C for 30 seconds and 
72 °C for 30 seconds and then 72 °C for 5 minutes. The reactions were performed in 
four replicates to assess experimental error. A ‘no template control’ (NTC) was also 
included in every PCR. The PCR products were analysed on a 2% agarose gel containing 
ethidium bromide to confirm successful amplification.  
A 5 μl aliquot of each PCR product was transferred to a 384-PCR well microtitre plate 
and was transferred to Newgene (Newcastle upon Tyne, UK), where it was then 
processed using the protocol summarised below.  
Five microlitres of PCR product was incubated with 0.5 U of Shrimp alkaline 
phosphatase (SAP; Sequenom, Hamburg, Germany) at 37 °C for 40 minutes and 85 °C 
for 5 minutes to dephosphorylate unincorporated dNTPs. The multiplex extension 
reaction was then carried out in a 9 μl volume with 10X iPLEX buffer, iPLEX termination 
mix, extension primer mix (primers at 7 to 14 μM each in multiplex pool) and iPLEX 
enzyme (Sequenom). The extension reaction products were then purified with 
SpectroCLEAN (Sequenom), a cationic resin that removes residual salts including Na+, 
K+ and Mg2+ from the reaction. The purified products were arrayed on to spots on a 
SpectroCHIP which contains 3-hydroxypicolinic acid, the appropriate matrix for matrix 
assisted laser desorption ionisation-time of-flight (MALDI-TOF) mass spectrometry. The 
chip was placed in a MassARRAY analyzer (Sequenom) mass spectrometer and the 
spots were excited with a laser under a vacuum. The matrix absorbs the laser light 
energy causing the sample molecules to vaporise and ionise, which are then 
transferred electrostatically into the mass spectrometer tube (Gabriel et al., 2009). The 
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molecules are detected individually at the end of the tube based on their flight time 
and are analysed by the SpectroTYPER software (Sequenom).  A peak is generated for 
each extension fragment at the expected mass, which corresponds to the amount of 
each allele in the sample analysed.  
The peak height ratios were calculated for genomic DNA and cDNA. The average peak 
height ratio for gDNA, which represents the 1:1 ratio, was used to normalise the cDNA 
peak height ratio to generate a normalised allelic ratio using the following formula: 
Normalised allelic ratio = Average allelic ratio of cDNA/average allelic ratio of gDNA 
2.22 Allelic Expression Imbalance (AEI) analysis using real time quantitative 
PCR genotyping assays 
Ready-made quantitative real time PCR genotyping assays were used (Table 2.9). These 
are standard real time assays except that they employ a probe (FAM or VIC labelled) 
specific to each of the two alleles of a SNP. Real time PCR was carried out according to 
the manufacturer’s instructions. In brief, 4 μl of gDNA diluted to 5 ng/μl or 4 μl of 
cDNA corresponding to 10ng of RNA were added to 5 μl of TaqMan Universal Master 
Mix II no UNG (Applied Biosystems) and 0.25 μl of 40X or 0.5 μl of 20X TaqMan assay 
(Applied Biosystems) in a 10 μl reaction. The samples were then amplified on an ABI 
PRISM 7900HT Sequence Detection System. Table 2.9 shows the cycle conditions for 
each assay. The reactions were performed in four replicates for assays rs11538 and 
rs5992854. For assay rs2463018, 5 replicates were performed for gDNA samples and 5 
to 10 replicates were performed for cDNA samples.  The allelic ratios were calculated 
using the formula (2^-FAM Ct)/ (2^-VIC Ct) and normalised to the allelic ratios of gDNA.  
 
Gene SNP PCR cycle conditions 
BID rs11538 50 °C for 2 minutes, 95 °C for 10 minutes and 40 cycles of 92 
°C for 15 seconds and 60°C for 1 minute MICAL3 rs5992854 
CHST11 rs2463018 
50 °C for 2 minutes, 95 °C for 10 minutes and 40 cycles of 92 
°C for 15 seconds and 60 °C for 90 seconds 
Table 2.9: Real time quantitative genotyping assays used for AEI analyses 
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2.23 OA patients used for coding DNA variant detection in CHST11 
DNA previously extracted from the peripheral blood of a total of 751 OA hip cases 
were analysed for DNA variant detection in the CHST11 coding region. In 192 of the 
cases the CHST11 coding sequence was sequenced to detect novel variants, which 
were then genotyped in the remaining 559 patients to accurately assess allele 
frequency. The 751 patients were composed of 281 males and 470 females and they 
derive from a large UK cohort that has been described in detail previously (Southam et 
al., 2007).  
2.24 Sequence analysis of the three exons of CHST11 
Primers were designed to amplify the coding region of CHST11 (Table 2.10, Figure 2.1). 
Exon 1 was amplified with a single primer pair (amplimer 1) as was exon 2 (amplimer 
2), whilst two primer pairs (amplimers 3 and 4) were used to amplify the larger exon 3. 
The primers contained 18 bp tag sequences (M13 forward primer 
5'TGTAAAACGACGGCCAGT3'; M13 reverse primer 5'CAGGAAACAGCTATGACC3') to 
ensure that consistent sequencing conditions could be used. The annealing 
temperature and final MgCl2 concentration for the 15 l PCR reactions for all four 
amplimers were 55 °C and 1 mM respectively. Each PCR reaction contained 50 ng of 
genomic DNA. For amplimer 1, 3.75 µl of Betaine (5 M, Sigma) was added to each PCR 
reaction. 
PCR products were incubated with 2.4 µl of SAP (2.4 U; Fisher Scientific, 
Loughborough, UK), 0.6 µl of Exonuclease I (12 U, New England Biolabs) and 1.4 µl of 
10X Exonuclease I reaction buffer (New England Biolabs) at 37 °C for 15 minutes and 
80 °C for 15 minutes. One microlitre of PCR product was diluted with 9 µl of water and 
transferred to Genome Enterprises (Norwich, UK) for Sanger sequencing using the M13 
forward primer 5'TGTAAAACGACGGCCAGT3' for amplimers 1, 2 and 3, and the M13 
reverse primer 5'CAGGAAACAGCTATGACC3' for amplimer 4. 
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Amplimer Target exon Forward primer (5'-3') Reverse primer (5'-3') Size of amplimer (bp) 
1 Exon 1 TGTAAAACGACGGCCAGTGCATCTCAGCACTTCCAGACC CAGGAAACAGCTATGACCGGAGCCGGTAGGAAGAAGAGG 558 
2 Exon 2 TGTAAAACGACGGCCAGTATCTAGATCCTTCTGGGTGTG CAGGAAACAGCTATGACCGGAGAAAGCAACCACTGAAGG 443 
3 Exon 3 TGTAAAACGACGGCCAGTAAAGGCATGAGCCACTGCAC CAGGAAACAGCTATGACCCTTCTGGGTGAACTTGTTG 534 
4 Exon 3 TGTAAAACGACGGCCAGTACATGAAGTTCCTGTTTGTCC CAGGAAACAGCTATGACCTAATTCTCACTATGCTGCTCG 661 
Table 2.10: Primers designed to amplify and sequence the CHT11 coding region. The M13 sequences are shown in bold. 
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Exon 1  
 
ATATATAGATCGTTGGAGCGCAATGAAGTAGCCTTTGGAGAGAAGGGAGAGGGCCCGTCGGACAGCCACA
GCGGCCAGCGCAGCGGCAGCGGCGGCGGCACCACCATCACCGCTCGCACCCCAGCCGCCCGGCCCGCGAC
CAGGCAGCGGCGGCCGCCGGCGGGATCGGAGGAGGCGGCGGAGCGGCGAGGAGGAGGAGCAGGAGCGCGC
AGCCAGCGGGTCCACGCATCTCAGCACTTCCAGACCAACTCCGGCACCTTCCACACCCCTGCCCGGGCTG
GGGGCTCCGAGAGCGGCCGCGAAGCGACTCCGATCCTCCCTCTGAGCCTTGCTCAGCTCTGCCCCGCGCC
TCCCGGGCTCCGGTCCGCGCGGCGGGGTCCCTGCTCCTGCGCCCCGGGCGCGCTTCCCGGACACCCCGGT
CCCCGCAGCCAGGACAAAGCCATGAAGCCAGCGCTGCTGGAAGTGATGAGGATGAACAGAATCTGCCGGA
TGGTGCTGGCCACTTGCTTGGGATCCTTTATCCTGGTCATCTTCTATTTCCAAAGTATGTTGCACCCAGG
TAGGGGGCGCGTTAGCGTGGTTTTGTTGGATATTTTCTTCTCTCTCGCGCTCTAGCTCGCTCCGCCTGAT
TTCTGCCTCTTCCAACCCTACCTCTCCGCCTTCGGCCTCTTCGGGGCTCCTGGCTGCCCAGAGCTCCTGG
CTGCCCAGATCTACCCGGGTCACCGCGTCGGGATGGGGAGGAGAAGGGAAGGTGTGCTTCGCCCTCTTCT
TCCTACCGGCTCCGGGCTGGAGGATGGGACCAGGAGGGGCGGTAGTTTTTTTTTTTTTTTTTTTCTTCTT
CTTTTTTTCTTTGTGTCCCTTGTCTGTCTGTCTGCGAGGTAGCAGGGAAACGGAGAGGTG 
 
Exon 2 
 
CTTGCTGTCTTGAAGCAGCCATTACGCCATCTTTTGTAAGTGGTTTCATTTCAATGAGCTTTAGATGCCT
GTCCTGTTTTCTTAAAACACTTGCTGGGGAGACTTTTTAGCATGATCTAGATCCTTCTGGGTGTGGAGAT
GCCTGAATGTTGGGAAGACAGACAGCAGCTGTGCTGTTGGAGAAGGGACAGTGTGGAAATCTTCCTTTGC
TAGAAGCTGGTTTTCTCTTTCTTTCCTGCCTGTTTCTTCTTCCCTACTCTGTGCCTTTTTCTTTGACAGA
CAACAAATCTTTGTTGCTCATTTCTGATGAGCCTTCACTTTCTTTCCTCAGTCATGCGGAGGAATCCCTT
TGGTGTGGACATCTGCTGCCGGAAGGGGTCCCGAAGCCCCCTGCAGGAACTCTACAACCCAATCCAGGTA
AGCTTCAAGCACTCTGTCAGCATGTGAATTTTTTTTTTTTGTAGGTATGGATACTAAAAACTCTAAAATT
GTGGTCTTTGGGGGATTTAAAACTTCCTTTCACAGCCTGGCATTTTACCTTCAGTGGTTGCTTTCTCCGT
CACCCTTTTTCTATGTAGCATCTCTGAAAAATCTAGCAGGGGATGTTTAGAATTAGAGAAATGCCTAGGT
TTAGTGCTAAGCATTCAGACCTGCCCAGGGTTTGAACTCCTGAGA 
 
Exon 3 
 
TGAGGTCTCACTATGTTGCCAAGGCTGGTCTTGAACTTGTGGCCTCAAGCGATCCTCCTGCCTCAGCTTC
CCAGAGTGCTGGGATTAAAGGCATGAGCCACTGCACCCAGCTTAGATATGTGTTTGAACGGGTGGATTTA
TGATCTACTTGTAGCCAAGTGGAAATGTTTCAGGCAAGTACTGAGTTCTTATTCGTCTTGTGTCTCCTCT
GCAGCTGGAGCTCTCAAACACTGCTGTCCTGCACCAGATGCGGCGGGACCAGGTGACAGACACGTGCCGA
GCCAACAGCGCCACAAGCCGTAAGCGGAGGGTGCTGACCCCCAACGACCTGAAGCACTTGGTGGTGGATG
AGGACCACGAGCTCATCTACTGCTACGTGCCCAAGGTGGCCTGCACCAACTGGAAGCGGCTCATGATGGT
CCTGACCGGGCGGGGGAAGTACAGCGACCCCATGGAGATCCCGGCCAACGAGGCACACGTCTCCGCCAAC
CTGAAGACCCTGAACCAGTACAGCATCCCAGAAATCAACCACCGCTTGAAAAGCTACATGAAGTTCCTGT
TTGTCCGGGAGCCCTTCGAGAGGCTAGTGTCCGCCTACCGCAACAAGTTCACCCAGAAGTACAACATCTC
CTTCCACAAGCGGTACGGCACCAAGATCATCAAACGCCAGCGGAAGAACGCCACCCAGGAGGCCCTGCGC
AAAGGGGACGATGTCAAATTCGAGGAGTTTGTGGCCTATCTCATCGACCCACACACCCAGCGGGAGGAGC
CTTTCAACGAACACTGGCAAACCGTCTACTCACTCTGCCATCCCTGCCACATCCACTATGACCTCGTGGG
CAAGTACGAGACACTGGAAGAGGATTCTAATTACGTCCTGCAGCTGGCAGGAGTGGGCAGCTACCTGAAG
TTCCCCACCTATGCAAAGTCTACGAGAACTACTGATGAAATGACCACAGAATTCTTCCAGAACATCAGCT
CAGAGCACCAAACGCAGCTGTACGAAGTCTACAAACTCGATTTTTTAATGTTCAATTACTCAGTGCCAAG
CTACCTGAAATTGGAATAAAGGGGGTGGGGAGAGGGAGAGAATCATGCTTTTTAATTTAAGATTTTTATT
TGTCAAAAGAATTATATGGATATTGGGTTATTTTGTAAATTAATATTTCTTTGGGGATGATGCTGCGAGC
AGCATAGTGAGAATTATTTAAAATCCTTCGTAGGGAAGGACAGCTGTCTTTGCAGGGGAAATAGGATGGG
TCGTCCTTGTCTGTAGAAGTGAATACTGCAACACTGTCTCAAAGGTTTCTTGTGTTCTGGTGAATTCCAT
GAATTGTGCATTCCATAAATTCTAATTAATATTATTTATAGTTATTTAAACATGGTCTCATTATTTCTTT
TTGTGGCAGCAAAATTCTAACATCTTTCCAGAAGAAATCTATGATTCCTGCTTTGCTTGCTACAGCTCAT
TTGGGGGCATGAATGTTCTCCTTACTAACCTCTCATGGAGTCATGTGATAACAGCCATTGTCATGTGTAT
GGATGCCACCATTCTTGAATTTCTGCTAGAAATAAGTAGGTTGCTATTGCACTTAGAGTCATCTTTGCAA
GGGACTCATTCCAAACCAATTCCAATCGACCTGAAAGTCCCTTGCACTAAAGAAATGTGATTTTTTTTTA
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ACCCAAGGAGAAAGTTGGTTGTAACAATTTTTCACCAGAATTAGCAATCTGATAGAATAGGCTTTTTTAA
CAGGAATTTTAAACTGGCGGTGCCAGTTGCAGTGAAGGTGAAGTGGCTATTGCTTTATATTCGACAAATA
TTTATTGAGCATCTACTATATACTAGGCCCTGAAGATAGAGCGTTGAACAAACCCAATAGTCTTGGCCCT
CAAAAAGCTTTATGTGACATAGAGCATCCAGCTCGACAATTAGCAAACCCCTGATATTATTCATGGACTT
GACATGAGGTTTGGACTATTCATGAGCAACAGCAGAAGGTCCATGACCCCTACAAATTTACATTTTTCTA
TGGCCCATATTTGAAAACCTCACATTCGGAGCAGGCCACTTTATATTCGTGAGTGATCCCAAGCTCACTG
ACCAACAGAAAAGATGCTAAAAAAATGTGTCCTATCATGTGCCTGCTCCAACTGATGGGTAATGTCTGCC
TTTAAGCCCCAGAATGGATTCTCCAGGCACAGTGTGGAAGAGTGCTGTGGTTGATTAGCAATGTCTGCCT
TGGGTGAGGAAAGGGGAACACTCCTCAAGTGCCTCCTACTGTCATCTCCATTCAGCCTAGCACCACATCC
CCATGTAGAAGTGTTGTCTTCTACTGCTTGCCACGTACAAGTGTGAAATGCCAAGGTGAGACTCGTACAC
TTGGGGATTTGCAATGGTTTTTACCCCTCATGAAGGTCAGAGGTGGACTATTTGTACACATACACACATG
CACACCCTCTCACGTCCTCCAGAGGCTGAAAGACTATCAGCATCTTGGTAACTGCCATGCATGAGCAGCA
AGGACAGCCTTCCATAATCCATGCCCCATTTCCTCTGGAAGCCTGGAAACTTTTCATTTCCTGTTCCTTG
CTAATTAACATCTAAACATGCTTCTCATTTCCAGCCATTGCTGATGCTTCTCAGTTGAAGTTTGAGCCAC
ATCCCTCTTACAGCTAGTGAATGAGTTGGTAGCAGCTACTGTATATAATAATAATAATAGTTTTAATAAT
AGGGGAGGGTGGGATGGGGTGTGGGTAAGTTTTGCCTTTTGTTTTGTTTTTGATGCCGTATATAGTGAAG
GGGTGAGGATATTCTAAACAAACAAAAATTGAATAATTTATTCACAGAAACTATTAAGATTGTATTGTAA
AGCTCACAGCAAGCTCAGTGGGCAGCAGCTGCAACATCTCACCGGGGAAATTATTTTATTTAACGTGAGT
GAGATGTGGGCCGGAGAAGGTAGCTGAAGCTATTTATAAAACGTTGTGTACCTTCTTCCGAGCTCTCTCC
CCTTTGTGAAGGGCGCAGCAACTATACCCTTGATGGATGGAGATTTACGCAATGTGTTTTACTGGGTAGA
GTGACAGACCTTGGCTGTCCCTGGAATTGAGAATCTGGACCTTATTTCCAGGCAGAGAACACTGTCCTCA
GAAATGGGACTTCTGATAATGAAACAGGTTGTCCAACATTTTCTAATACGCATTCTACAGAACACAGGTT
CCAGGAGGCATCAGGTTGGTGTGATGCAGACTAAGGGTTTTGTGGTCAAATATCCTTAAGAAACAAAGTT
AAGTCAGTTTCCTTTCTGCAAGGACTTTTCAGCCTTCAATGTGTGCTGTGCATGGTGAATCCCCAAAAAT
AATCCTTGAGTCTGTAGCATTTCCTGAACTTACATGACCAGGATACTCTATTTTGCAGATCACCCCACAG
AGCTAGGGTTCCACCGAGTATACTTTGCTTAGGTTGACTTAGCATATCTGAGGTCTTCAAGGATAAAAAC
TGCCACCCCAACACCCTTCCATTAAAAAAAAAATACAAAATAGCACCACAGTCTCCATCTGGTTTATAGC
AACAGAGGTACTTTATTTAATGAAGCAATGGTTCTAATCCTGGATACTGCCACGGACTACAATTCTATCC
CTCCCAGAGGGAGTGGAGGAAGTCTTGGGTGGTGTGGACAGAAGGAAGAGAGGAGAGGGTGAGTGGGGTA
TAGGGCCCAGGGTGGCTCCCTACTCCTCAGGCTCAAAAGGATGCTCAGTGGGAACAGATGATCTCTTGAT
GAGTGCTTCTTCAGTTTCATAGTTTGGAATCGTTCACTGTGTGCTTTTTGGGGGGTTTTCAATGGAAATT
CACGTTGCTTTGCATTTCTGTGTCCGTCTTTGGTCAGTTGTGCAAGCCTGCTCACTGTCATGTGAAGATG
GCCTTTCATCTGGCTTCTCTCTCTTAAGTGAGAAAGATTGTCCTTCAGGGGACATGACATCAATAGGTTT
CTGGAATGAGGGACTCTTTCTCCCCGTGTTTTGCTTTGTGTTCACATTTTCTTTTCTAATGGCATTGAAA
CTTTAAAAAAAATGGATTCAACTGTTTTTGCAGAATGTAGAAAGTATTCTGTGTCCTTGGTTAAAGAAAT
CCACTTGTGAAGTGTGCCTGGAAAATGAAAGTTTGTGTTTTTTAAAGAGGAATATTTGAAACTGCTTTCT
ATGCATGCTTAGCTGGAGAAAAGTACAGGCAGGCGTCCCATCTCCCAGCCACTTCTCAAAGGTGCTGCTG
TGTTTTAAAGACCAGGTACAGCCAGGGCAGTATTTGCAAGGACATTCCTGCTTACTTTATCCCTTTGGTT
GGAAAGCTCTAGATGATTCCCGCAGCTCCTCCAGACCCCGCCTCCCTGCCCTCCCCAGCTGGTCTGGGAA
GAGGTGGTCTGCTGACCTGTGGTATCTCAGAGGGGACGTTCCTCCTCCTCCCTGTGCACCAGGTGGGCTG
CACCCTCCTGCCTATTCAGGATGTGGATGCCACAGGAGAGCAGCAGGCAGTGGAAACTTCAGTTGCACTG
GTTCTCCTGGTGGCAAAGGCATGAAGCACAGGGGTCGATTAATCCAGGCTACTAGAAAGCTCCAGAGCAA
AGTGTGCGGGTCCCACAAATGCTTGGCTGGTGGGGTCTGGATCAGTGCTGAGATAGAGTTGGCAGAAGAA
GCAGAGGCACTCTGCTTGCTTTCCTAGCCAGTCCTCCCCTACACACACACACACACACACACACACACAC
ACACACAATCTCAGCTGCGCCATTCTGTGCAATCCCAGTGACCAAATCCCTTCCTTGCCCACCTCTATGT
CAGCAGGACTGACCACATCACTCCCCCGAGTTCCCACCACCAGCATTTCCTCCAACCTTTTTCCATCACA
ACCAGTTAGAACCCTACAGGCAACAAGGCCTTCTAGAATCCGCTTAACCCTTGGCTGATAACAGGCAAAT
TTCAGTCTGCTACACTTTGTTAGGTCCAGAAGGAGCTGCCCATACTACTTTCTTATGAGCATGCTCAGTA
TGGCATATGGACATGTAATGTCACATCTTTGTGGAGTGTGATTTTCTTTTTTCACATATTTGTATGCAGT
AGAGAGCCTGTTGTAGAAAACGCTCCCTGTATCTTGCTGTACTGTTAAAGAAAGCTGAATTCCACATTGC
CAACAAAAGCGTGAAAATGTTCATGAACCTTCCTCCAGGAAAAGCCATTCAAGCCTGATTATTTTTCTAA
GTAACTTCAATTAAATTGAAGAAAAAAGAA 
 
 
Figure 2.1: Amplimers designed for sequence analysis of CHST11 coding region. 
Untranslated regions are highlighted in yellow. Exons are highlighted in red with             
alternating colours for codons. Primer sequences for amplimers 1, 2 and 3 are underlined. 
Primer sequences for amplimer 4 are shown in blue bold text. 
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2.25 Human mesenchymal stem cell culture 
One million cryo-preserved human bone marrow mesenchymal stem cells (hMSC) from 
two donors (a black male aged 22 and a black female aged 24; Lonza Biosciences) were 
resurrected from liquid nitrogen storage and cultured in monolayer in Mesenchymal 
Stem Cell Growth Medium (Lonza, cat no. PT-3001) supplemented with 5 ng/ml 
fibroblast growth factor-2 (FGF2; R&D Systems) in 75 cm2 flasks.  
2.26 siRNA transfection 
On-TARGETplus SMART pool human CHST11 siRNA (Dharmacon, Thermo Scientific, cat 
no. L-008882-01-0005) was resuspended in 250 μl of 1X siRNA Buffer (Dharmacon) to 
make 20 μM siRNA. On-TARGETplus control pool Non-targeting siRNA (Dharmacon, cat 
no. D-001810-10-20) at 20 µM was used as a control. 
Chondrocytes from eight OA and one NOF patient were cultured in DMEM culture 
media at 37 °C until they reached 80% confluence. The cells were lifted off the surface 
using trypsin, counted and seeded at 10,000 cells/well in 200 μl of media in a 96- well 
plate for gene expression analysis.  Eighteen wells of the 96-well microtitre plate were 
used for six replicates for three different treatments. Untransfected cells and cells 
transfected with non-targeting (NT) siRNA were used as controls. Six wells were 
transfected with siRNA against CHST11.   
For western blot analysis, chondrocytes were seeded at 350,000 cells/well in 2 ml of 
media in 3 wells of a 6-well plate, for the 3 treatment groups.  
Mesenchymal stem cells, once 80% confluent, were trypsinised, counted and seeded in 
three 10 cm tissue culture dishes (for untransfected, NT siRNA and CHST11 siRNA) with 
1.2 million cells in each dish.  
The cells were cultured at 37 °C for 24 hours and transfected with Dharmafect 
transfection reagent 1 (Dharmacon). Table 2.11 shows the master mixes that were 
made for each of the culture conditions. 
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 96-well plate 6-well plate 
10 cm culture 
dish 
siRNA (NT or 
CHST11) 
0.5 μl siRNA + 
14.5 μl SFM 
5 μl siRNA + 
245 μl SFM 
35 μl siRNA + 
665 μl SFM 
Transfection 
reagent 
0.26 μl TR + 
14.74 μl SFM 
3.25 μl TR + 
246.75 μl SFM 
14 μl TR + 
686 μl SFM 
Total volume 30 μl 500 μl 1.4 ml 
Table 2.11: Mastermixes for siRNA transfection. NT: Non-targeting siRNA, SFM: Serum Free 
Media 
First, siRNA/media mix and transfection reagent/media mix were incubated at room 
temperature for 5 minutes before combining. Then the reaction mixture was 
incubated at room temperature for 20 minutes. Cells were transfected in 100 μl, 1 ml 
and 7 ml in 96-well, 6-well plates and 10 cm dishes respectively, by removing the 
required amount of media already in the wells. The cells were incubated at 37 °C for 48 
hours. The cells in 96-well plates were lysed and the lysate was reverse transcribed for 
gene expression analyses. The 6-well plates were used for protein extraction and 
western blot analysis. Following transfection the mesenchymal stem cells were carried 
forward for chondrocyte differentiation experiments.  
2.27 Differentiation of transfected hMSC to chondrocytes 
Three 10 cm dishes were cultured with 1.2 million cells each for three different 
treatment groups; untransfected, cells transfected with NT siRNA and cells transfected 
with siRNA against CHST11. Forty eight hours post transfection, the cells were isolated 
with trypsin and 1.5 million cells from each dish were centrifuged at 240 x g for 5 
minutes at room temperature. The cells from each disc were to be differentiated into 
three cartilage discs to be processed for gene expression analyses at days 3, 7 and 14 
during chondrogenesis.  The remaining cells in the dishes were centrifuged, the cell 
pellet was washed with PBS, resuspended in 250 µl of Trizol reagent (Ambion) and 
stored at -80 °C to be used as a day 0 time point. RNA was extracted from these cells 
using the Trizol/Chloroform method and used for gene expression analyses.  
The centrifuged cells were washed with pre-warmed PBS and were centrifuged at 240 
x g for 5 minutes at room temperature. The PBS was removed and the cells were 
resuspended in 450 µl of chondrogenic differentiation media consisting of 47.5 ml of 
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DMEM containing 4.5 g/l glucose (Lonza, cat no. 12-614), 10 ng/ml TGF-β3 (PeproTech, 
London, UK) 100 mM dexamethasone (Sigma), 50 µg/ml ascorbic acid-2-phosphate 
(Sigma), 40 µg/ml proline (USB, High Wycombe, UK), 1X Insulin, Transferin, Selenium, 
Linoleic acid premix (ITS+L; BD Biosciences, Oxford, UK), 500 µl of 2mM glutamine 
(Sigma) and 500 µl of 100 U/ml penicillin and 100 µg/ml streptomycin mix (Sigma). 
Millicell 0.4 µm hanging PET cell culture inserts (Merck Millipore, Watford, UK, cat no. 
PIHT12L04) were placed in a 24-well plate (VWR) and 150 µl of cells were transferred 
to each insert. The plates were spun at 200 x g for 5 minutes at room temperature and 
750 µl of differentiation media were added to the bottom of the wells, such that the 
cells received media from above and below. The surrounding empty wells were filled 
with 1 ml of PBS to avoid evaporation and the plates were incubated at 37 °C. The 
media above and below the inserts were replaced with fresh differentiation media 
every two days and up to the 14 days.  
At each time point, the media from the Transwell inserts was removed and replaced 
with PBS to wash the membrane and the disc. The membrane containing the disc was 
cut using a scalpel blade and the disc was weighed on a piece of parafilm to obtain the 
wet mass. The discs were placed in 1.5 ml eppendorf tubes and stored at -80 °C until 
all time points were reached. 
2.28 Cartilage disc grinding 
The eppendorfs containing the cartilage discs were placed on dry ice and 20 µl of 
molecular grinding resin (G-Biosciences, St. Louis, USA) was added to each tube. The 
tubes were spun at 13000 rpm for 30 seconds at room temperature and the water was 
removed from the tubes. For RNA extraction, the discs were ground using a pestle in 
250 µl of Trizol reagent (Ambion), until the disc disappeared. The tubes were 
centrifuged at 13000 rpm for 30 seconds at room temperature and the supernatant 
was transferred to a fresh tube. RNA was extracted using the Trizol/chloroform 
method. For protein extraction, the discs were ground in 250 µl of protein lysis buffer 
using a pestle. Protein extraction was carried out following the method outlined in 
section 2.13. 
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2.29 RNA extraction (Trizol/chloroform method) 
The cell pellets or ground cartilage discs resuspended in 250 µl Trizol were incubated 
at room temperature for 5 minutes. To each tube, 50 µl of chloroform (Fisher 
Scientific) was added and the tubes were shaken vigorously and incubated at room 
temperature for 2 minutes. The tubes were centrifuged at 4 °C at 13000 rpm for 15 
minutes. The aqueous phase was transferred to a fresh tube and mixed with 125 µl of 
isoproponol. The tubes were vortexed, incubated at room temperature for 10 minutes, 
and centrifuged at 4 °C at 13000 rpm for 10 minutes. The supernatant was discarded 
and the pellets were washed with 250 µl of 75% ethanol made up in DEPC-treated 
water (Invitrogen). The tubes were vortexed and spun at 4 °C at 10000 rpm for 5 
minutes. The ethanol was removed, the pellets were left to air dry for 10 minutes and 
resuspended in 20 µl of DEPC-treated water. The RNA was quantified using a 
NanoDrop 1000 spectrophotometer and the RNA was stored at -80 °C. One microgram 
of RNA was used for cDNA synthesis. 
2.30 Micromass culture of transfected chondrocytes and mesenchymal stem 
cells 
Chondrocytes and mesenchymal stem cells grown in monolayer were transfected with 
NT siRNA and siRNA against CHST11 in 6-well cell culture plates and 10 cm dishes 
respectively. After 48 hours, the cells were trypsinised, counted and centrifuged to 
obtain a cell pellet. The cell pellet was resuspended in the required amount of media. 
Chondrocytes were cultured at high density at 400,000 cells per well in 20 µl of 
complete chondrocyte growth media in 24-well culture plates. Mesenchymal stem 
cells were seeded at 250,000 cells per well in 15 µl of differentiation media in 24-well 
culture plates. The cells were left for two hours in a 37 °C incubator to allow the cells 
to adhere to the bottom of the wells, and were then submerged in 400 µl of media. 
Seven replicates were made in total for NT siRNA and CHST11 siRNA transfected cells. 
Three replicates were utilised for Alcian blue staining, two replicates for gene 
expression analysis and two for western blot analysis. The cells were incubated at 37 
°C for 5 days. For gene expression and western blot analysis, the media was removed, 
the cells were washed in PBS and scraped off the surface of the well using a pipette tip. 
The cells in PBS were transferred to an eppendorf tube and pelleted by centrifugation 
at 13000 rpm for 5 minutes. RNA was extracted using the Trizol/chloroform method 
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(Chapter 2.29). Protein was extracted by following the method described in section 
2.13. 
2.31 Alcian blue staining 
The media was removed from the cells and washed in 1 ml of PBS. The cells were fixed 
with 500 µl of 100% methanol overnight at -20 °C. The methanol was removed and the 
cells were washed with 1 ml of distilled water and incubated with 500 µl of 1% Alcian 
blue solution (0.5 g Alcian blue 8GX (Sigma) in 50 ml of 0.1 M HCl, pH 1) overnight at 
room temperature on a rocker. The Alcian blue was removed and the cells were 
washed with distilled water for two hours. The cells were then incubated with 200 µl 
of 6 M guanidine hydrochloride (0.57 g of guanidine hydrochloride (Sigma) per 1 ml of 
water) for two hours at room temperature on a rocker. One hundred microlitres of 
guanidine hydrochloride was transferred to a 96-well glass microtiter plate and the 
absorbance was measured at 600 nm using a microplate reader (Tecan). The 
absorbance was normalised to the average protein content of the cells (absorbance/µg 
of protein). 
2.32 Statistical analysis 
GraphPad Prism software was used for generating graphs and statistical analyses. A P- 
value of less than 0.05 was considered significant. 
2.32.1 Luciferase activity  
The absorbance measurements for firefly luciferase were divided by that for Renilla 
luciferase. A two tailed student’s t-test was used to compare the normalised values for 
untreated cells versus cells stimulated with exogenous growth factors.  
2.32.2 Gene expression analysis post stimulation with exogenous growth 
factors  
The gene expression relative to housekeeping genes (2^-delta Ct) was calculated for 
each treatment. A two tailed student’s t-test was performed to compare the untreated 
cells against the treated cells. A Wilcoxon signed rank test was then performed on the 
fold change in gene expression for each gene analysed, to determine if the data 
deviate significantly from a hypothetical value of 1, which signifies no change in gene 
expression.   
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2.32.3 Gene expression stratified by genotype 
Linear regression analysis was used to determine if the gene expression relative to 
genotype differed significantly from the null. 
2.32.4 Allelic expression imbalance analysis 
Tissue samples were considered to show an allelic imbalance if the fold difference in 
expression from the two alleles was 20% or greater. The normalised allelic expression 
ratios were plotted against the genotype at the associated SNP. A Kruskal-Wallis test 
was performed to assess the association between allelic expression imbalance and the 
genotype. 
2.32.5 Gene expression analysis post transfection with CHST11 siRNA 
The gene expression relative to housekeeping genes was compared between cells 
transfected with NT siRNA and cells transfected with siRNA against CHST11 using a two 
tailed student’s t-test. A Wilcoxon signed rank test was then performed on the fold 
change in gene expression for each gene analysed, to determine if the data deviate 
significantly from a hypothetical value of 1, which signifies no change in gene 
expression.   
2.32.6 Alcian blue staining  
The absorbance measurements were divided by the average protein content of the 
cells to obtain the absorbance values per microgram of protein. A two tailed student’s 
t test was performed to compare the cells transfected with NT siRNA against cells 
transfected with CHST11 siRNA.  
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Chapter 3: Investigation of the effect of exogenous growth factor 
GDF5 on primary chondrocytes 
3.1 Introduction 
Growth and differentiation factor-5 (GDF5), also known as cartilage-derived 
morphogenetic protein-1 (CDMP-1), is closely related to the Bone Morphogenetic 
Proteins (BMPs) and is a member of the Transforming Growth Factor- β (TGF-β) 
superfamily. GDF5 is involved in bone and cartilage development, maintenance and 
repair and is a marker for early joint formation (Luyten, 1997). GDF5 expression is 
mainly detected during embryonic development, in precartilaginous mesenchymal 
condensations and cartilaginous cores of the developing long bones (Storm et al., 
1994; Storm and Kingsley, 1996). Low expression levels of GDF5 are seen postnatally in 
cartilage, brain and placenta (Storm et al., 1994; Chang et al., 1994; Krieglstein et al., 
1995).  
GDF5 protein is synthesised intracellularly, and is then cleaved at a consensus 
sequence Arg-X-X-Arg to form the mature form, which is then secreted as a dimer. 
GDF5 signals through BMP receptor type II (BMPR-II), which upon ligand binding, 
transphosphorylates BMP receptor type IB (BMPR-IB). This leads to the 
phosphorylation and activation of the downstream Smad1/5/8 signalling pathway (R-
Smads). Although GDF5 shows binding affinity towards BMP receptor type IA (BMPR-
IA), GDF5 has been shown to exhibit a 17-fold higher affinity towards BMPR-IB, 
compared to BMPR-IA (Nishitoh et al., 1996). The phosphorylated Smad 1/5/8 then 
complexes with Smad 1/4 (Co-Smads), which translocates into the nucleus and 
regulates transcription of target genes (Massagué, 1998; Figure 3.1). These include 
COL2A1, which encodes the α1 polypeptide chain of type II collagen, and ACAN, which 
encodes aggrecan (Mikic, 2004). GDF5 signalling can be negatively regulated by soluble 
proteins including noggin, chordin and gremlin (Piccolo et al., 1996; Cho and Blitz, 
1998; Merino et al., 1999b). These bind to GDF5 extracellularly and block its 
interaction with the cell surface receptors (Piccolo et al., 1996; Zimmerman et al., 
1996). In addition, GDF5 signalling can be inhibited by the action of inhibitory Smads. 
Smad 6 binds stably to BMPR-IB, thus competing with Smad 1/5/8 at the receptor level 
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(Imamura et al., 1997). It has also been shown that Smad 6 can bind to activated Smad 
1, therefore competing with Smad 4 to form a complex with Smad 1 (Hata et al., 1998). 
 
Figure 3.1: GDF5 signalling 
GDF5 binding activates BMP receptor type II which in turn activates BMP receptor type IB, 
leading to the phosphorylation (denoted by Ⓟ) of Smad 1/5/8 (R-Smads). These form a 
heterotrimer with Smad 4 (Co-Smads) consisting of two R-Smad molecules and one Co-Smad. 
This translocates to the nucleus to activate target gene transcription. Adapted from (Varga 
and Wrana, 2005). 
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The importance of GDF5 in the development of synovial joints has been shown in 
mouse models and human diseases. The presence of a frame shift mutation in GDF5 in 
the brachypodism (bp) mouse results in the inability to form normal synovial joints. 
The homozygous mice exhibit multiple skeletal abnormalities including shortened 
limbs, loss of proximal interphalangeal joints, bone fusion and abnormal knee joints 
(Storm et al., 1994). The heterozygous mice do not show obvious abnormalities, 
however they have been shown to develop an osteoarthritis-like phenotype when 
challenged (Settle Jr et al., 2003; Daans et al., 2011). Human chondrodysplasias caused 
by mutations in GDF5 include Hunter-Thompson syndrome, Grebe syndrome and 
Brachydactyly type C. Hunter-Thompson syndrome is a autosomal recessive condition 
caused by a tandem duplication of 22 bp, resulting in 43 out-of-frame amino acids in 
GDF5, producing a non-functional protein (Thomas et al., 1996). Grebe syndrome is an 
autosomal recessive chondrodysplasia caused by a non synonymous mutation, 
producing an abnormal GDF5 protein. The mutant protein does not contain 1 of 7 
highly conserved cysteine residues, which disrupts correct protein folding, resulting in 
the inability of the protein to be processed or secreted (Thomas et al., 1997). 
Brachydactyly type C is an autosomal dominant chondrodysplasia, caused by single 
base pair insertion or deletion mutations in GDF5 that create a premature stop codon, 
giving rise to a non-functional protein (Polinkovsky et al., 1997). These three conditions 
are associated with the failure to form normal joints (Table 3.1).  
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Disease 
Gene 
abnormality 
Phenotype Reference 
Hunter-Thompson 
syndrome 
22 bp frame shift 
Short limbs, absent carpal 
bones and middle phalanx of 
fifth finger 
Thomas et 
al., 1996 
Grebe syndrome Point mutation  
Short limbs, fusion of carpal 
and tarsal bones, loss of 
metacarpal and tarsal bones 
and proximal and middle 
phalanges 
Thomas et 
al., 1997; 
Costa et al., 
1998 
Brachydactyly type C Point mutation 
Fusion of phalanges, loss of 
middle phalanges 
Polinkovsky 
et al., 1997 
Table 3.1: Human conditions associated with GDF5 mutations. (Adapted from Edwards and 
Francis-West, 2001) 
As the role of GDF5 in skeletogenesis is well established, GDF5 was utilised in a 
candidate analysis to identify genes that harbour OA susceptibility loci in Japanese and 
Han Chinese populations (Miyamoto et al., 2007). The authors identified a single 
nucleotide polymorphism (SNP) in the 5' untranslated region (UTR) of GDF5 (rs143383, 
C/T) which was reported as being associated with OA. This was then replicated in a 
European study (Chapman et al., 2008). The major T- allele was found to be more 
common in OA cases (a frequency of 74% in controls versus 84% in cases) in the Asian 
study (Miyamoto et al., 2007). The same group reported that the T- allele mediated 
reduced GDF5 expression compared to the C- allele in an in-vitro functional study using 
a luciferase reporter assay and a chondrogenic cell line. Furthermore, Southam et al. 
(2007) reported that there was up to 27% reduced transcription from the T- allele 
relative to the C- allele in cartilage of OA patients heterozygous at this SNP. Also, 
Valdes et al (2011) conducted a combined meta-analysis, which showed that 
harbouring the T-allele at rs143383 led to a 17% increased risk for knee OA, with an 
odds ratio of 1.17 and P-value of 6.2x10-11. 
Aside from OA, the T-allele mediates increased susceptibility to other musculoskeletal 
conditions. For example, individuals homozygous for the T-allele were shown to have 
twice the risk of developing Achilles tendon pathology (Posthumus et al., 2010). 
Furthermore, the T-allele was also shown to be associated to congenital dysplasia of 
the hip in Han Chinese populations (Dai et al., 2008) and in Caucasians (Rouault et al., 
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2010), and to lumbar disc degeneration in Northern European women (Williams et al., 
2011).  These findings suggest that a slight reduction in GDF5 expression increases the 
risk for OA and for some other musculoskeletal diseases. 
 Several animal studies have reported on the use of GDF5 in therapeutics. Studies in 
rats have shown that GDF5 can be used to stimulate tendon healing (Forslund et al., 
2003; Rickert et al., 2005). GDF5 has also been shown to be effective in repair or 
slowing down the degeneration of intervertebral discs in mouse, rabbit and bovine 
models (Walsh et al., 2004; Chujo et al., 2006; Liang et al., 2010).  Also, human clinical 
trials are underway for the use of GDF5 in regenerative periodontal therapy and 
recombinant GDF5 is being pursued as a therapeutic for intervertebral disc repair 
(Zhang et al., 2011; Windisch et al., 2012). Also, it has been reported that GDF5 
enhanced chondrogenic differentiation and hypertrophy of human MSCs, thus showing 
potential to be used as a therapeutic in fracture repair (Coleman et al., 2013). 
Two publications have shown promising results of the stimulatory effects of GDF5 on 
matrix synthesis in human articular chondrocytes in vitro. Bobacz et al. (2002) used hip 
cartilage from 17 individuals with no OA and 13 OA patients. The authors showed an 
increase in glycosaminoglycan (GAG) synthesis in normal and OA chondrocytes 
cultured with GDF5, using [35S] sulphate incorporation assays.   They also observed an 
increase in ACAN mRNA levels using northern blot analysis, but no change in COL2A1 
expression. Chubinskaya et al, (2008) carried out alginate bead culture of chondrocytes 
harvested from ankle joints of 9 donors with no history of joint disease. Culturing in 
the presence of GDF5 led to an increase in GAG synthesis, measured by radiolabeled 
sulphate incorporation assays.   
The fact that the OA associated T-allele of rs143383 mediates reduced expression of 
GDF5 has led to us hypothesising that one means of alleviating this genetic deficit 
could be via the supply of exogenous GDF5 to chondrocytes. Investigating the logistics 
of this is the aim of this chapter. Chondrocytes harvested from patients that had 
undergone total hip or total knee replacement surgery were cultured with or without 
recombinant GDF5. I then assessed whether this triggers expression changes of genes 
involved in metabolic processes in chondrocytes.  
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3.2 Results 
3.2.1 GDF5 receptor gene expression in OA and NOF tissue 
In order to investigate the effect of adding exogenous GDF5 to chondrocytes, it was 
important to first assess whether chondrocytes expressed the genes that encode the 
receptors that GDF5 binds to (BMPR-II, BMPR-IA and BMPR-IB). Complimentary DNAs 
(cDNAs) were synthesised from RNA extracted from the cartilage of 3 hip OA and 7 
knee OA patients and from 10 neck-of-femur fracture (NOF) patients, the latter 
representing healthy cartilage. Gene expression was assessed using real time PCR 
assays designed for BMPR-II, BMPR-IA and BMPR-IB (Chapter 2.17, Table 2.2). 
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Figure 3.2: GDF5 receptor gene expression profile in 10 OA and 10 NOF cartilage tissue. 
Gene expression was measured relative to three housekeepers, 18S, GAPDH and HPRT1. The 
error bars represent the standard error of the mean. 
OA and NOF chondrocytes expressed all three genes analysed, in particular, BMPR-II 
and BMPR-IA (Figure 3.2). The expression of BMPR-IA, which encodes the alternative 
type I receptor that GDF5 binds to, was 60 (P=7.2 x 10-7) and 16 fold (P=0.02) higher in 
OA and NOF cartilage respectively, compared to BMPR-IB, which encodes the receptor 
towards which GDF5 shows preferentially activity. There was no significant difference 
(P<0.05) in the expression of BMPR-II, BMPR-IA or BMPR-IB when OA was compared to 
NOF. 
I next measured the gene expression of BMPR-II, BMPR-IA and BMPR-IB in 
chondrocytes that had been extracted from OA cartilage and then cultured in 
monolayer, to assess if the gene expression profile would change under culture 
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conditions. These cells showed a similar gene expression pattern to that observed in 
cartilage, with a 22 fold (P=0.02) higher BMPR-IA expression compared to BMPR-IB 
expression (Figure 3.3). 
BMPR-II BMPR-IA BMPR-IB
3.110 -05
9.810 -04
0.03125
1
G
e
n
e
 e
x
p
re
s
s
io
n
 r
e
la
ti
v
e
 t
o
 h
o
u
s
e
k
e
e
p
e
rs
 (
2
^
-d
e
lt
a
 C
t)
 
Figure 3.3: GDF5 receptor gene expression profile in OA chondrocytes cultured in monolayer. 
Gene expression was measured relative to three housekeepers, 18S, GAPDH and HPRT1. The 
error bars represent the standard error of the mean.  
3.2.2 The GDF5 proteins used 
The above results showed that the expression of BMPR-IA was higher in chondrocytes 
compared to expression of BMPR-IB. Therefore, I chose to use a recombinant GDF5 
protein that was designed by Biopharm GmbH (Heidelberg, Germany) to show 
increased specificity for BMPR-IA compared to BMPR-IB. I also used another variant 
that was designed by Biopharm, which is insensitive to the GDF5 antagonist noggin. 
Therefore, I have used four different recombinant GDF5 proteins in total; wildtype 
mouse (R&D Biosystems), wildtype human (Biopharm) and the two variants (A and B). 
All recombinant proteins used are the mature form of GDF5. The amino acid sequence 
difference between the mature forms of recombinant wildtype mouse GDF5 and the 
wildtype human GDF5 is a single amino acid: asparagine at position 380 in mouse is a 
threonine at the comparable position (386) in human. Table 3.2 shows the sequence of 
the four GDF5 proteins encompassing the changes introduced in variants A and B. 
Human GDF5 variant A was designed by introducing two point mutations in GDF5 to 
swap two methionine residues to valine residues at positions 453 and 456 (Kasten et 
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al., 2010). Variant B was designed by exchanging the asparagine residue at position 
445 in GDF5 to threonine (Seemann et al., 2009).  
Wildtype mGDF5 430 PLRSHLEPTNHAVIQTLMNSMDPESTPPTCCVPTRL 466 
Wildtype hGDF5 436 PLRSHLEPTNHAVIQTLMNSMDPESTPPTCCVPTRL 472 
hGDF5 variant A 436 PLRSHLEPTNHAVIQTLVNSVDPESTPPTCCVPTRL 472 
hGDF5 variant B 436 PLRSHLEPTTHAVIQTLMNSMDPESTPPTCCVPTRL 472 
Table 3.2: Partial amino acid sequences of the GDF5 proteins used. 
The amino acid sequences from 430-466 for mouse GDF5 and from 436-472 for 
human GDF5 proteins are shown with the change in amino acid sequence in variant A 
and B highlighted in red.  (mGDF5, mouse GDF5; hGDF5, human GDF5) 
3.2.3 Analysis of dose-dependent response to exogenous GDF5 in SW1353 cells 
using a luciferase reporter assay 
Previous reports have shown the optimal dose of GDF5 to be used for the stimulation 
of chondrocytes in monolayer is 100 ng/ml (Erlacher et al., 1998). In order to test this, I 
carried out a dose response analysis using a Smad 1/5/8 reporter assay, which is a 
pGL3 basic vector containing Smad 1/5/8 binding elements that drive firefly luciferase 
transcription (Mitchell et al., 2010). I transfected OA chondrocytes with the vector and 
stimulated cells with 10 ng/ml, 30 ng/ml, 100 ng/ml and 300 ng/ml exogenous GDF5 
24 hours post transfection (Chapter 2.9). Unfortunately, I was unable to transfect OA 
chondrocytes. I therefore used instead the human SW1353 chondrosarcoma cell line 
to carry out the dose response analyses.  
Initially, I transfected the cells with an empty (no insert) pGL3 basic plasmid vector (as 
a negative control) in addition to the Smad 1/5/8 reporter vector. The cells were 
cultured with 100 ng/ml of wildtype human GDF5 24 hours post transfection. The cells 
were also cultured with 100 ng/ml of human BMP2 (Chubinskaya et al., 2008) and 5 
ng/ml of human TGF-β1 (Baugé et al., 2008) as positive controls. The cells were lysed 
at 6 hours and 24 hours post stimulation and luciferase activity was measured (Figure 
3.4).  
At both time points, luciferase activity was significantly increased after stimulation 
with GDF5, BMP2 and TGF-β1 in the cells transfected with the Smad 1/5/8 reporter 
vector. There was no significant increase in luciferase activity between the different 
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treatments in the cells transfected with the empty pGL3 vector. This showed that the 
SW1353 cells are responsive to exogenous GDF5, BMP2 and TGF-β1 at the doses used.   
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Figure 3.4: Luciferase activity in response to GDF5 treatment, post transfection with empty 
pGL3 vector as negative control and with pGL3 vector containing Smad 1/5/8 reporter insert. 
BMP2 and TFG-β1 stimulations were used as positive controls. The error bars represent the 
standard error of the mean.  
**     P≤0.01, ***   P≤0.001, ****  P≤0.0001, ***** P≤0.00001 
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I next stimulated the cells with all four recombinant GDF5 proteins at 10ng/ml, 30 
ng/ml, 100 ng/ml and 300 ng/ml post transfection with the Smad 1/5/8 reporter 
vector. The cells were lysed at four time points, 6, 12, 24 and 48 hours post stimulation 
(Chapter 2.11.1, Figure 3.5). BMP2 and TGF-β1 were again used as positive controls at 
each time point.  
The cells stimulated with 10 ng/ml and 30 ng/ml of mouse GDF5 showed a significant 
increase in luciferase activity at 6 hours after stimulation, compared to untreated cells. 
However a significant effect was not seen at these doses at the two other time points 
analysed. The cells treated with 100 ng/ml and 300 ng/ml of mouse GDF5 showed a 
significant increase in luciferase activity compared to untreated cells at all time points 
analysed. 
Stimulation of cells with 10 ng/ml of wildtype human GDF5 did not increase luciferase 
activity compared to untreated cells at any of the time points analysed. Stimulation 
with 30 ng/ml increased luciferase activity only at 6 hours after stimulation. Cells 
cultured with 100 ng/ml GDF5 showed a significant increase in luciferase readings at all 
time points. Treatment with 300 ng/ml of wildtype human GDF5 resulted in a 
significant increase in luciferase activity at 6, 12 and 48 hour time points, but not at 24 
hours. 
Stimulation of cells with 10 ng/ml of human GDF5 variant A did not result in a 
significant increase in luciferase activity, and cells stimulated with 30 ng/ml of GDF5 
variant A showed a significant increase only at 6 hours post stimulation. Cells cultured 
with 100 ng/ml of GDF5 variant A showed a significant increase in luciferase readings 
at all time points. Stimulation with 300 ng/ml of GDF5 variant A resulted in a significant 
increase in luciferase at 6, 24 and 48 hours post stimulation, but not at 12 hours.  
The cells cultured with 10 ng/ml of GDF5 variant B showed an increase in luciferase 
activity at 6 and 12 hours, but not at 24 or 48 hours after stimulation. The cells 
cultured with 30 ng/ml, 100 ng/ml and 300 ng/ml of this variant showed significantly 
higher luciferase activity at all time points.  
At all four time points, stimulation with BMP2 and TGF-β1 resulted in a significant 
increase in luciferase activity. Furthermore, BMP2 and TGF-β1 stimulations clearly 
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elicit a greater response at all time points than do any of the GDF5 proteins. 
Stimulation with 100 ng/ml of each of the four recombinant GDF5 proteins 
consistently and significantly increased luciferase activity at all time points. 
Furthermore, there was no significant difference between the luciferase readings 
generated in cells stimulated with 100 ng/ml and 300 ng/ml of GDF5 protein. In 
addition, a previous report has shown that 100 ng/ml is the optimal concentration of 
recombinant GDF5 to be used in chondrocyte culture (Erlacher et al., 1998). Based on 
my results and this previous data, I therefore chose to use 100 ng/ml GDF5 for the 
stimulation of OA and NOF chondrocytes in subsequent experiments. 
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Figure 3.5: Luciferase activity readings generated in SW1353 cells in response to exogenous 
wildtype mouse GDF5 (A), wildtype human GDF5 (B), human GDF5 variant A (C) and human 
GDF5 variant B (D) at 6, 12, 24 and 48 hours post stimulation.  
BMP2 and TGF-β1 stimulations were used as positive controls. Error bars represent standard 
error of the mean. GDF5 10, 10 ng/ml; GDF 30, 30 ng/ml; GDF5 100, 100 ng/ml; GDF5 300, 
300 ng/ml 
* P<0.05, **     P<0.01, ***   P<0.001, **** P<0.0001, ***** P<0.00001 
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3.2.4 Activation of Smad signalling in chondrocytes after stimulation with 
GDF5  
Chondrocytes from two OA patients were cultured in monolayer with or without 100 
ng/ml of exogenous GDF5 for 15 minutes, 30 minutes, 1 hour and 2 hours (Chapter 
2.11.2). Protein extracted from the cells was subjected to western blot analysis using 
an antibody against phospho-Smad 1/5/8 (Chapter 2.13, 2.14 and 2.15). The cells were 
also stimulated with TGF-β1 for 1 hour as a positive control. Anti-β-actin antibody was 
used as a loading control for western blot analysis. The data for one of the two 
individuals is shown in Figure 3.6. The second individual produced the same results. 
This experiment may need to be repeated in more individuals to determine if this 
result can be replicated multiple times. 
Figure 3.6: Western blot images at 15 minutes, 30 minutes, 1 hour and 2 hours post 
stimulation with GDF5.  
TGF-β1 stimulation was used as a positive control. Lane 1, Untreated; 2, wildtype mouse 
GDF5; 3, wildtype human GDF5; 4, human GDF5 variant A; 5, human GDF5 variant B and 6, 
human TGF-β1. Anti-pSmad 1/5/8, Anti-phospho-Smad1 (Ser463/465)/ Smad5 (Ser463/465)/ 
Smad8 (Ser426/428) 
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The Smad 1/5/8 signalling pathway was activated in response to stimulation with all 
types of GDF5 proteins used at all time points analysed. 
In summary of the above two sections, all four of the exogenous GDF5 proteins were 
able to activate the Smad 1/5/8 signalling pathway in SW1353 cells, as demonstrated 
by a luciferase reporter assay, and in chondrocytes, as confirmed by western blot 
analysis, at a concentration of 100 ng/ml. Having established that the chondrocytes 
respond to stimulation by the GDF5 proteins, I next assessed the effect that this 
stimulation has on the expression of a panel of relevant genes. 
3.2.5 Changes in gene expression in response to exogenous GDF5 in OA 
chondrocytes  
Chondrocytes harvested from 20 OA patients (Patients A-T, Table 3.3) were cultured 
with (treated) or without (untreated) 100 ng/ml of each of the GDF5 proteins (Chapter 
2.11.3). Nine of the 20 were cultured with wildtype mouse GDF5 (patients A-I), three 
of whom were also separately cultured with TGF-β1 (patients G-I). Seven of the 20 
were cultured with wildtype human GDF5 (patients J, K and N-R), five of whom were 
also separately cultured with variant A and separately with variant B (patients N-R). 
Two of the 20 were cultured with variant A and separately with variant B (patients L 
and M). Finally, two of the 20 were cultured only with TGF-β1 (patients S and T). To 
reiterate, none of the culturing was performed with two or more of the GDF5 proteins 
in the same culture mix.  
The cells were lysed at four time points after stimulation (6, 12, 24 and 48 hours; 
Chapter 2.16).  Changes in the expression of six genes that code for proteins that have 
anabolic and catabolic roles in chondrocyte biology were then assessed by quantitative 
real time PCR (Chapter 2.17). The genes studied were COL2A1, ACAN, SOX9, TIMP1, 
MMP1 and MMP13. As a positive control, chondrocytes from patients A-F and J-R were 
stimulated with TGF-β1 for 48 hours. The relative gene expression of the test genes 
was compared between the treated and the untreated cells by performing a student’s 
two tailed t-test. Values of P<0.05 were considered significant.  
The significant up/down changes in gene expression in response to stimulation with 
the GDF5 proteins and with TGF-β1 were then plotted and are shown in Figures 3.7 to 
3.11. The actual values of these significant changes are listed in Tables 3.4-3.8. A 
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Wilcoxon signed rank test was performed to assess whether the chondrocytes showed 
a significant trend in response to each GDF5 and to TGF-β1. P-values are listed in Table 
3.9. 
Patient  
Age at 
surgery 
Sex Joint Growth factor  
A 59 M Knee  Wildtype mGDF5 
B 70 M Knee  Wildtype mGDF5 
C 68 F Knee  Wildtype mGDF5 
D 45 F Knee  Wildtype mGDF5 
E 75 M Knee  Wildtype mGDF5 
F 46 M Knee  Wildtype mGDF5 
G 73 F Knee  Wildtype mGDF5, TGF-β1 
H 77 M Knee  Wildtype mGDF5, TGF-β1 
I 68 M Knee  Wildtype mGDF5, TGF-β1 
J 66 M Hip  Wildtype hGDF5 
K 64 F Knee  Wildtype hGDF5 
L 63 M Knee  hGDF5 variant A, hGDF5 variant B 
M 78 F Knee  hGDF5 variant A, hGDF5 variant B 
N 84 M Hip  Wildtype hGDF5 and hGDF5 variant A, hGDF5 variant B 
O 82 M Knee  Wildtype hGDF5 and hGDF5 variant A, hGDF5 variant B 
P 70 F Knee  Wildtype hGDF5 and hGDF5 variant A, hGDF5 variant B 
Q 70 F Knee  Wildtype hGDF5 and hGDF5 variant A, hGDF5 variant  B 
R 68 F Knee  Wildtype hGDF5 and hGDF5 variant A, hGDF5 variant  B 
S 67 F Knee  TGF-β1 
T 58 F Knee  TGF-β1 
Table 3.3: Details of the OA patients studied in this section and of the growth factors used to 
stimulate their chondrocytes. 
F, female; M, male; mGDF5, mouse GDF5; hGDF5, human GDF5 
My results show that OA chondrocytes respond to exogenous GDF5, but not in a 
consistent manner. Some patients did not show a significant response to GDF5 
stimulation at all (for example, patient B), and where a response was observed at one 
time point, this did not persist through to further time points. For example, patient I 
showed a 1.64 fold significant upregulation of MMP13, 6 hours post stimulation with 
wildtype mouse GDF5. But, there was no change in MMP13 expression at 12, 24 or 48 
hours post stimulation (Table 3.4). Also, the changes in gene expression observed were 
not predictable, in that they were not always in the same direction. For example, 
 
 
79 
MMP13 was both up and down regulated in response to  wildtype mouse, wildtype 
human and human variant A GDF5.  
All five patients cultured with TGF-β1 did however respond in a clearly consistent 
manner, showing an upregualtion of TIMP1 (P=0.0005) and COL2A1 (P<0.0001) and a 
down regulation of MMP13 (P=0.035), MMP1 (P=0.0001), ACAN (P=0.042) and SOX9 
(P=0.0021; Table 3.9). 
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Figure 3.7: Gene expression changes in cells treated with mouse GDF5 compared to 
untreated cells. Each cross represents a significant (P<0.05) up/down regulation of gene 
expression relative to untreated cells in one patient. Nine patients were studied in total. 
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Figure 3.8: Gene expression changes in cells treated with wildtype human GDF5 compared to 
untreated cells. Each cross represents a significant (P<0.05) up/down regulation of gene 
expression relative to untreated cells in one patient. Seven patients were studied in total. 
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Figure 3.9: Gene expression changes in cells treated with human GDF5 variant A compared to 
untreated cells. Each cross represents a significant (P<0.05) up/down regulation of gene 
expression relative to untreated cells in one patient. Seven patients were studied in total. 
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Figure 3.10: Gene expression changes in cells treated with human GDF5 variant B compared 
to untreated cells. Each cross represents a significant (P<0.05) up/down regulation of gene 
expression relative to untreated cells in one patient. Seven patients were studied in total. 
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Figure 3.11: Gene expression changes in cells treated with human TGF-β1 compared to 
untreated cells. Each cross represents a significant (P<0.05) up/down regulation of gene 
expression relative to untreated cells in one patient. Five patients were studied in total. 
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Gene 
Time point 
after 
stimulation 
Patient 
A B C D E F G H I 
MMP13 
6 hours 0.48 - - 1.57 1.53 - - - 1.64 
12 hours - - - 4.62 - - - - - 
24 hours - - - 0.30 1.89 - 0.52 - - 
48 hours 0.65 - - - - - 0.74 - - 
MMP1 
6 hours - - - 1.50 - - - - - 
12 hours - - - 6.62 - - - - - 
24 hours - - - - - 1.52 - - - 
48 hours - - - - - - - - - 
TIMP1 
6 hours - - - - - - - - - 
12 hours - - - - 0.56 - - - - 
24 hours - - - 0.49 - 1.41 - - - 
48 hours - - - - - - - - - 
COL2A1 
6 hours - - - 2.97 - - - 2.63 - 
12 hours - - - 10.30 - - - - - 
24 hours - - 5.28 0.27 - - - - - 
48 hours - - 0.35 - - - - 1.68 1.80 
ACAN 
6 hours - - - 2.18 - - - - - 
12 hours - - 4.28 2.37 0.59 - - - - 
24 hours - - - - 1.57 - - - - 
48 hours - - 1.61 0.27 - - - 1.72 - 
SOX9 
6 hours - - - 0.52 1.69 - - - - 
12 hours - - 3.08 - - - - - - 
24 hours - - - 0.37 - - - 1.65 - 
48 hours - - - - - - - 1.84 - 
Table 3.4: Significant (P<0.05) fold changes in gene expression in response to stimulation with wildtype 
mouse GDF5 at 6, 12, 24 and 48 hours post stimulation in 9 OA patients, relative to untreated cells.  
A value greater than 1 denotes a significant upregulation of gene expression and a value less than 1 
denotes a significant down regulation of gene expression. A dash (-) indicates no significant change in 
gene expression. 
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Gene 
Time point 
after 
stimulation 
Patient 
J K N O P Q R 
MMP13 
6 hours - 0.39 - - - 2.27 - 
12 hours - 0.65 - - - - - 
24 hours - - - - - - - 
48 hours - - - - - 0.58 - 
MMP1 
6 hours - - - 2.87 - - - 
12 hours - - - - - - - 
24 hours - - - - - - - 
48 hours - - - - - - - 
TIMP1 
6 hours - 0.52 - 3.46 - - - 
12 hours - - - - - - - 
24 hours - - - - - - - 
48 hours - - - - - - - 
COL2A1 
6 hours - 0.52 - - 0.21 - - 
12 hours - - - - - - - 
24 hours - - - - - - - 
48 hours - - - - - - - 
ACAN 
6 hours - 0.44 - - 0.21 - - 
12 hours - - - - - - - 
24 hours - - - - - - - 
48 hours - - - - 3.80 0.65 - 
SOX9 
6 hours - - 1.72 - 0.37 - - 
12 hours - - - - - - - 
24 hours - - - - - - - 
48 hours - - - - - - - 
Table 3.5: Significant (P<0.05) fold change in gene expression in response to stimulation with 
wildtype human GDF5 at 6, 12, 24 and 48 hours post stimulation in 7 OA patients, relative to 
untreated cells.  
A value greater than 1 denotes a significant upregulation of gene expression and a value less 
than 1 denotes a significant down regulation of gene expression. A dash (-) indicated no 
significant change in gene expression. 
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Gene 
Time point 
after 
stimulation 
Patient 
L M N O P Q R 
MMP13 
6 hours 0.54 - - 1.83 - - - 
12 hours 0.56 1.88 0.63 - - - - 
24 hours - - - - - - - 
48 hours - - - - - 0.67 - 
MMP1 
6 hours 0.55 - - 2.34 - - - 
12 hours - 2.01 - - - - - 
24 hours - 1.21 - - - - - 
48 hours - 1.55 - - - - - 
TIMP1 
6 hours 0.39 - - - - - - 
12 hours - - 0.54 - - - - 
24 hours - 1.64 - - - - - 
48 hours - 1.54 - - - - - 
COL2A1 
6 hours 0.50 - - - 0.36 - - 
12 hours 0.60 - - - 0.38 - - 
24 hours - 0.65 - - - - - 
48 hours - - - - - - - 
ACAN 
6 hours - - 2.00 3.03 - - - 
12 hours 0.66 2.58 - - 0.36 - - 
24 hours - - - - - - - 
48 hours 1.75 - - - - - - 
SOX9 
6 hours - - - 5.54 0.56 - - 
12 hours - 2.13 - - 0.43 - - 
24 hours - - - - - - - 
48 hours - - 3.22 - - - - 
Table 3.6: Significant (P<0.05) fold change in gene expression in response to stimulation with 
human GDF5 variant A at 6, 12, 24 and 48 hours post stimulation in 7 OA patients, relative to 
untreated cells.  
A value greater than 1 denotes a significant upregulation of gene expression and a value less 
than 1 denotes a significant down regulation of gene expression. A dash (-) indicates no 
significant change in gene expression. 
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Gene 
Time point 
after 
stimulation 
Patient 
L M N O P Q R 
MMP13 
6 hours 0.63 0.55 - - - - 0.42 
12 hours 0.63 - 0.57 - - - 0.19 
24 hours - - - - - - - 
48 hours - - - - - - - 
MMP1 
6 hours - - - - 0.30 - - 
12 hours - - 0.67 - 2.23 - - 
24 hours - 1.22 - - - - - 
48 hours - - - - - - - 
TIMP1 
6 hours 0.51 0.75 - - - - - 
12 hours 0.44 - 0.63 - - - - 
24 hours - 1.45 - - - - - 
48 hours 0.47 - - - - - - 
COL2A1 
6 hours - 0.33 - - - - - 
12 hours - - - - 0.21 - - 
24 hours 0.50 0.37 - - - - - 
48 hours - - 3.85 - - - - 
ACAN 
6 hours - - - - - - - 
12 hours - - 0.58 - 0.14 - - 
24 hours - - - - - - - 
48 hours - - - - - - - 
SOX9 
6 hours 0.47 - - - 0.39 - - 
12 hours - - - - 0.26 - 0.49 
24 hours - - - - - - - 
48 hours 0.51 - - - - - - 
Table 3.7: Significant (P<0.05) fold change in gene expression in response to stimulation with 
human GDF5 variant B at 6, 12, 24 and 48 hours post stimulation in 7 OA patients, relative to 
untreated cells.  
A value greater than 1 denotes a significant upregulation of gene expression and a value less 
than 1 denotes a significant down regulation of gene expression. A dash (-) indicates no 
significant change in gene expression. 
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Gene 
Time point 
after 
stimulation 
Patient 
G H I S T 
MMP13 
6 hours - - - 0.54 - 
12 hours - - - 0.58 - 
24 hours 0.43 0.56 - - - 
48 hours 0.20 0.41 - 0.42 - 
MMP1 
6 hours - - 0.64 - - 
12 hours 0.50 0.33 0.45 0.67 - 
24 hours 0.18 0.30 0.49 0.16 - 
48 hours 0.11 0.16 0.23 0.17 0.45 
TIMP1 
6 hours 5.55 2.21 - - - 
12 hours 7.85 2.15 1.61 1.45 - 
24 hours 6.73 3.34 1.66 1.85 1.52 
48 hours 11.30 3.40 2.31 1.75 2.00 
COL2A1 
6 hours - 4.56 - 1.60 - 
12 hours 1.69 2.91 1.79 1.71 2.61 
24 hours 2.70 3.95 2.80 2.09 4.01 
48 hours 5.67 1.72 3.84 2.91 2.70 
ACAN 
6 hours - - - - - 
12 hours - - - - - 
24 hours 0.59 - 0.36 - 0.45 
48 hours 0.43 0.29 0.45 0.54 0.37 
SOX9 
6 hours - - - - - 
12 hours - - - - - 
24 hours 0.25 - 0.45 0.59 - 
48 hours 0.36 0.52 - 0.55 - 
Table 3.8: Significant (P<0.05) fold change in gene expression in 
response to stimulation with TGF-β1 at 6, 12, 24 and 48 hours post 
stimulation in 5 OA patients, relative to untreated cells.  
A value greater than 1 denotes a significant upregulation of gene 
expression and a value less than 1 denotes a significant down 
regulation of gene expression. A dash (-) indicates no significant 
change in gene expression. 
 
 
 
 
90 
 
Target 
gene 
Growth factor 
wildtype 
mGDF5 
wildtype 
hGDF5 
hGDF5 A hGDF5 B TGF-β1 
MMP13 0.8015 0.1300 0.0314 0.2794 0.035 
MMP1 0.5144 0.1299 0.9546 0.4123 0.0001 
TIMP1 0.8314 0.2146 0.7413 0.2794 0.0005 
COL2A1 0.0974 0.8287 0.2896 0.3331 < 0.0001 
ACAN 0.0552 0.3109 0.3109 0.4592 0.042 
SOX9 0.9812 0.1035 0.5164 0.2597 0.0021 
Table 3.9: P-values calculated using the Wilcoxon signed rank test for each target gene 
following growth factor stimulation.  
mGDF5, mouse GDF5; hGDF5, human GDF5. P<0.05 are highlighted in red. 
 
In summary, chondrocytes from OA patients did not respond consistently to 
exogenous GDF5, whereas chondrocytes from OA patients showed a very consistent 
response to stimulation with TGF-β1. 
3.2.6 Changes in gene expression in response to IL-1α and oncostatin M in OA 
chondrocytes  
In order to determine if the chondrocytes are able to respond to exogenous stimuli 
other than members of the TGF-β superfamily, chondrocytes harvested from the 20 
OA patients used in section 3.2.5 were cultured with IL-1α (0.05ng/ml) and 
recombinant oncostatin M (OSM; 10ng/ml) for 24 hours (Chapter 2.11.3). IL-1α and 
OSM stimulations have been shown previously to significantly increase MMP1 and 
MMP13 gene expression (Koshy et al., 2002). All patients studied showed a significant 
upregulation of MMP1 (P<0.0001) and MMP13 (P<0.0001) expression in response to 
IL-1α and OSM stimulation, therefore, these cells are capable of responding to these 
cytokines (Figure 3.12, Table 3.10 and 3.11).   
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Figure 3.12: Fold change in MMP1 and MMP13 gene expression in response to IL-1α and 
OSM simulation for 24 hours. Each cross represents a significant (P<0.05) up/down 
regulation of gene expression relative to untreated cells in one patient. Twenty patients 
were studied in total. 
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Patient 
Gene 
MMP1 MMP13 
A 2.07 1.62 
B 1.33 1.25 
C 3.59 1.61 
D 1.48 1.72 
E 4.53 3.06 
F 1.33 1.83 
G 9.67 5.03 
H 1.45 1.14 
I 2.62 1.36 
J 4.43 3.05 
K 13.80 8.64 
L 1.57 2.77 
M 5.41 3.08 
N 1.74 2.95 
O 9.32 9.40 
P 2.64 4.09 
Q 15.20 4.66 
R 4.90 2.86 
S 6.98 5.76 
T 11.80 5.07 
Table 3.10: Significant (P<0.05) fold change in gene expression in 
response to stimulation with IL-1α and OSM at 24 hours post 
stimulation in 20 OA patients, relative to untreated cells.  
 
Target gene IL-1α and OSM 
MMP1 < 0.0001 
MMP13 < 0.0001 
Table 3.11:P-values calculated using the Wilcoxon signed rank test for each target gene 
following IL-1α and OSM stimulation.  
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3.3 Discussion 
Chondrocytes from OA patients express the genes coding for the GDF5 receptors, in 
particular, BMPR-II and BMPR-IA. The gene expression of BMPR-IB, which encodes the 
type I receptor that GDF5 preferentially binds to, was 60 and 16 fold lower in OA and 
NOF cartilage respectively, than that of the alternative type I receptor BMPR-IA. 
Drabobinac et al., 2008 have carried out immunohistochemistry on OA and normal 
articular cartilage to examine the expression pattern of BMPR-II, BMPR-IA and BMPR-
IB. They observed strong expression of BMPR-II and BMPR-IA with no difference in 
expression levels between OA and normal cartilage. However, the expression of BMPR-
IB was low in normal cartilage and was not detected in OA cartilage (Drabobinac et al., 
2008). My results show a 2.5 fold lower expression of BMPR-IB in OA cartilage 
compared to NOF cartilage, however this was not significant. In addition to wildtype 
forms of GDF5 from mouse and human, I have also utilised two variants of human 
GDF5 in this study, which were designed by Biopharm. One was designed to 
preferentially bind to BMPR-IA, and the other variant was insensitive to the GDF5 
antagonist noggin. This allowed me to determine if chondrocytes will better respond 
to these variants, compared to the wildtype form. 
Stimulation of SW1353 with all four forms of GDF5 at 100 ng/ml significantly increased 
luciferase activity of the Smad 1/5/8 vector at 6, 12, 24 and 48 hours after stimulation. 
This suggests that the GDF5 signal was translocated to the nucleus.  
Western blots carried out using phosphorylated Smad 1/5/8 antibody showed that 
stimulation of  chondrocytes with all four types of recombinant GDF5 protein activates 
this signalling pathway.  
I then carried out real time PCR analysis on a panel of genes that encode anabolic and 
catabolic markers after stimulation of the chondrocytes with the four GDF5 proteins. 
The proteins triggered gene expression changes of all genes analysed, however, a 
predictable response was not seen among patients with any of the four different forms 
of GDF5. Although variant A has been manufactured to show higher affinity to BMPR-
IA, which chondrocytes abundantly express, and variant B is insensitive to noggin, a 
consistent response was not observed in cells treated with these variant forms of 
GDF5.  
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In contrast, TGF-β1 treatment in these cells upregulated TIMP1, COL2A1 and down 
regulated MMP1, MMP13, SOX9 and ACAN in all patients analysed. Also, IL-1α and 
OSM treatment upregulated MMP1 and MMP13 in all patients. The chondrocytes were 
therefore clearly capable of responding to exogenous stimuli, including to growth 
factors of the TGF-β superfamily. 
Together, these data indicate that the cells are not responding to exogenous GDF5 in a 
consistent manner, whereas a consistent response was observed in these cells when 
treated with exogenous TGF-β1.  
Age-related reduction in chondrocytes’ response to growth factors may account for 
the observed inconsistency in response to exogenous GDF5. Guerne et al. (1995) have 
shown a reduction in proliferative response with increasing age in chondrocytes in 
response to exogenous growth factors. In that study chondrocytes were harvested 
from the articular cartilage of donors aged 11-83 years and who had no history of joint 
disease. The cells were cultured in the presence of PDGF-AA, FGF-2, IGF-1 and TGF-β1, 
and the rate of cell proliferation was measured by 3H-thymidine incorporation. The 
proliferative response of chondrocytes to all growth factors tested was reduced with 
increasing age. Interestingly, the authors observed that TGF-β1 was the most potent 
stimulant analysed, and was the only factor that consistently and significantly 
increased the proliferation rate in chondrocytes from older donors (those aged 44 and 
above).   
Loeser et al. (2000) assessed the effect of ageing and OA on the response of 
chondrocytes to IGF-1 in cynomolgus monkeys that have naturally occurring OA. The 
authors observed a significant reduction in response to IGF-1 with increasing age and 
histologic OA score, as measured by radiolabeled sulphate and proline incorporation 
assays. The authors suggest that possible causes for a reduction in response may 
include an age-related reduction in the levels of IGF-1 receptors, defective signal 
transduction or a change in the synthesis of certain molecules necessary to achieve the 
full response to IGF-1.  
My results showed that the Smad 1/5/8 signalling pathway was activated in 
chondrocytes in response to exogenous GDF5. However, other intracellular events 
downstream of Smad 1/5/8 may be suboptimal, which may explain the cells’ inability 
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to show a consistent response to exogenous GDF5. It has been reported that the 
cellular environment within a damaged joint can alter the response to members of the 
BMP family. For example IL-1β, which is upregulated in OA can increase the expression 
of Smad 7 (an inhibitor of BMP intracellular signalling; Goldring and Berenbaum, 2004; 
Baugé et al., 2008). Also, fibroblast growth factor (FGF) signalling can directly inhibit 
Smad 1 activity, which in turn inhibits BMP intracellular signalling (Kretzschmar et al., 
1997). FGFs have also been shown to down regulate BMPR-IB expression in avian limb 
cells (Merino et al., 1998). 
Therefore, the loss of the chondrocytes’ response to growth factors, including GDF5, 
can be a cause or a consequence of the OA disease process. A loss of response to 
growth factors during ageing may contribute to the development and progression of 
OA, resulting in an altered balance between anabolism and catabolism. Furthermore, 
an increase in cytokine production during the disease process can result in defective 
downstream signalling that may give rise to the observed inconsistency in response to 
exogenous GDF5. Hence, it is important to develop a means to enhance the responsive 
capacity of chondrocytes to exogenous growth factors if treatment with GDF5 is going 
to be advanced as a potential therapeutic to overcome the genetic deficit mediated by 
the OA risk allele at rs143383. 
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Chapter 4: Allelic expression analysis of the osteoarthritis 
susceptibility locus that maps to MICAL3 
4.1 Introduction 
Stage one of the arcOGEN GWAS with over 67,000 individuals of European descent 
identified an association to SNP rs2277831 (A/G), with a P-value of 2.3x10-5 and an 
odds ratio for allele G of 1.07 in knee and/or hip OA (Panoutsopoulou et al., 2011).  
rs2277831 is located within an intron of the MICAL3 gene, which codes for the 
microtubule-associated monoxygenase, calponin and LIM domain containing 3 protein. 
The MICAL3 protein is thought to be involved in the vesicle transport system in 
mammalian cells through the interaction with Rabs, which are small GTPases (Fischer 
et al., 2005; Grigoriev et al., 2011). Two additional genes map close by and are 
encompassed by the association signal. These are BCL2L13, which codes for the BCL2-
like 13 (also known as BCL-Rambo) protein, and BID, which codes for the BH3 
interacting domain death agonist protein.  
The BCL2L13 protein is a pro-apoptotic member of the BCL2 family of proteins. It has 
been reported that BCL2L13 induces apoptosis by reducing the mitochondrial 
membrane potential, which results in the activation of Caspase-3 (Kataoka et al., 2001; 
Kim et al., 2012). The BID protein is another member of the BCL2 family of proteins 
and also has pro-apoptotic roles. BID is cleaved by Caspase-8, which once cleaved, 
translocates to the mitochondria where it forms heterodimers with BAX, triggering the 
release of cytochrome c. This leads to the activation of apoptotic pathways (Desagher 
et al., 1999). BID can also be phosphorylated in response to DNA damage, which is 
mediated by ataxia-telangiectasia mutated (ATM) kinase. This results in cell cycle 
arrest at the S phase, which is important for maintaining genomic stability through 
activating DNA repair pathways or by triggering apoptosis (Zinkel et al., 2005; Gross, 
2006).  
As chondrocyte apoptosis is a characteristic of OA, it is interesting that the OA 
associated locus maps closely to two genes whose products belong to the BCL2 family 
of proteins that play crucial roles in apoptosis. Furthermore, it has been documented 
that OA cartilage shows increased expression of BCL2 and Caspase-3, which correlates 
with chondrocyte apoptosis and OA lesions (Kim et al., 2000; Blanco et al., 2004). Also, 
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OA chondrocytes have been shown to have a reduced mitochondrial membrane 
potential, which is associated with mitochondrial swelling, disruption of the outer 
membrane of the mitochondria and the release of cytochrome c (Crompton, 1999). 
 Scrutinizing public databases reveals that BCL2L13, BID and MICAL3 are expressed in 
various tissue types, including adipose tissue, blood, bone, brain, cartilage, heart, liver, 
kidney and muscle.  
BCL2L13 has 14 transcript isoforms, of which 8 are protein coding (Figure 4.1). Ensembl 
transcript ID ENST00000317582 codes for the longest BCL2L13 protein isoform, which 
is 485 amino acids in length. BID has 10 transcript isoforms, of which 6 are protein 
coding (Figure 4.2). The longest BID protein isoform, which is 241 amino acids in 
length, is coded by ENST00000317361 transcript isoform. MICAL3 has 19 transcript 
isoforms, of which 15 are protein coding (Figure 4.3). The longest MICAL3 protein 
isoform is 2002 amino acids in length and is coded for by transcript isoform 
ENST00000441493. rs2277831 resides in an intron in 3 of the 19 MICAL3 transcript 
isoforms, which are all protein coding. The SNP resides in intron 27 of 
ENST00000441493 and in intron 2 of ENST00000577821 and ENST00000579997. 
 
Figure 4.1: The eight protein coding transcript isoforms of BCL2L13 (from www.ensembl.org). 
The horizontal bar across the top of the figure shows the forward strand of chromosome 
22q11.21 from left to right. The transcript isoforms of BCL2L13 are shown as horizontal lines 
and rectangles within the area highlighted in green. The shaded rectangles represent the 
coding part of exons, whilst the unshaded rectangles represent the UTRs. The horizontal 
lines show the introns of BCL2L13. The ensembl transcript IDs are shown below each 
transcript. 
ENST00000317582  
ENST00000543133  
ENST00000538149 
ENST00000337612 
ENST00000493680  
ENST00000355028  
ENST00000418951 
ENST00000399782  
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Figure 4.2: The six protein coding transcript isoforms of BID (from www.ensembl.org). The 
horizontal bar across the top of the figure shows the forward strand of chromosome 
22q11.21 from left to right. The transcript isoforms of BID are shown as horizontal lines and 
rectangles within the area highlighted in green. The shaded rectangles represent the coding 
part of exons, whilst the unshaded rectangles represent the UTRs. The horizontal lines show 
the introns of BID. The ensembl transcript IDs are shown below each transcript. 
 
Figure 4.3: The fifteen protein coding transcript isoforms of MICAL3 (from 
www.ensembl.org). The horizontal bar across the top of the figure shows the forward strand 
of chromosome 22q11.21 from left to right. The transcript isoforms of MICAL3 are shown as 
horizontal lines and rectangles within the area highlighted in green. The shaded rectangles 
represent the coding part of exons, whilst the unshaded rectangles represent the UTRs. The 
horizontal lines show the introns of MICAL3. The transcript names are shown below each 
transcript, and the corresponding ensembl transcript IDs are listed in Table 4.1. 
 
 
ENST00000317361 
ENST00000399767 
ENST00000399774  
ENST00000399765  
ENST00000342111  
ENST00000551952  
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Transcript name Ensembl transcript ID 
MICAL3-001 ENST00000383094 
MICAL3-002 ENST00000414725 
MICAL3-003 ENST00000400561 
MICAL3-004 ENST00000461307 
MICAL3-006 ENST00000424046 
MICAL3-010 ENST00000441493 
MICAL3-011 ENST00000498573 
MICAL3-012 ENST00000585038 
MICAL3-015 ENST00000577821 
MICAL3-017 ENST00000578984 
MICAL3-018 ENST00000584751 
MICAL3-019 ENST00000579997 
MICAL3-201 ENST00000207726 
MICAL3-202 ENST00000429452 
MICAL3-203 ENST00000444520 
Table 4.1: The fifteen protein coding MICAL3 transcript isoform names and their 
corresponding ensembl transcript IDs  
As the number of susceptibility loci that are identified for common human diseases 
increases, it is becoming clear that many, if not the majority, of associated alleles 
contribute to disease risk by acting as expression quantitative trait loci (eQTLs), 
influencing the expression or stability of a transcript  (Cookson et al., 2009; 
Montgomery and Dermitzakis, 2011). In the majority of cases eQTLs act in an organ or 
even tissue specific manner. It is important therefore to study RNA extracted from 
tissues relevant to the disease when assessing the potential effect of eQTLs. 
I hypothesised that the OA association to rs2277831 may be marking an eQTL. To 
assess this I have measured the overall expression of BCL2L13, BID and MICAL3 using 
real time PCR and stratified the expression by the genotype at rs2277831. I also tested 
for allelic expression imbalance (AEI) of BCL2L13, BID and MICAL3 using transcript SNPs 
and assays that can accurately discriminate and quantify the mRNA synthesised from 
each allele. I examined RNA extracted from the joint tissues of patients undergoing 
elective joint replacement surgery. 
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4.2 Results 
4.2.1 Qualitative gene expression analysis of BCL2L13, BID and MICAL3 in joint 
tissue cDNAs 
In order to assess if BCL2L13, BID and MICAL3 were expressed in joint tissues, RNA 
extracted from cartilage, fatpad, synovium, cancellous bone and osteophytes from OA 
patients were reverse transcribed to synthesise complimentary DNAs (cDNAs; 
Chapter2.3). These were then PCR amplified using primers listed in Table 2.4 (Chapter 
2.4).  
The primers that were designed for BCL2L13 targeted common regions in 4 of 8 
protein coding transcript isoforms (ENST00000317582, ENST00000543133, 
ENST00000538149 and ENST00000337612) of the gene. These transcript isoforms 
were the only isoforms that carry the SNPs which were later selected for AEI analyses.  
BCL2L13 was expressed in all tissues of the joint analysed, with particularly high levels 
observed in cartilage, fatpad and cancellous bone (Figure 4.4). 
The primers designed for BID targeted all 6 protein coding transcript isoforms of this 
gene. BID was expressed in all tissues of the joint analysed, with particularly high levels 
observed in cartilage, fatpad and synovium (Figure 4.5). 
Initially, MICAL3 expression in joint tissues was assessed using primers that targeted 
common regions in 9 of 15 protein coding transcript isoforms. These transcripts of 
MICAL3 were expressed in all tissues of the joint analysed, with particularly high levels 
observed in synovium, cancellous bone and osteophyte tissue (Figure 4.6).  
The expression of transcript isoforms derived from the part of the MICAL3 gene that 
harbours the associated SNP rs2277831 were assessed using a different set of primers 
listed in Table 2.4 (MICAL3 (2), Chapter 2.4). This amplimer targeted common regions 
of ENST00000441493, ENST00000577821 and ENST00000579997. The primer pair used 
in this experiment targeted exons 26 and 28 of ENST00000441493 and exons 1 and 3 
of ENST00000579997, producing a PCR product of 177 bp in length. The expression of 
at least one of these two transcript isoforms were observed in all tissues of the joint 
analysed, with particularly high levels observed in cancellous bone (Figure 4.7). 
ENST00000577821 contains an additional 51 bp exon, which is absent in 
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ENST00000441493 and ENST00000579997, producing a PCR product of 228 bp in 
length. The expression of ENST00000577821 was observed in cartilage and synovium 
tissue and was absent in other tissues of the joint analysed (Figure 4.7). Expression of 
ensembl transcript IDs ENST00000461307, ENST00000498573, ENST00000578984 and 
ENST00000584751 were not assessed in this experiment. 
In summary of section 4.2.1, BCL2L13, BID and MICAL3 were expressed in all joint 
tissues tested. 
 
Figure 4.4: BCL2L13 expression in joint tissue cDNAs.  
Lane 1: cartilage, 2: fatpad, 3: synovium, 4: cancellous bone, 5: osteophyte, 6: PCR blank. 
The PCR products were run on a 2% agarose gel containing ethidium bromide. A 100 bp 
DNA ladder was used for sizing of PCR products.  
 
1      2     3     4     5     6  
300 bp 
200 bp 
100 bp 
400 bp 
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Figure 4.5: BID expression in joint tissue cDNAs.  
Lane 1: cartilage, 2: fatpad, 3: synovium, 4: cancellous bone, 5: osteophyte, 6: PCR blank. 
The PCR products were run on a 2% agarose gel containing ethidium bromide. A 100 bp 
DNA ladder was used for sizing of PCR products.  
 
Figure 4.6: MICAL3 expression in joint tissue cDNAs.  
Lane 1: cartilage, 2: fatpad, 3: synovium, 4: cancellous bone, 5: osteophyte, 6: PCR blank. 
The PCR products were run on a 2% agarose gel containing ethidium bromide. A 100 bp 
DNA ladder was used for sizing of PCR products.  
1     2     3     4     5     6  
100 bp 
200 bp 
300 bp 
1      2     3    4      5     6  
300 bp 
200 bp 
100 bp 
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Figure 4.7: MICAL3 ensembl transcript IDs ENST00000441493, ENST00000577821 and 
ENST00000579997 expression in joint tissue cDNAs. 
Lane 1: cartilage, 2: fatpad, 3: synovium, 4: cancellous bone, 5: osteophyte, 6: PCR blank. 
The PCR products were run on a 2% agarose gel containing ethidium bromide. A 100 bp 
DNA ladder was used for sizing of PCR products.  
4.2.2 BCL2L13, BID and MICAL3 expression in cartilage tissue stratified by 
genotype at rs2277831 
To assess whether the OA association to rs2277831 can influence the expression of 
BCL2L13, BID or MICAL3, I measured the expression of these genes quantitatively using 
real time PCR and cDNA synthesised from RNA that had been extracted from cartilage 
tissue. A total of 55 OA patients were studied, 12 who had hip OA and 43 who had 
knee OA. Cartilage tissue was analysed as this is the principle tissue type involved in 
OA. Gene expression was measured using the real time PCR assays listed in Table 2.2 
(Chapter 2.17). The real time PCR assay for BCL2L13 captures 4 of the 8 protein coding 
transcript isoforms (ENST00000399782, ENST00000317582, ENST00000543133 and 
ENST00000493680) and that for BID captures all 6 protein coding transcript isoforms. 
The real time PCR assay for MICAL3 targets 9 of 15 protein coding transcript isoforms: 
ENST00000383094, ENST00000414725, ENST00000400561, ENST00000461307, 
ENST00000441493, ENST00000585038, ENST00000207726, ENST00000429452 and 
ENST00000444520. The expression data were then stratified by the genotype at 
rs2277831. This SNP was genotyped using DNA extracted from the cartilage samples 
1     2     3    4     5     6  100 bp 
200 bp 
300 bp 
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(Chapter 2.20). Linear regression was then performed to determine if the gene 
expression relative to genotype differed significantly from the null (Figure 4.8).  
 Of the 55 OA patients analysed, three patients were homozygous GG, 21 were 
heterozygous and 31 were homozygous AA. There was no significant correlation 
between genotype at rs2277831 and the expression of BCL2L13, BID or MICAL3, with 
P-values of 0.06, 0.51 and 0.38, respectively (Figure 4.8).  
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Figure 4.8: Expression of (A) BCL2L13, (B) BID and (C) MICAL3 stratified by the genotype at 
the OA associated SNP rs2277831 in cartilage tissue from 55 OA patients. The data points 
represent the average of three technical replicates for each sample. The expression of 
BCL2L13, BID and MICAL3 were compared to the average of the housekeeping genes and the 
2^-delta Ct values were plotted against genotype. The horizontal bars represent the mean 
plus the standard error of the mean. A linear regression was performed to assess the 
correlation between gene expression and genotype and the P-values are shown below each 
graph. 
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Correlating genotype with overall gene expression is vulnerable to the natural 
fluctuation in gene expression, which can be influenced by patient gender, age and 
ethnic background. Therefore this technique is liable to generating false-negative 
results, due to the reduced sensitivity and accuracy of this method (Johnson et al., 
2008). Directly testing for allelic expression differences can overcome this, therefore 
this was the technique that I then used. 
4.2.3 Database searching for polymorphisms  
HapMap genome browser (http://hapmap.ncbi.nlm.nih.gov/) was used to query the 
genotype frequency and linkage disequilibrium (LD) database to search for 
polymorphisms on chromosome 22q11.21 that have been genotyped in the CEU 
population (individuals of European ancestry). Transcribed polymorphisms in BCL2L13, 
BID and MICAL3 with high minor allele frequency (MAF) of more than 15% in the 
population were selected using the National Centre for Biotechnology Information 
(NCBI) variation database (dbSNP; http://www.ncbi.nlm.nih.gov/projects/SNP/).  
Eight transcribed SNPs were selected on chromosome 22q11.21: rs4488761, 
rs2587100, rs9967, rs11538, rs5992854, rs11917, rs1057721 and rs4819639. These 
transcribed SNPs were used to carry out AEI analyses (Table 4.2, Figure 4.9).  
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SNP 
Position on 
chr. 22 on 
NCBI 
genome 
build 37.3 
Alleles MAF
*
 Gene 
Location of SNP 
in gene 
Pairwise linkage 
disequilibrium relative 
to the OA associated 
SNP rs2277831 
 
D' r
2
 
rs4488761 18209613 A/G 0.46 BCL2L13 3'UTR/exonic
^
 0.11 0.00 
rs2587100 18210704 C/G 0.40 BCL2L13 3'UTR 0.02 0.00 
rs9967 18211205 C/T 0.38 BCL2L13 3'UTR 0.21 0.01 
rs11538 18220831 T/C 0.18 BID 3'UTR/exonic
^
 0.12 0.00 
rs5992854 18300240 T/C 0.32 MICAL3 exonic 1.00 0.71 
rs11917 18343011 G/T 0.41 MICAL3 3'UTR 0.76 0.11 
rs1057721 18343843 G/A 0.41 MICAL3 3'UTR 0.78 0.13 
rs4819639 18347127 C/T 0.29 MICAL3 3'UTR 0.74 0.06 
Table 4.2:  The eight transcript SNPs studied at chr22q11.21 
*Minor Allele Frequency in Europeans (dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/) 
^Multiple predicted splice isoforms result in different potential locations in the transcript 
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Figure 4.9: Linkage disequilibrium around BCL2L13, BID and MICAL3 showing the eight 
transcript SNPs and the associated SNP rs2277831, outlined in red 
(http://hapmap.ncbi.nlm.nih.gov/). The numbers within boxes represent the r2 values 
between each SNP. The blocks illustrate a group of SNPs which are in high linkage 
disequilibrium with each other. Arrows indicate the direction in which each gene is 
transcribed. 
4.2.4 Allelic expression imbalance at BCL2L13, BID and MICAL3 in cartilage 
tissue 
I identified 33 patients who were heterozygous at one or more of the eight transcript 
SNPs using RFLP assays listed in Table 2.6 (Chapter 2.20). Thirty-two of the 33 were OA 
patients whereas patient 15 had undergone joint surgery due to a neck-of-femur (NOF) 
fracture. For two of the OA patients, more than one tissue type was collected: fatpad 
and synovium for patient 25, cancellous bone and osteophyte for patient 33. For all 
other patients only one tissue type per patient was collected (Table 4.3). I performed 
AEI analysis on cDNA synthesised from the RNA extracted from the patient tissues 
either by using Sequenom iPLEX assays or real time quantitative PCR genotyping assays 
(Chapter 2.21 and Chapter 2.22). The patients’ genomic DNA (gDNA) from the 
MICAL3 BCL2L13  BI
D 
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corresponding tissues were used to normalise the allelic expression ratios, and a two-
tailed Mann-Whitney exact test was performed to compare the distribution between 
allelic ratios of gDNA and cDNA replicates. A patient was considered to show AEI if the 
P-value was less than 0.05 and the AEI observed was 20% or greater (Chapter 2.32.4).  
Twenty-eight of the 33 patients were heterozygous for one or more of the three 
BCL2L13 transcript SNPs. Twelve of the 28 demonstrated AEI (data highlighted in 
yellow in Table 4.3). Of these 12 patients, three were heterozygous for the associated 
SNP rs2277831 (patients 6, 27 and 28), three were homozygous GG at rs2277831 and 
six were homozygous AA at rs2277831. AEI at BCL2L13 did not therefore correlate with 
the genotype at rs2277831. The largest allelic ratio observed at BCL2L13 was 2.82 
(P=0.004) at transcript SNP rs2587100 for patient 11 (Figure 4.10), who is homozygous 
AA at rs2277831. 
Eleven patients were heterozygous for the BID transcript SNP rs11538. Three of the 
eleven demonstrated AEI, patients 8, 30 and 31 (data highlighted in blue in Table 4.3). 
There was no correlation between genotype at rs2277831 and AEI at BID, with all three 
patients being homozygous AA at this SNP. The largest allelic ratio observed at BID was 
2.09 (P=0.001) in patient 30 (Figure 4.10).  
Twenty-seven patients were heterozygous for one or more of the four MICAL3 
transcript SNPs, of which 19 demonstrated AEI (data highlighted in green in Table 4.3). 
Of these 19, five were heterozygous for the associated SNP rs2277831 (patients 4, 6, 
18, 28 and 32), one was homozygous GG at rs2277831 and 13 were homozygous AA. 
AEI at MICAL3 did not therefore correlate with genotype at rs2277831. The largest 
allelic ratio observed at MICAL3, and at any of the three genes studied, was 5.47 
(P=0.001) at transcript SNP rs5992854 for patient 9 (Figure 4.10), who is homozygous 
AA at rs2277831. 
The average allelic expression ratios for the heterozygotes at the eight transcript SNPs 
were plotted and stratified by genotype at rs2277831 (Figure 4.11). At any of the 
transcribed SNPs, a Kruskal-Wallis test showed no significant evidence of a difference 
in the allelic expression ratios between the different genotypes at rs2277831 (P-values 
of 0.45 at rs4488761, 0.11 at rs2587100, 0.20 at rs9967, 0.15 at rs11538, 0.88 at 
rs5992854, 0.35 at rs11917, 0.41 at rs1057721 and 0.53 at rs4819639). 
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Overall, I have studied hip cartilage, knee cartilage, fatpad, synovium, cancellous bone 
and osteophyte tissue in OA patients and hip cartilage from a NOF patient. Although I 
observed AEI for one or more of the tissues in each gene, the AEI does not correlate 
with genotype at the OA associated SNP rs2277831. 
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Patient 
number 
Sex 
Age at 
surgery 
(years) 
Tissue* 
BCL2L13 BID MICAL3 
rs4488761 rs2587100 rs9967 rs11538 rs2277831 rs5992854 rs11917 rs1057721 rs4819639 
Gen
^
 
AER† 
(A/G) 
Gen
^
 
AER† 
(C/G) 
Gen
^
 
AER† 
(C/T) 
Gen
^
 
AER† 
(T/C) 
Gen
^
 Gen
^
 
AER† 
(T/C) 
Gen
^
 
AER† 
(T/G) 
Gen
^
 
AER† 
(G/A) 
Gen
^
 
AER† 
(C/T) 
1 F 55 Cart (K) AG 1.04 CG 0.67 CT 0.71 TC 0.90 GG CC - GG - AA - CC - 
2 M 74 Cart (K) AG 1.15 CG 1.03 CT 0.91 TT - GG CC - GG - AA - CC - 
3 M 82 Cart (K) AA - CG 0.83 TT - TC 1.10 GA TC 1.13 GG - AA - CT 0.96 
4 M 57 Cart (K) AG 0.95 CG 0.87 CT 1.09 TC 1.06 GA TC 0.56 TG 1.30 GA 2.10 CT 1.38 
5 F 57 Cart (K) AA - GG - TT - TT - GA TC 1.14 TG 0.88 GA 0.84 CT 0.90 
6 M 58 Cart (K) AA - CG 0.78 TT - TT - GA TC 1.30 TG 1.11 GA 0.87 CT 1.02 
7 M 71 Cart (K) GG - GG - CC - TT - GA TC 1.02 GG - AA - CC - 
8 F 72 Cart (K) AG 1.09 CG 0.91 CT 1.15 TC 1.54 AA TT - TG 1.51 GA 0.85 CT 0.87 
9 M 64 Cart (K) AG 0.91 CG 1.01 CT 1.09 TT - AA TC 5.47 TT - GG - CC - 
10 M 76 Cart (K) GG - CG 0.88 CT 1.33 TT - AA TT - TG 1.01 GA 1.51 CT 0.82 
11 F 66 Cart (K) AG 1.40 CG 2.82 CT 0.57 TT - AA TC 1.22 TT - GG - TT - 
12 F 67 Cart (H) AG 1.67 CG 1.98 CT 1.01 TT - AA TC 0.83 TT - GG - TT - 
13 F 76 Cart (H) AG 1.04 CG 0.99 CT 1.22 TC 1.01 AA TT - TG 0.76 GA 1.14 CT 1.49 
14 F 50 Cart (H) GG - CG 0.94 CC - TT - AA TT - TT - GG - CT 0.83 
15 M 83 Cart (H) AG 0.97 CG 1.00 CT 1.18 TC 0.96 AA TC 1.03 TG 1.00 GA 1.16 CT 0.93 
16 M 62 Fatpad AG 1.06 CG 1.00 CT 1.01 TC 0.94 GG CC - TG 1.09 GA 1.39 CC - 
17 M 57 Fatpad AG 1.01 GG - CT 0.80 TT - GG TT - GG - AA - CC - 
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18 M 76 Fatpad GG - GG - CC - TT - GA TC 1.92 GG - AA - CC - 
19 M 79 Fatpad GG - GG - CC - TT - GA TC 0.96 TG 1.03 GA 1.13 CT 1.02 
20 M 58 Fatpad AG 0.99 CC - TT - TT - GA TT - GG - AA - CC - 
21 M 58 Fatpad AG 1.02 CG 1.00 CT 1.36 TT - AA TT - TG 0.80 GA 0.63 CT 1.09 
22 F 42 Fatpad AG 1.05 CG 0.94 CT 1.15 TT - AA TT - TG 2.13 GA 1.22 CT 0.92 
23 M 71 Fatpad GG - CG 1.00 CT 1.13 TT - AA TT - TG 1.27 GA 1.23 CC - 
24 F 67 Fatpad AG 0.95 CG 1.05 CT 0.95 TT - AA TC 0.75 TT - GG - TT - 
25 F 78 Fatpad AG 1.15 CG 0.89 CT 0.92 TT - AA TT - GG - AA - CC - 
26 M 74 Syn AG 0.80 GG - CT 1.33 TT - GG CC - GG - AA - CC - 
27 M 62 Syn AG 0.99 CG 0.85 CT 1.23 TT - GA TC 1.12 GG - AA - CC - 
28 M 67 Syn AG 0.97 CG 0.98 CT 1.32 TC 0.83 GA TC 0.81 TG 0.57 GA 0.75 CT 1.24 
29 M 60 Syn AG 1.11 GG - CT 1.14 TT - AA TT - TG 1.19 GA 1.32 CC - 
30 M 69 Syn AG 0.85 CG 1.98 CT 0.72 TC 2.09 AA TT - TT - GG - CT 0.77 
31 F 54 Syn AG 0.90 CG 1.16 CT 1.19 TC 1.56 AA TT - TG 1.85 GA 1.89 CC - 
25 F 78 Syn AG 1.00 CG 0.95 CT 1.02 TT - AA TT - GG - AA - CC - 
32 F 72 Can bn AA - CG 1.10 TT - TC 1.14 GA TC 0.96 TG 0.86 GA 1.23 CT 1.07 
33 M 86 Can bn GG - GG - CC - TT - AA TT - TG 1.43 GA 1.10 CC - 
33 M 86 OP GG - GG - CC - TT - AA TT - TG 1.27 GA 1.31 CC - 
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Table 4.3: Allelic expression imbalance analysis for 33 patients 
*Cart (H), hip cartilage; Cart (K), knee cartilage; Syn, synovium; Can bn, cancellous bone; OP, osteophyte. ^Gen, genotype. †AER, allelic expression ratio. Text 
highlighted in yellow, blue and green denote AEI at the 20% threshold at BCL2L13, BID and MICAL3 respectively.
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Figure 4.10: Allelic expression imbalance in patients 11, 30 and 9, who showed the largest 
allelic ratios at BCL2L13 (rs2587100), BID (rs11538) and MICAL3 (rs5992854) respectively.  
Data points represent log2 of the normalised allelic ratio of genomic DNA (gDNA) or cDNA 
for each replicate. A value of 0 on the Y-axis denotes an allelic ratio of 1:1. A two-tailed 
Mann-Whitney exact test was performed to compare the distribution between allelic ratios 
of gDNA and cDNA replicates. (A) Patient 11 demonstrated a 2.82 fold greater expression of 
the C allele relative to the G allele (P=0.004) at BCL2L13 SNP rs2587100. (B) Patient 30 
demonstrated a 2.09 fold greater expression of the T allele relative to the C allele (P=0.001) 
at BID SNP rs11538. (C) Patient 9 demonstrated a 5.47 fold greater expression of the T allele 
relative to the C allele (P = 0.001) at MICAL3 SNP rs5992854. Four gDNA and four cDNA 
replicates are shown. 
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Figure 4.11: Allelic expression imbalance at the transcript SNPs (A) rs4488761, (B) rs25687100, (C) rs9967, (D) rs11538, (E) rs5992854, (F) rs11917, (G) rs1067721 
and (H) rs3819639, stratified by genotype at rs2277831.  
A total of 33 patients were studied who were heterozygous at one or more of the eight transcript SNPs. The averaged log2 of the normalised allelic ratios are 
shown for each patient, categorised according to the genotype at the associated SNP, rs2277831. The shaded area represents a 20% fold difference in 
expression between the two alleles. A Kruskal-Wallis test was performed to assess the correlation between AEI and the genotype at rs2277831.
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4.3 Discussion 
It is becoming more apparent that most common traits are influenced by large 
numbers of alleles that individually have small effects (Allen et al., 2010). It has also 
been shown that most complex trait alleles influence gene expression by modulating 
transcription or transcript stability (Montgomery and Dermitzakis, 2011). I therefore 
hypothesised that the OA association signal that maps to chromosome 22q11.21, 
detected at SNP rs2277831, may mediate its effect on OA susceptibility by modulating 
the expression of one or more of the three genes from within the signal. I chose to 
focus the gene expression studies on joint tissues from patients who had undergone 
joint replacement surgery rather than a tissue unrelated to OA, such as blood.  
I first looked at overall expression of BCL2L13, BID and MICAL3 in a variety of joint 
tissues. The three genes were expressed in all tissue types assessed.  
I then quantitatively measured gene expression of BCL2L13, BID and MICAL3 in 
cartilage tissue RNA extracted from OA patients and stratified the expression by 
genotype at rs2277831, with no significant correlations observed. As the real time PCR 
assays used to assess BCL2L13 and MICAL3 did not capture all transcript isoforms of 
these two genes, this may have contributed to a false negative result. Therefore, it will 
be of interest to measure the expression of the other transcript isoforms and stratify 
the expression by genotype to see if there is a correlation between expression and 
genotype at rs2277831.  
I subsequently tested each gene for the activity of cis-regulatory polymorphisms by 
measuring AEI at eight transcribed SNPs, three residing in BCL2L13, one in BID and 
three in MICAL3. My results revealed that AEI was common at these loci and was not 
restricted to a particular tissue type. If the OA associated G allele of rs2277831 is a 
marker for altered expression of one or more of the three genes tested, then a 
heterozygote for this SNP would tend to demonstrate AEI. However, I did not observe 
any correlation between the genotype at rs2277831 and AEI, with an individual 
heterozygous for rs2277831 being no more likely to demonstrate AEI at one of the 
three genes than an individual homozygous at this SNP.  
Some individuals who were heterozygous for more than one transcript SNP at a 
particular gene showed an AEI pattern that was not always consistent between the 
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transcript SNPs. For example, for BCL2L13 patient 1 shows AEI at rs2587100 (allelic 
expression ratio; AER; of 0.67) and at rs9967 (AER of 0.71), but not at rs4488761 (AER 
of 1.04). BCL2L13 has 14 transcript isoforms and rs4488761 exists in 9 of these 
whereas, rs2587100 and rs9967 exist in five. Therefore, perhaps isoform specific eQTL 
effects exist and such variability could account for the AEI differences observed. It will 
therefore be of interest to utilise AEI assays specific for different transcript isoforms to 
detect isoform specific AEI. 
Although AEI was common in all joint tissues analysed, there was inter and intra-
individual variation. For example, AEI at rs9967 was observed in both directions in 
cartilage tissue in patients 1 and 10. Also, in patient 33, for whom I analysed both 
cancellous bone and osteophyte tissue, AEI at rs1057721 was apparent only in 
osteophyte tissue. This suggests that different cellular environments can give rise to 
differential allelic expression in different tissues in the same individual. This has been 
shown previously in OA joint tissues in expression studies of the gene BMP5 (Wilkins et 
al., 2007). 
Overall, BCL2L13, BID and MICAL3 are subject to cis-acting polymorphisms that 
influence the expression of the genes in the joint tissues of patients who have 
undergone surgery. My data do not however support a role for such cis-regulation at 
these genes as accounting for the OA association signal at chromosome 22q11.21 in 
the tissues that I have looked at. It is possible that there are transcript isoform specific 
effects or a cis-effect related to OA susceptibility at this locus is not active in end stage 
OA tissue.  
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Chapter 5: Assessing whether the OA associated locus mapping to 
chromosome 12q23.3 mediates its effect by influencing the 
expression of CHST11 
5.1 Introduction 
The arcOGEN GWAS identified an association of hip OA to SNP rs835487 (G/A), with an 
odds ratio of 1.13 for allele G and a P-value of 1.64 x 10-8. The SNP is located on 
chromosome 12q23.3 within intron 2 of CHST11 (Zeggini et al., 2012). The associated G 
allele has a frequency of 0.37 in Europeans. As shown in Figure 5.1, the association 
signal spans approximately 200 kb of the gene and includes exon 2 and regions of 
intron 1 and 2. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Association plot of the chromosome 12q23.3 hip-OA signal from the arcOGEN 
GWAS. Case-control association results (-log10 p-value) for genotyped SNPs in the discovery 
set are plotted against genomic position. The rs835487 SNP is denoted by a purple diamond 
in the discovery set (p=3.26 x 10-6) and by a purple square in the final meta-analysis (p=1.64 
x 10-8). The circles indicate association results of genotyped SNPs in the region; the colour 
reflects the correlation coefficient (r2) of each genotyped SNP with rs835487 estimated using 
the CEU HapMap panel. Estimated recombination rates (in centimorgans per megabase) are 
plotted in light blue. The region shown extends to 500kb upstream and downstream of 
rs835487. Figure adapted from Zeggini et al. (2012). 
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The gene codes for the Golgi enzyme, carbohydrate sulfotransferase 11 (CHST11), 
which is also known as chondroitin-4-sulfotransferase-1 (C4ST1). The gene has 6 
transcript isoforms, 5 of which are protein coding (Figure 5.2). Of these 5, isoforms 
ENST00000549260 and ENST00000303694 are the only ones that produce an enzyme 
molecule containing the catalytic domain. The longest isoform spans 301 kb of 
genomic sequence and encodes a protein of 352 amino acids, which is the most well 
characterised. The amino acid identity between human CHST11 and mouse CHST11 is 
95% and between human and zebrafish is 78%, suggesting highly conserved functions 
across species (www.ncbi.nlm.nih.gov). CHST11 is a type II transmembrane protein 
with an N-terminal cytoplasmic domain, Golgi transmembrane domain and a luminal 
catalytic domain (Kang et al., 2002). The protein is expressed in a variety of adult 
tissues, with highest levels observed in lung, placenta, spleen, thymus and peripheral 
leukocytes (Klüppel, 2010).  
 
Figure 5.2: The five protein coding transcript isoforms of CHST11 (from www.ensembl.org). 
The horizontal bar across the top of the figure shows the forward strand of chromosome 
12q23.3 from left to right. The transcript isoforms of CHST11 are shown as horizontal lines 
and rectangles within the area highlighted in green. The shaded rectangles represent the 
coding part of exons whilst the unshaded rectangles represent the UTRs. The horizontal lines 
show the introns of CHST11. The ensembl transcript IDs are shown below each transcript. 
CHST11 is a member of the Golgi-associated chondroitin sulfotransferases, which are 
involved in the modification of chondroitin sulphates in the Golgi apparatus. 
Chondroitin sulphates are synthesised in the Golgi and undergo sulphation at specific 
positions on the sugar moieties during chain elongation. CHST11 is one of the enzymes 
that catalyses the transfer of sulphate groups onto chondroitin at the 4-hydroxyl group 
of N-acetylgalactosamine (GalNAc) sugars, to form chondroitin-4- sulphate (CS-A; 
(Klüppel et al., 2010).  
ENST00000303694 
 
ENST00000549260 
ENST00000546689
  
ENST00000547956 
ENST00000303694 
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Related proteins of CHST11, which also catalyse the transfer of sulphate groups to the 
4-hydroxyl position, include CHST12, CHST13 and CHST14. CHST11 and CHST13 
preferentially use chondroitin as a substrate, although they also show activity towards 
dermatan (Mikami et al., 2003). CHST12 and CHST14 show preferential activity 
towards dermatan disaccharides to form dermatan sulphate (DS or CS-B), but are also 
able to use chondroitin as a substrate (Mikami et al., 2003). CHST11, CHST12 and 
CHST14 show a wide spread expression pattern in adult human tissues, but expression 
of CHST13 is mainly observed in liver, kidney and lymph nodes (Kang et al., 2002). 
Chondroitin sulphate is a major component of the glycosaminoglycan (GAG) chains, 
which in cartilage interacts with the core protein to form the proteoglycan aggrecan. 
This is a major component of the cartilage extracellular matrix and interacts with 
hyaluronan to form large, complex aggregates. Sulphation of chondroitin provides a 
strong negative charge to GAG chains, which show a high affinity to water and 
generate electrostatic forces that help maintain the structural integrity of the cartilage. 
Chondroitin sulphation is also essential in the interaction of the extracellular matrix 
with many cationic macro molecules including growth factors (Gama et al., 2006).  
It has been shown that CHST11 is involved in cellular signalling events including TGF-β 
and Wnt signalling. Willis et al (2009) identified TGF-β responsive regulatory modules 
in CHST11 that can positively and negatively regulate CHST11 transcription in a cell 
type specific manner (Willis et al., 2009). They used luciferase reporter assays to show 
enhanced transcriptional activity of these modules post treatment with TGF-β ligand in 
human embryonic kidney (HEK293T) and mouse mammary gland (NmuMG) cells. 
Shortkroff and Yates (2007) have reported that a decrease in chondroitin sulphation or 
CS levels can lead to a reduction in β-catenin accumulation in articular chondrocytes, 
which therefore demonstrates  a role of CHST11 in the canonical Wnt signalling 
pathway. 
To determine the role of CHST11 in mammalian development, Klüppel et al. (2005) 
generated a loss of function mutation of the gene in mouse embryonic stem cells 
through gene trapping. This mutation created a fusion transcript of Chst11 that 
disrupted the expression of exons 2 and 3, which encode the transmembrane and 
intra-Golgi catalytic domains of the enzyme. Whilst the heterozygous mice were fertile 
and viable, the homozygous mice displayed severe dwarfism and died within six hours 
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of birth due to respiratory distress (Klüppel et al., 2005). The mutant mice showed 
multiple skeletal abnormalities compared to the wildtype mice, including a smaller rib 
cage, shortened limbs and a dome-shaped skull. The growth plates of these mutants 
were disorganised with alterations in the orientation of chondrocyte columns. They 
also showed a reduction in CS and aggrecan content, which is often observed in 
osteoarthritis. These results demonstrate an important role for CHST11 in mammalian 
development.  
It has been reported that CHST11 has a role in human diseases, including cancer and 
OA. There is evidence of an alteration of the pattern of chondroitin sulphation in colon 
adenocarcinoma, such that the ratio of 4-hydroxyl sulphated and 6-hydroxyl sulphated 
chondroitin changes from 4:1 in normal colon tissue to 1:3 in malignant cells 
(Theocharis, 2002). This implies that it is important to tightly regulate the balance and 
pattern of chondroitin sulphation.  A genome-wide gene expression microarray 
analysis in human subjects identified CHST11 as one of the genes that showed highly 
significant upregulation in knee OA cartilage versus normal cartilage, with a 6.8 fold 
increase observed (Karlsson et al., 2010). Another microarray analysis on cartilage 
from hip OA and from neck-of-femur (NOF) fracture patients, which is often used as a 
control cartilage due to the absence of any OA lesions, showed a 1.9 fold upregulation 
of CHST11 in OA compared to control cartilage (Xu et al., 2012).  
Monoclonal antibodies that specifically recognise native CS/DS sulphation motif 
epitopes were found to stain positively on newly synthesised aggrecan extracted from 
human OA cartilage, but not in normal adult human cartilage (Caterson et al., 1990; 
Slater et al., 1995). Other studies have also shown an increase in expression of native 
CS/DS sulphation motif epitopes in OA hyaline articular cartilage in early stages of OA 
(Rizkalla et al., 1992). 
Upregulation of CHST11, together with an increased expression of native CS/DS motif 
epitopes, during OA may be a result of the cartilage attempting to repair the damage, 
and have the potential to be used as biomarkers to monitor the development and 
progression of OA (Caterson, 2012). 
Overall, CHST11 harbours genetic susceptibility that is relevant to OA disease 
development at the hip. The gene codes for an enzyme that post-translationally 
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modifies GAGs, a component of the functionally critical and abundant cartilage protein 
aggrecan. I hypothesised that the OA susceptibility acted by modulating the expression 
of CHST11 and in this chapter I report on the experiments that I performed to test this 
hypothesis.  
5.2 Results 
5.2.1 Qualitative gene expression analysis of CHST11 in joint tissue cDNAs 
To assess in which joint tissues CHST11 was expressed, complimentary DNAs (cDNAs) 
were synthesised from RNAs extracted from the cartilage, cancellous bone, fatpad, 
meniscus, synovium and ligament tissues from OA patients (Chapter 2.3). CHST11 was 
then PCR amplified using primers listed in Table 2.4 (Chapter 2.4). Initially, the overall 
expression of CHST11 was assessed using primers that target a common region in four 
of the five protein coding transcript isoforms. The primers used were designed to 
target exon 1 and 2 of ensemble transcript IDs ENST00000303694, ENST00000549260, 
ENST00000546689 and ENST00000547956. Expression of ensembl transcript ID 
ENST00000549016 was not assessed in this experiment.  CHST11 was expressed in all 
tissues of the joint analysed, with particularly high levels observed in cartilage, 
meniscus and ligament (Figure 5.3). 
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Figure 5.3: CHST11 expression in joint tissue cDNAs. Lane 1: 
cartilage, 2: cancellous bone, 3: fatpad, 4: meniscus, 5: 
synovium, 6: ligament, 7: PCR blank. The PCR products were 
run on a 2% agarose gel containing ethidium bromide. A 100 
bp DNA ladder was used for sizing of PCR products. 
The expression of the five protein coding transcript isoforms of CHST11 were then 
assessed by PCR using cDNAs synthesised from RNAs extracted from the cartilage, 
fatpad and synovium of OA patients. Cartilage from a patient who had undergone a 
NOF fracture was also studied. The primers used are listed in Table 2.5.   
The difference between transcript ENST00000303694 and transcript 
ENST00000549260 (the two longer isoforms; Figure 5.2) is an additional 15 bp at the 
end of exon 1 of transcript ENST00000549260. Therefore, the forward primer designed 
for transcript ENST00000549260 contained these 15 bp, whilst that designed for 
ENST00000303694 spanned the exon-exon boundary, and did not contain the 
additional 15 bp. Similarly, transcripts ENST00000546689 and ENST00000547956 (the 
two shorter isoforms) were different in the same additional 15 bp sequence, which is 
present at the end of exon 1 of ENST00000547956. Hence the same forward primers 
used to distinguish between the two longer isoforms were utilised, with the reverse 
primer designed to the unique 3'UTR sequence present in ENST00000546689 and 
ENST00000547956. Exon 1 of transcript ENST00000549016 is not present in any of the 
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other transcripts, hence a forward primer was designed to this exon to distinguish this 
isoform from the others. 
Four of the five transcript isoforms were expressed in all the joint tissues analysed, 
whilst the expression of ENST00000549016 was not detected in any of the tissues 
analysed (Figure 5.4). Due to the unavailability of a suitable positive control for the PCR 
of this transcript, I cannot exclude the possibility that my failure to observe its 
expression is a false negative. However, although this transcript isoform is listed on the 
ensembl and UCSC genome browsers, it is absent on the NCBI database. I conclude 
therefore that it is not expressed in the tissues that I have tested. 
The intensity of the bands corresponding to the PCR products from cDNAs used in this 
experiment is not directly comparable with that from the earlier experiment (Figure 
5.3). This is probably because the cDNAs used were from different individuals, 
reflecting inter-individual variation in the level of CHST11 expression. 
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Figure 5.4: CHST11 transcript isoform expression in joint tissue cDNAs. Different primer pairs 
were used to amplify ensembl transcript ID ENST00000303694 (A), ENST00000549260 (B), 
ENST00000549016 (C), ENST00000546689 and ENST00000547956 (D). Lane 1: OA cartilage, 2: 
NOF cartilage, 3: fatpad, 4: synovium 5: PCR blank. The PCR products were run on a 2% 
agarose gel containing ethidium bromide. A 100 bp DNA ladder was used for sizing of PCR 
products. 
In summary, CHST11 expression was observed across all joint tissues analysed. The 
expression of four of the five protein coding transcript isoforms was also detected 
across the joint tissues.  
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5.2.2 Gene expression of CHST11 in hip OA versus NOF cartilage 
It has previously been shown that CHST11 expression is 6.8 fold higher in OA knee 
cartilage compared to normal knee cartilage in a study which used whole genome 
microarray analysis on 5 OA and 8 normal donors (Karlsson et al., 2010), whilst a 
microarray analysis on 9 OA hip and 10 NOF patients revealed a 1.9 fold increase in 
CHST11 expression in hip OA (Xu et al., 2012).  
The CHST11 genetic association is to hip OA and I therefore set out to confirm the 
observation of an increased expression of the gene in a larger sample. I used real time 
quantitative PCR gene expression analysis and a cohort of 28 hip OA patients and 19 
NOF patients (Chapter 2.17). CHST11 expression was measured using the assay listed 
in Table 2.2. The gene showed a 2.6 fold greater expression in hip OA compared to 
NOF cartilage with a P-value of 0.007 (Figure 5.5). This result is clearly comparable to 
that from the microarray study. 
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Figure 5.5: CHST11 expression relative to housekeeping 
genes in cartilage from hip OA and NOF patients. The error 
bars represent the mean plus the standard error. 
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5.2.3 Database searching for common non-synonymous mutations in CHST11  
In order to determine if the OA association to CHST11 is caused by an amino acid 
substitution, I searched the ensembl online database (www.ensembl.org) for common 
variants within the CHST11 coding region, in particular, within exon 2, which lies within 
the association interval. 
There are no common (minor allele frequency greater than 15%) non-synonymous 
SNPs in the gene that can account for the association signal. 
5.2.4 CHST11 expression in cartilage, fatpad and synovium tissue stratified by 
genotype at rs835487 
If the OA association at CHST11 influences expression of the gene, then one way to 
assess this is to measure CHST11 expression in a large number of individuals and to 
then stratify expression level by genotype at rs835487; a correlation would support an 
effect of the association signal on CHST11 expression. I was able to perform this 
analysis on cartilage from OA patients. My group also has a biobank of cartilage from 
NOF patients and of fatpad and synovium tissue from knee OA patients. These were 
also studied.  
CHST11 expression was measured using the real time PCR assay listed in Table 2.2 
(Chapter 2.17). Linear regression was performed to determine if the gene expression 
relative to genotype differed significantly from the null.  
Of a total of 113 patient cartilage cDNAs analysed, 94 were synthesised from OA knee 
and OA hip cartilage RNAs whilst 19 were from NOF cartilage RNAs. Of the 94 OA 
patients, 14 were homozygous GG, 42 were heterozygous and 38 were homozygous 
AA at rs835487. There was no significant correlation between genotype at rs835487 
and CHST11 expression, with a P-value of 0.67 (Figure 5.6). As the association of this 
SNP is seen in hip OA, the hip cartilage samples were analysed separately from the 
knee cartilage samples. Of the 94 cartilages, 28 were from the hip joints of OA 
patients. There was no correlation between genotype at rs835487 and CHST11 
expression in these hip OA cartilage samples, with a P-value of 0.76 (Figure 5.6). 
CHST11 expression in NOF cartilage was also stratified by genotype at rs835487. Of the 
19 NOF samples, 6 were heterozygous and 13 were homozygous AA. There were no 
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homozygous GG patients in this cohort.  Again, there was no correlation between 
CHST11 expression and genotype, with a P-value of 0.83 (Figure 5.6).  
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Figure 5.6: Expression of CHST11 stratified by the genotype at the OA associated SNP 
rs835487 in (A) hip or knee cartilage of 94 OA patients (B) hip cartilage of 28 OA patients and 
(C) hip cartilage of 19 NOF patients. The data points represent the average of the three 
replicates for each sample. The expression of CHST11 was compared to the average of the 
housekeeping genes and the 2^-delta Ct values were plotted against genotype. The 
horizontal bars represent the mean plus the standard error of the mean. A linear regression 
(A and B) and a two-tailed Mann-Whitney exact test (C) were performed to assess the 
correlation between gene expression and genotype. The P-values are shown below each 
graph. 
A B 
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Of the 30 fatpad samples from knee OA patients, 5 were homozygous GG, 12 were 
heterozygous and 13 were homozygous AA for rs835487. Of the 25 synovium samples 
from knee OA patients, 3 were homozygous GG, 12 were heterozygous and 10 were 
homozygous AA for the SNP. No significant correlation between CHST11 expression 
and the genotype at rs835487 was observed in the fatpad or synovium samples, with 
P-values of 0.37 and 0.27 respectively (Figure 5.7). 
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Figure 5.7: Expression of CHST11 stratified by the genotype at the OA associated SNP 
rs835487 in (A) fatpad of 30 OA patients and (B) synovium of 25 OA patients. The data points 
represent the average of the three replicates for each sample. The expression of CHST11 was 
compared to the average of the house keeping genes and the 2^-delta Ct values were 
plotted against genotype. The horizontal bars represent the mean plus the standard error of 
the mean. A linear regression was performed to assess the correlation between gene 
expression and genotype. The P-values are shown below each graph. 
 
In summary, this analysis did not find evidence for a correlation between CHST11 
expression in cartilage, fatpad and synovium tissue and genotype at the associated 
SNP rs835487. 
A B 
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5.2.5 Allelic expression imbalance of CHST11 in cartilage, fatpad and synovium 
tissue 
The above technique of measuring the expression of a gene and then stratifying this by 
genotype is vulnerable to the natural fluctuation in gene expression, which can 
decrease the technique’s sensitivity and accuracy and potentially lead to false negative 
results (Johnson et al., 2008). Therefore I directly measured allelic expression which 
can circumvent this possibility.  
Since CHST11 does not harbour any common variants (minor allele frequency greater 
than 15%) in its coding region, the SNP rs2463018, located in the 3'UTR of the gene 
was used to test for allelic expression imbalance (AEI; Table 2.9). Of the five protein 
coding transcript isoforms of CHST11, ENST00000303694 and ENST00000549260 
harbour this polymorphism. These are the only two isoforms that produce the 
functional enzyme. The SNP was selected as it has a high minor allele frequency in the 
European population (29%; Table 5.1) and because there is a validated real time PCR 
genotyping assay available for it from Applied Biosystems (Chapter 2.22).   
The allelic expression ratios (AERs) were calculated using the formula (2^-FAM Ct)/ (2^-
VIC Ct) and normalised to the allelic expression ratios of genomic DNA (Chapter 2.22).  
I initially performed AEI analysis on cDNA synthesised from the RNA extracted from the 
cartilage tissue of knee and hip OA patients. I then separated the hip cartilage samples. 
The average AERs were plotted against the genotype at rs835487 to assess whether 
there was a correlation between AEI and genotype at the SNP, using a Kruskal-Wallis 
test. I also carried out AEI analysis on NOF cartilage, on fatpad and on synovium tissue. 
SNP 
Position on 
chr. 12 on 
NCBI 
genome 
build 37.3 
Alleles MAF
*
 
Location of SNP 
in CHST11 
Pairwise linkage 
disequilibrium relative 
to the OA associated 
SNP rs835487 
D' r
2
 
rs2463018 18343843 C/T 0.29 3'UTR 0.05 0.002 
Table 5.1: The SNPs studied for AEI analysis of CHST11.  
*Minor allele frequency in Europeans (dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/). 
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Of 96 cartilages analysed, 39 patients were heterozygous at rs2463018. The 
normalised AERs for those heterozygotes are summarised in Table 5.2. Of the 39, 10 
patients demonstrated AEI at a value of 20% or greater and with a P-value of less than 
0.05. Two were homozygous GG, 6 were heterozygous and 2 were homozygous AA at 
the OA associated SNP rs835487. The largest AER observed was 2.08 for patient 12, 
who is heterozygous at rs835487 (P=0.008, Figure 5.8).  Of the 39 heterozygotes, 11 
were hip OA patients, of which 3 demonstrated AEI. Two of these 3 were heterozygous 
and one was homozygous AA at the associated SNP rs835487. 
Five of 19 NOF patients used in this study were heterozygous at rs2463018 (Table 5.3). 
Two of five showed AEI at the 20% threshold and a P-value of less than 0.05, and both 
were homozygous AA at rs835487. The largest AER observed in NOF cartilage was 0.70 
in patient 44 (P=0.001, Figure 5.8). 
 
gDNA cDNA
-1.0
-0.5
0.0
0.5
1.0
1.5
2.0
rs2463018 (T/C) - Patient 12 (OA Cartilage)
P=0.008
L
o
g
2
 A
ll
e
li
c
  
E
x
p
re
s
s
io
n
  
R
a
ti
o
 (
T
/C
)
gDNA cDNA
-1.0
-0.5
0.0
0.5
1.0
1.5
2.0
rs2463018 (T/C) - Patient 44 (NOF Cartilage)
P=0.001
L
o
g
2
 A
ll
e
li
c
  
E
x
p
re
s
s
io
n
  
R
a
ti
o
 (
T
/C
)
Figure 5.8: Allelic expression imbalance in patients 12 and 44, who showed the largest allelic 
ratios in OA cartilage and NOF cartilage, respectively. Data points represent log2 of the 
normalised allelic ratio of genomic DNA (gDNA) or cDNA for each replicate. A value of 0 on 
the Y-axis denotes an allelic ratio of 1:1. A two-tailed Mann-Whitney exact test was 
performed to compare the distribution between allelic ratios of gDNA and cDNA replicates. 
(A) Patient 12 demonstrated a 2.08 fold greater expression of the T allele relative to the C 
allele (P=0.008). Five genomic DNA and five cDNA replicates are shown. (B) Patient 44 
demonstrated a 0.70 fold lower expression of the T allele relative to the C allele (P=0.001). 
Five gDNA and 10 cDNA replicates are shown. 
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The average AERs at rs2463018 were then plotted against the genotype at rs835487. 
There were no significant correlations between AERs and genotype at rs835487 in OA 
cartilage, in OA hip cartilage or in NOF cartilage, with P-values of 0.32, 0.92 and 0.80 
respectively (Figure 5.9). 
Of 30 fatpad samples analysed, 17 were heterozygous at rs2463018. Of the 17, 6 
showed AEI at 20% or greater with a P-value less than 0.05 at rs2463018 (Table 5.4). 
One was homozygous GG, 2 were heterozygous and 3 were homozygous AA at 
rs835487. The largest AER observed was 1.61 in patient 51, who was heterozygous at 
the associated SNP (P=0.02, Figure 5.10).  
Twelve of 25 synovium samples analysed were heterozygous at rs2463018. At 
rs2463018, 4 patients showed AEI at the 20% threshold with a P-value less than 0.05 
(Table 5.5). One patient was heterozygous at the associated SNP (patient 16) and 
showed the largest AER, with a ratio of 1.68 (P=0.008, Figure 5.10). The remaining 
three patients were homozygous AA at rs835487.  
The average AERs for the fatpad and synovium tissues were then stratified by the 
genotype at the associated SNP and a Kruskal-Wallis test was performed to assess the 
association between AERs and rs835487 genotype (Figure 5.11). No significant 
correlations were observed. 
 Of the OA patients who were subject to AEI analyses, for 8 of them multiple joint 
tissues were collected. The 8 patients were: Patient 1 and 27, for whom cartilage, 
fatpad and synovium were collected; patient 5, 12 and 31, for whom cartilage and 
fatpad were collected, patient 16 and 28, for whom cartilage and synovium were 
collected and patient 54, for whom fatpad and synovium were collected. Patient 27 did 
not demonstrate AEI at either one of the tissues analysed. However, AEI observed in 
one tissue type was not necessarily replicated in other tissue types. For example, 
patient 16 did not demonstrate AEI in cartilage tissue, but showed a 1.68 fold AEI in 
synovium. Similarly, patient 54 showed a 1.21 fold AEI in fatpad, but did not 
demonstrate AEI in synovium tissue.  
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Figure 5.9: Allelic expression imbalance stratified by genotype at rs835487 in (A) the 39 hip 
or knee OA patients, (B) the 11 hip OA patients and (C) the 5 NOF patients all heterozygous 
at rs2463018. The averaged log2 of the normalised allelic ratios are shown for each patient, 
categorised according to the genotype at the associated SNP, rs835487. The shaded area 
represents a 20% fold difference in expression between the two alleles of rs2463018. A 
Kruskal-Wallis test was performed in OA cartilage (A and B) and a two-tailed Mann-Whitney 
exact test was performed in NOF cartilage (C) to assess the correlation between AEI and the 
genotype at rs835487. 
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Figure 5.10: Allelic expression imbalance in patients 51 and 16, who showed the largest 
allelic ratios in fatpad and synovium, respectively. Data points represent log2 of the 
normalised allelic ratio of genomic or cDNA for each replicate. A value of 0 on the Y-axis 
denotes an allelic ratio of 1:1. A two-tailed Mann-Whitney exact test was performed to 
compare the distribution between allelic ratios of gDNA and cDNA replicates. Five genomic 
DNA and five cDNA replicates are shown. (A) Patient 51 demonstrated a 1.61 fold greater 
expression (P=0.02) and (B) patient 16 demonstrated a 1.68 fold greater expression 
(P=0.008), both of the T allele relative to the C allele. 
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Figure 5.11: Allelic expression imbalance stratified by genotype at rs835487 in (A) the fatpad 
from 17 OA patients and (B) the synovium from 12 OA patients, all heterozygous at 
rs2463018. The averaged log2 of the normalised allelic ratios are shown for each patient, 
categorised according to the genotype at the associated SNP, rs835487. The shaded area 
represents a 20% fold difference in expression between the two alleles of rs2463018. A 
Kruskal-Wallis test was performed to assess the correlation between AEI and the genotype 
at rs835487. 
In summary, although AEI at CHST11 was observed in all tissues analysed, this did not 
correlate with the genotype at the associated SNP, rs835487.  
 
 
 
 
A B 
 
 
137 
Patient 
number 
Sex 
Age at 
surgery 
Tissue* 
Gen^ at 
rs835487 
AER† at 
rs2463018 
log2 standard 
error 
1 M 74 Cart (K) GG 1.04 0.07 
2 M 76 Cart (K) GG 1.29 0.12 
3 M 63 Cart (K) GG 1.62 0.26 
4 M 70 Cart (K) GG 1.18 0.11 
5 M 71 Cart (K) GG 1.76 0.39 
6 M 74 Cart (K) GG 0.98 0.17 
7 M 71 Cart (H) GG 1.01 0.16 
8 M 50 Cart (K) AG 0.76 0.07 
9 F 81 Cart (K) AG 1.11 0.22 
10 M 74 Cart (K) AG 1.03 0.17 
11 M 82 Cart (K) AG 0.93 0.32 
12 F 69 Cart (K) AG 2.08 0.04 
13 F 67 Cart (K) AG 0.80 0.10 
14 F 73 Cart (K) AG 1.32 0.46 
15 F 80 Cart (K) AG 1.07 0.11 
16 M 67 Cart (K) AG 0.99 0.12 
17 M 64 Cart (K) AG 0.99 0.11 
18 F 64 Cart (K) AG 0.74 0.38 
19 F 80 Cart (K) AG 0.94 0.14 
20 F 58 Cart (H) AG 2.04 0.13 
21 F 78 Cart (H) AG 0.80 0.07 
22 F 69 Cart (H) AG 1.22 0.15 
23 F 77 Cart (H) AG 1.38 0.67 
24 F 71 Cart (H) AG 0.99 0.26 
25 F 65 Cart (H) AG 1.00 0.13 
26 F 50 Cart (H) AG 1.19 0.47 
27 F 78 Cart (K) AA 1.15 0.09 
28 M 56 Cart (K) AA 1.04 0.19 
29 F 66 Cart (K) AA 0.87 0.13 
30 M 68 Cart (K) AA 1.14 0.16 
31 F 67 Cart (K) AA 0.81 0.12 
32 F 64 Cart (K) AA 1.03 0.09 
33 F 67 Cart (K) AA 1.01 0.20 
34 M 86 Cart (K) AA 1.07 0.15 
35 M 46 Cart (K) AA 1.21 0.21 
36 F 62 Cart (K) AA 0.73 0.38 
37 F 67 Cart (H) AA 0.86 0.10 
38 M 66 Cart (H) AA 1.04 0.12 
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39 F 67 Cart (H) AA 1.23 0.17 
Table 5.2: Allelic expression analysis of CHST11 in cartilage from 39 OA patients, 
heterozygous at rs2463018. 
 *Cart (H), hip cartilage; Cart (K), knee cartilage; ^Gen, genotype; †AER, allelic expression 
ratio. Bold text denotes allelic expression imbalance (AEI) at the 20% threshold and with a P-
value less than 0.05. 
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Patient 
number 
Sex 
Age at 
surgery 
Gen^ at 
rs835487 
AER† at 
rs2463018 
log2 
standard 
error 
40 F 84 AG 0.85 0.40 
41 F 89 AG 0.88 0.14 
42 F 79 AA 0.74 0.51 
43 F 94 AA 1.71 0.32 
44 F 91 AA 0.70 0.06 
Table 5.3: Allelic expression analysis of CHST11 in cartilage from 5 NOF patients, 
heterozygous at rs2463018. 
 ^Gen, genotype; †AER, allelic expression ratio. Bold text denotes allelic expression 
imbalance (AEI) at the 20% threshold and with a P-value less than 0.05. 
 
Patient 
number 
Sex 
Age at 
surgery 
Gen^ at 
rs835487 
AER† at 
rs2463018 
log2 standard 
error 
1 M 74 GG 1.19 0.02 
5 M 71 GG 0.94 0.03 
45 F 65 GG 1.00 0.01 
46 F 60 GG 1.13 0.03 
47 F 68 GG 1.45 0.06 
12 F 69 AG 0.96 0.02 
48 F 81 AG 1.10 0.03 
49 F 88 AG 1.05 0.06 
50 F 81 AG 1.34 0.03 
51 M 63 AG 1.61 0.05 
52 M 85 AG 1.05 0.02 
27 F 78 AA 1.14 0.03 
31 F 67 AA 1.19 0.01 
53 M 71 AA 1.17 0.04 
54 F 64 AA 1.21 0.02 
55 F 62 AA 1.21 0.02 
56 F 82 AA 1.32 0.04 
Table 5.4: Allelic expression analysis of CHST11 in fatpad from 17 OA patients, 
heterozygous at rs2463018. 
 ^Gen, genotype; †AER, allelic expression ratio. Bold text denotes allelic expression 
imbalance (AEI) at the 20% threshold and with a P-value less than 0.05.  
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Patient 
number 
Sex 
Age at 
surgery 
Gen^ at 
rs835487 
AER† at 
rs2463018 
log2 
standard 
error 
1 M 74 GG 0.99 0.31 
16 M 67 AG 1.68 0.16 
57  F 73  AG 1.07 0.22 
58 M 75 AG 0.82 0.11 
59 F 64 AG 1.16 0.19 
27 F 78 AA 1.07 0.06 
28 M 56 AA 1.16 0.08 
60 F 72 AA 1.37 0.12 
61  F 69  AA 1.23 0.11 
62  M 69  AA 1.37 0.44 
54 F 64 AA 1.15 0.08 
63  M 72  AA 0.81 0.08 
Table 5.5: Allelic expression analysis of CHST11 in synovium from 12 OA patients, 
heterozygous at rs2463018. 
 ^Gen, genotype; †AER, allelic expression ratio. Bold text denotes allelic expression 
imbalance (AEI) at the 20% threshold and with a P-value less than 0.05.  
5.3 Discussion 
I have initially looked for overall gene expression, then the expression of five protein 
coding transcript isoforms of CHST11 in a variety of joint tissues. CHST11 was 
expressed in all tissue types assessed, and the expression of four of five transcript 
isoforms was detected in the joint tissues that I have looked at.  
It has been reported that the expression of CHST11 is elevated in OA knee and hip 
cartilage compared to healthy cartilage by 6.2 and 1.9 fold respectively (Karlsson et al., 
2010; Xu et al., 2012). These studies used micro array analysis to measure gene 
expression changes. I have used real time PCR to quantify CHST11 expression in hip OA 
cartilage and in NOF cartilage using a larger sample size. I observed a 2.6 fold 
difference in CHST11 expression in OA versus NOF cartilage. This increase in gene 
expression can perhaps be a cause or a consequence of cartilage damage. An increase 
in CHST11 expression may result in an altered sulphation balance of chondroitin, 
leading to a reduction in cartilage extra cellular matrix synthesis, or an increase in 
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CHST11 can be a result of the damaged cartilage attempting to repair itself by 
upregulating genes, whose products are involved in cartilage anabolism. 
In order to look for possible causes for the OA association to CHST11, I have searched 
online databases for common coding SNPs in exon 2 of CHST11, which is the only 
CHST11 exon that maps within the association signal. CHST11 does not harbour any 
common coding SNPs. Therefore, the association to rs835487 is not mediated by an 
amino acid change. 
Hence my hypothesis was that the association to rs835487 on CHST11 was marking an 
expression quantitative trait locus (eQTL), which may influence the expression of 
CHST11. Therefore I have followed the same approach I used to characterise the locus 
on MICAL3 (Chapter 4).  I initially measured overall gene expression of CHST11 in 
cartilage, fatpad and synovium and stratified this by the genotype at rs835487. There 
was no correlation between gene expression and the genotype in the tissues that I 
have analysed. Then I have tested for AEI of CHST11 using a transcript SNP in the 3'UTR 
of CHST11 to quantify the amount of mRNA synthesised from each allele. I stratified 
the allelic expression ratios from the two alleles by the genotype at rs835487 in 
cartilage, fatpad and synovium tissue. There was no correlation between allelic 
expression and the genotype at the OA associated SNP in the tissues I have looked at. 
A heterozygote at this SNP was no more likely to show AEI than would a homozygote 
at this SNP, therefore, rs835487 was unlikely to have an influence on CHST11 
expression in these tissues. 
 Although AEI was common in all joint tissues analysed, there was inter and intra-
individual variation. In individuals for whom more than one tissue type was available, 
in some instances, AEI was apparent in one tissue type, but not in others. Also, in some 
individuals AEI was observed in every tissue analysed, but to different extents, and also 
in opposite directions. This suggests that different cellular environments can give rise 
to differential allelic expression in different tissues in the same individual. This has 
been shown previously for a locus on BMP5 across osteoarthritic and joint tissues from 
the same patient (Wilkins et al., 2007).  
My results show no evidence for a role for cis regulation at CHST11 that can account 
for the association signal at chromosome 12q23.3 in the tissues that I have analysed. It 
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can be presumed that the cis-effect at this locus may not be active in adult tissue 
obtained from end-stage OA patients. A role for CHST11 during mammalian 
development has previously been characterised (Klüppel et al., 2005), hence it may 
mean that cis regulation of CHST11 is more important during early developmental 
stages in mammals, hence is absent in adult tissue. Therefore, cartilage from OA 
patients may not be a suitable tissue type to be used for the search for functional 
effects at this locus. 
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Chapter 6: Sequence analysis of CHST11 coding exons 
6.1 Introduction 
As mentioned in Chapter 5.2.3, there are no common (MAF ≥ 15%) coding variants in 
CHST11 as suggested by online DNA variant databases. My aim was to search for rare 
penetrant variants in CHST11 that can account for OA susceptibility. The online 
databases contain population controls, therefore, I directly looked at hip OA patients, 
as CHST11 association was to hip OA. 
6.2 Results 
Primers listed in Table 2.10 were used to PCR amplify the coding region of CHST11 in 
192 hip OA patients (Chapter 2.24, Figure 2.1). The sequences were analysed for novel 
mutations using the Sequencing Analysis software (Applied Biosystems). One mutation 
was observed in a male patient, involving a G to C transition that would result in the 
non conservative amino acid change of lysine to asparagine (Figure 6.1).  
 
Figure 6.1: Electropherogram showing the partial sequence of CHST11 exon 3, that harbours 
the novel mutation (G/C). 
The Y-axis denotes the relative fluorescent units. The different colours of the peaks 
represent different dyes used to detect the alleles: red, T; blue, C; black, G and green, A. The 
novel mutation is boxed in red. 
 
An additional 599 OA hip patients were genotyped for this novel mutation to assess its 
frequency. The genotyping was performed using the RFLP assay listed in Table 2.6. The 
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mutation was absent in these additional samples. A representative assay is shown in 
Figure 6.2. The allele frequency of this mutation is estimated to be at most 0.063%. 
 
Figure 6.2: RFLP carried out on hip OA patients.  
Lane 1 to 9: Digestion products of PCR amplified DNA from Hip OA patients, 
Lane 10: Undigested PCR product, Lane 11: PCR blank.  The heterozygote 
carrying the rare variant is boxed. The digestion products were run on a 2% 
agarose gel containing ethidium bromide. A 100 bp DNA ladder was used for 
sizing of PCR products.  
 
6.3 Discussion 
Of 192 hip OA patients that were sequenced for the CHST11 coding region, one carried 
a novel mutation in exon 3 of CHST11. This is a G to C transition resulting in a non 
conservative amino acid change from lysine to asparagine. The mutation was absent in 
an additional 599 hip OA patients that were subsequently genotyped for this variant. 
The allele frequency of this mutation is estimated therefore to be 0.063%. 
Therefore, I did not find any variants in the CHST11 coding region that can contribute 
to OA susceptibility at a population level.  
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Chapter 7: The role of CHST11 in chondrocyte differentiation 
7.1 Introduction 
Studies carried out in mouse and zebrafish have shown the importance of CHST11 
during development. Klüppel et al. (2005) generated a Chst11 knockout mouse which 
showed severe chondrodysplasia, alterations in cartilage growth plate morphogenesis, 
and disturbed TGFβ signalling in the cartilage growth plate (Chapter 5.1). A study in 
zebrafish where Chst11 was knocked-down with the use of specific antisense 
morpholino oligonucleotides showed reduced 4-O sulphation and reduced chondroitin 
sulphate (CS) levels in the mutant embryos (Mizumoto et al., 2009). The mutants also 
showed multiple embryonic morphological defects including a ventrally bent trunk and 
a curled tail. A recent study that used a forward genetic screen of zebrafish to screen 
for cartilage and bone phenotypes that resemble OA, identified chst11 as the mutant 
gene (CL Hammond, personal communication, 18th July 2012). The mutants showed an 
alteration in the assembly of the cartilage matrix, premature chondrocyte hypertrophy 
and osteoblast formation. Hence there is clear evidence for a role of CHST11/Chst11 
during embryonic development in mouse and zebrafish.  
As discussed in Chapter 5, the OA association to rs835487 in CHST11 was not mediated 
by a change in CHST11 expression in adult OA joint tissues. Hence I have now 
hypothesised that the cis effect is active during development but not active in the 
adult OA tissues that I had analysed in that chapter. Therefore, I concluded that adult 
OA tissue was not a suitable tissue type to be used for functional studies of CHST11. 
Hence I have now utilised mesenchymal stem cells (MSCs) extracted from human hip 
joints to assess and explore the role of CHST11 in MSCs during chondrogenesis. That is 
the principle aim of this chapter. 
Under appropriate culture conditions, MSCs are capable of undergoing differentiation 
into chondrocytes, osteoblasts and adipocytes (Dominici et al., 2006). Many cell 
culture methods have been developed to drive MSCs towards chondrogenesis, 
including monolayer culture, pellet culture, micromass culture and polymer or 
biomaterial based scaffold culture (Djouad et al., 2006). It has been shown by Murdoch 
et al. (2007) that Transwell culture is a more efficient method for MSC differentiation 
since it results in greater cartilage-like matrix synthesis and deposition compared to 
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other established methods. This is primarily because the cells that are cultured in 
Transwell inserts have access to the nutrient supply from above and below the 
permeable insert, which creates a strong pro-chondrogenic environment. In this 
chapter, I have used the Transwell culture method to differentiate MSCs into 
chondrocytes after CHST11 knockdown, to assess the role of CHST11 during 
chondrogenesis. To complement the MSCs study I have also investigated the role of 
CHST11 in adult chondrocytes, also by CHST11 knockdown. 
7.2 Results 
7.2.1 Validation of the Transwell culture of mesenchymal stem cells as a tool to 
investigate chondrogenesis 
The gene expression changes that take place during the differentiation of MSCs from a 
donor (black, male, aged 22) from day 0 to 14 in Transwell culture were previously 
analysed by Dr. Matt Barter (Newcastle University; Figure 1A; Appendix 2; Chapter 
2.25 and 2.27). The gene expression of cartilage specific genes COL2A1 and ACAN were 
elevated approximately 1000 and 100 fold by day 1 of chondrogenesis respectively, 
and the gene expression levels were maintained up to 14 days. The expression of 
SOX9, which encodes a chondrogenic transcription factor, showed an approximately 10 
fold increase by day 1, and varied during the 14 day time course. Expression of COL1A1 
and RUNX2, which encode osteogenic markers, and MMP13, which encodes a 
hypertrophic marker, were down regulated during chondrogenesis. The upregulation 
of chondrocyte marker genes and the down regulation of osteogenic and hypertrophic 
marker genes demonstrated that the MSCs progressed towards chondrogenesis. 
However, the expression of COL10A1, which encodes a marker of hypertrophy, 
followed a similar pattern to COL2A1, where the gene expression was elevated by 
approximately 1000 fold by day 1, and remained at similar levels up to day 14. The 
large increase in COL2A1 and COL10A1 expression at the same time during 
chondrogenesis has been reported previously in MSC Transwell disc culture (Murdoch 
et al., 2007). However, the authors suggest that the down regulation of RUNX2, 
upregulation of its repressor BAPX1, down regulation of MATN1 (gene expressed in 
growth plate cartilage) and increased expression of MATN3 (gene expressed in 
articular cartilage) together show that there is no clear evidence for the progression 
towards hypertrophy in these cells. 
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7.2.2 CHST11 expression in mesenchymal stem cells during differentiation into 
chondrocytes 
To assess how the expression of CHST11 varies during chondrogenesis, I drove MSCs 
from towards chondrogenesis and measured CHST11 expression at days 0, 3, 7 and 14 
using the real time PCR assay listed in Table 2.2 (Chapter 2.17 and Chapter 2.27). This 
experiment was performed on the MSCs from two donors (Chapter 2.25).  
CHST11 expression was highest at day 7 and decreased 2.2 and 3.6 fold by day 14 in 
donor A and B respectively (Figure 7.1).  
 
Figure 7.1: CHST11 expression relative to housekeeping genes in MSCs from donors A and 
B during differentiation into chondrocytes. The gene expression was measured at 4 time 
points; days 0, 3, 7 and 14. The error bars represent standard error of the mean of three 
technical replicates. 
7.2.3 Effect of CHST11 knockdown in human mesenchymal stem cells during 
differentiation into chondrocytes 
Effect on wet mass of cartilage discs 
To assess the role of CHST11 during chondrogenesis, I knocked-down CHST11 in the 
MSCs from the two donors (Chapter 2.26). I used MSCs transfected with a non-
targeting siRNA as a negative control. CHST11 knockdown was confirmed using real 
time PCR at each time point (Figure 7.2) and CHST11 protein knockdown in day 7 discs 
was confirmed with western blot analysis (Chapter 2.15). Western blots showed two 
bands, one at the predicted size for CHST11 protein (42 kDa), and one slightly larger 
(Figure 7.3). Both bands disappeared when CHST11 was knocked-down. It has been 
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reported that CHST11 undergoes post-translational N-glycosylation, which can increase 
its molecular weight, producing the larger band (Yusa et al., 2005).  
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Figure 7.2: CHST11 expression in MSCs transfected with a non-targeting (NT) siRNA 
and with an anti-CHST11 siRNA. The error bars represent standard error of the mean 
(n=3). 
  
Figure 7.3: Western blot analysis on protein extracted from day 7 cartilage discs formed 
during MSC chondrogenesis. 
Arrows show the 42 kDa band corresponding to CHST11. Anti-β-actin antibody was used as a 
loading control. NT, protein extracted from cells transfected with the non-targeting siRNA; 
CHST11, protein extracted from cells transfected with the anti-CHST11 siRNA. 
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As the cells progress towards chondrogenesis, in addition to cell proliferation, a highly 
hydrated extracellular matrix is deposited in the discs (Tew et al., 2008). I therefore 
measured the wet mass of the discs at days 3, 7 and 14. 
 The wet mass of the discs formed by the cells transfected with the non-targeting 
siRNA control (control cells) and those formed by the CHST11 knocked-down cells 
increased during differentiation in both donors (Figure 7.4). Donor A and donor B 
showed a 3.5 and a 4.6 fold increase in the wet mass of control discs by day 14 
compared to day 3, respectively. Similarly, the wet mass of the discs formed in the 
CHST11 knocked-down cells increased by 2.7 and 4.8 fold by day 14 compared to day 3 
in donor A and B, respectively.  
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Figure 7.4: The change in wet mass in cartilage discs formed by MSCs from donors A and B 
during chondrogenesis. The weights were measured at 3 time points; day 3, 7 and 14. NT 
siRNA, non-targeting siRNA. 
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However, the wet mass of the cartilage discs formed by the CHST11 knocked-down 
cells was lower than that formed by the control cells at all time points and in both 
donors (Figure 7.4). In donor A, the fold decrease in wet mass was 1.2, 1.1 and 1.6 fold 
at day 3, 7 and 14, respectively. Donor B showed a 1.3, 1.2 and 1.3 fold decrease in wet 
mass at day 3, 7 and 14, respectively. This may reflect a reduction in extracellular 
matrix synthesis in the CHST11 knocked-down cells compared to the control cells. 
Effect on gene expression  
I next measured the gene expression changes of a panel of 13 genes in the CHST11 
knocked-down cells compared to the cells transfected with the non-targeting siRNA. 
The genes tested are listed in Table 7.1. They represent a range of genes whose 
proteins function in cartilage metabolism. This panel included genes whose products 
are catabolic, anabolic, osteogenic and hypertrophic markers. For each gene, 
expression was measured twice in each donor to assess the reproducibility of the 
experiment. CHST11 knockdown was successful in both donors at days 0, 3, 7 and 14. 
Gene expression was tested at these time points (Figure 7.2), whilst western blotting 
was carried out on protein extracted from day 7 cartilage discs. This showed successful 
knockdown of CHST11 (Figure 7.3). A two-tailed student’s t-test was performed to 
compare between the gene expression between control cells and the CHST11 knocked-
down cells at all time points. Significant (P<0.05) up/down regulation in gene 
expression was plotted for the two donors for each time point (Figure 7.5). The actual 
values of these significant changes are listed in Table 7.2. A Wilcoxon signed rank test 
was performed to assess whether gene expression in the cells showed a significant 
trend, following CHST11 knockdown. The P-values are listed in Table 7.3. 
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Gene Gene product Role in cartilage  
COL2A1 α-1 chain of type 2 collagen 
Anabolism ACAN Aggrecan 
SOX9 SRY-box 9 transcription factor 
TIMP1 Tissue inhibitor of matrix metalloproteinase 1 Anti-catabolism 
MMP1 Matrix metalloproteinase 1, a collagenase 
Catabolism 
MMP13 Matrix metalloproteinase 13, a collagenase 
ADAMTS4 
A disintegrin and metalloproteinase with 
thrombospondin motifs 4, an aggrecanase 
ADAMTS5 
A disintegrin and metalloproteinase with 
thrombospondin motifs 5, an aggrecanase 
COL1A1 α-1 chain of type 1 collagen 
Osteogenesis BGLAP Bone Ɣ-carboxyglutamate (gla) protein 
RUNX2 Runt-related transcription factor 2 
IHH Indian hedgehog 
Hypertrophy 
COL10A1 α-1 chain of type 10 collagen 
Table 7.1: List of the genes that were studied in this chapter, their protein products and their 
role in cartilage. 
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Figure 7.5: Fold change in gene expression in CHST11 knocked-down cells compared to 
control cells in MSCs from donors A and B during chondrogenesis. 
The passage number of the cells used in each experiment is given within brackets (P6, 
P7, P8). Gene expression was measured at four time points; days 0, 3, 7 and 14 (D0, D3, 
D7 and D14). Each data point represents a significant (P<0.05) up/down regulation of 
gene expression relative to housekeeping genes in response to CHST11 knockdown at 
different time points. Data points show results from two independent experiments 
carried out for each donor. 
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Gene Time point 
Donor A Donor B 
P6 P7 P 7 P8 
COL2A1 
Day 0 
    
Day 3 0.03 0.03 0.29 0.81 
Day 7 0.17 0.36 0.46 0.39 
Day 14 0.06 0.03 1.90 1.37 
ACAN 
Day 0 - 4.29 0.69 - 
Day 3 0.09 0.08 0.31 0.49 
Day 7 0.30 0.86 0.52 0.42 
Day 14 0.08 0.04 1.52 1.49 
SOX9 
Day 0 - - 0.58 0.65 
Day 3 0.64 0.62 0.24 - 
Day 7 - 0.67 0.55 0.53 
Day 14 0.40 0.34 0.87 0.54 
TIMP1 
Day 0 - 3.29 - - 
Day 3 1.33 1.74 1.22 - 
Day 7 1.76 8.47 1.57 1.43 
Day 14 1.87 7.69 - 0.62 
MMP1 
Day 0 - 6.68 - - 
Day 3 1.71 4.42 3.76 0.25 
Day 7 1.51 9.20 0.71 0.45 
Day 14 2.69 4.06 0.51 - 
MMP13 
Day 0 - 2.13 0.28 - 
Day 3 - 3.83 5.20 - 
Day 7 - 19.04 - 0.44 
Day 14 1.56 4.66 0.63 - 
ADAMTS4 
Day 0 - - - - 
Day 3 0.58 0.51 1.46 1.38 
Day 7 - - 0.59 2.51 
Day 14 0.25 - 1.82 0.40 
ADAMTS5 
Day 0 1.25 2.64 - - 
Day 3 2.37 3.31 5.47 - 
Day 7 3.12 10.57 1.66 1.83 
Day 14 1.99 5.33 0.63 0.57 
COL1A1 
Day 0 - - - 1.44 
Day 3 0.74 0.70 0.41 2.57 
Day 7 0.84 - 0.58 3.94 
Day 14 0.31 0.32 1.56 1.58 
BGLAP 
Day 0 - - - - 
Day 3 0.72 - - - 
Day 7 - 7.14 - 3.03 
Day 14 - - - 0.55 
RUNX2 
Day 0 - - - - 
Day 3 1.59 3.50 1.43 3.98 
Day 7 1.78 14.18 - 2.26 
Day 14 2.27 4.75 0.77 0.76 
IHH 
Day 0 - - - - 
Day 3 0.60 0.66 - 5.88 
Day 7 2.09 0.06 - 4.89 
Day 14 - - 4.00 - 
COL10A1 
Day 0 
    
Day 3 1.48 1.59 3.49 9.96 
Day 7 - 6.20 2.06 5.64 
Day 14 - - 2.70 1.69 
 
 
 
Table 7.2: Significant (P<0.05) fold 
change in gene expression following 
CHST11 knockdown in days 0, 3, 7 and 
14 MSC discs, relative to control discs.  
A value greater than 1 denotes a 
significant upregulation of gene 
expression and a value less than 1 
denotes a significant down regulation of 
gene expression. A dash (-) indicates no 
significant change in gene expression. 
COL2A1 and COL10A1 expression were 
not detected at day 0. Gene expression 
was measured using cDNA synthesised 
from RNA extracted from discs 
transfected with non-targeting siRNA 
and compared to that extracted from 
CHST11 knocked-down discs. Three 
technical replicates were performed for 
each disc. The experiment was 
performed twice for each donor. 
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Gene P-value 
COL2A1 0.0210 
ACAN 0.0105 
SOX9 0.0005 
TIMP1 0.0049 
MMP1 0.0525 
MMP13 0.0977 
ADAMTS4 1.0000 
ADAMTS5 0.0024 
COL1A1 0.9097 
BGLAP 0.6250 
RUNX2 0.0049 
IHH 0.2188 
COL10A1 0.0039 
Table 7.3: P-values calculated using the Wilcoxon signed rank test for each target gene 
following CHST11 knockdown.  
P<0.05 are highlighted in red. 
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COL2A1  
COL2A1 expression was not detected in the MSCs at day 0, before the addition of 
chondrogenic factors to the growth media. The CHST11 knocked-down cells from both 
donors showed a reduced expression of COL2A1 at day 3 and 7. At day 14, donor A 
showed a down regulation whilst donor B showed an upregulation of COL2A1 
expression.  
ACAN 
During differentiation up to day 7, ACAN expression was decreased in CHST11 
knocked-down cells from both donors. At day 14, donor A showed a down regulation 
and donor B showed an upregulation of ACAN expression after CHST11 knockdown.  
SOX9 
SOX9 expression was down regulated in donor A at all time points and in donor B at 
day 3, 7 and 14.  
TIMP1 
TIMP1 expression was increased in donor A at all time points and in donor B at day 3 
and 7. At day 14, there was reduced TIMP1 expression in CHST11 knocked-down cells 
in donor B. 
MMP1 
Donor A showed increased expression of MMP1 in CHST11 knocked-down cells at all 
time points. Donor B showed a down regulation of MMP1 expression after CHST11 
knockdown at day 7 and 14. This may explain the upregulation of COL2A1 seen in 
donor B at day 14 after knockdown of CHST11.  
MMP13 
MMP13 was upregulated in CHST11 knocked-down cells from donor A, however this 
effect was not replicated in both experiments. The increased expression of TIMP1 seen 
during chondrogenesis in this donor is perhaps a consequence of the cells attempting 
to regulate the increased levels of MMP1 and MMP13 expression. Donor B showed an 
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initial upregulation of MMP13 in response to CHST11 knockdown, and then showed a 
down regulation after day 3. 
ADAMTS4  
The expression of ADAMTS4 was variable between the two donors, as well as between 
the experimental replicates.  
ADAMTS5  
ADAMTS5 was upregulated at all time points in CHST11 knocked-down cells from 
donor A. Donor B also showed an upregulation of this gene at day 3 and 7. However,  
ADAMTS5 was down regulated in this donor at day 14. This may explain the 
upregulation of ACAN at day 14 in the CHST11 knocked-down cells from this donor. 
COL1A1, BGLAP, IHH 
A consistent effect was not seen between experiments or donors for COL1A1, BGLAP 
or IHH. 
RUNX2  
RUNX2 expression was upregulated in donor A at all time points during 
chondrogenesis after CHST11 knockdown. This gene was initially upregulated in donor 
B, but was down regulated by day 14. 
COL10A1  
Expression of COL10A1 was not detected at day 0 in either donor. Donor A showed an 
increase in COL10A1 in response to CHST11 knockdown at day 3. In donor B the gene 
was upregulated following CHST11 knockdown at all time points during 
chondrogenesis. 
In summary, CHST11 knockdown in MSCs led to a significant change in gene expression of 
anabolic marker genes COL2A1 (p=0.02), ACAN (0.01), SOX9 (0.0005) and TIMP1 (0.005), 
catabolic marker gene ADAMTS5 (0.002) and hypertrophic marker genes RUNX2 (0.005)and 
COL10A1 (0.004). 
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7.2.4 Proteoglycan quantification in CHST11 knocked-down mesenchymal stem 
cells 
Since the results from the above section showed a loss of wet mass in cartilage discs 
formed by the CHST11 knocked-down cells and a down regulation of ACAN during 
chondrogenesis in response to CHST11 knockdown, I hypothesised that these cells may 
produce less extracellular matrix compared to control cells. I therefore used Alcian 
blue staining to quantify the amount of sulphated GAGs in MSCs (Chapter 2.31). The 
cells were cultured as high density micromasses after transfection with the non-
targeting siRNA and the anti-CHST11 siRNA (Chapter 2.30). Real time PCR analysis 
showed a 7 fold and 15 fold decrease in CHST11 expression in cells transfected with 
anti-CHST11 siRNA versus control cells from donor A and B, respectively (Figure 7.6 ). 
The subsequent reduction in the level of CHST11 protein was confirmed using western 
blot analysis (Figure 7.7). The Alcian blue bound to sulphated glycosaminoglycans 
(GAGs) was quantified and normalised to the protein content of the CHST11 knocked-
down cells and control cells (Chapter 2.31). Three biological replicates were 
performed. The CHST11 knocked-down cells showed significantly reduced Alcian blue 
staining compared to control cells from both donors, suggesting that there is less 
sulphated GAGs produced in these cells after CHST11 knockdown (Figures 7.8 and 7.9). 
 
 
 
Figure 7.6: CHST11 expression in MSCs transfected with a non-targeting (NT) siRNA and with 
an anti-CHST11 siRNA. The error bars represent standard error of the mean (n=3). A 
student’s t-test was performed to calculate the P-value.  
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Figure 7.7:  Western blot analysis on protein extracted from micromass cultures of MSCs 
from donors A and B. Arrows show the 42 kDa band corresponding to CHST11. Anti-β-actin 
antibody was used as a loading control.  
 
    
Figure 7.8: Alcian blue staining in micromasses cultured from cells transfected with (A) a 
non-targeting siRNA and (B) with an anti-CHST11 siRNA. 
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Figure 7.9: Absorbance at 600 nm per microgram of protein in micromasses cultured from 
MSCs transfected with a non-targeting (NT) siRNA and with an anti-CHST11 siRNA. The error 
bars represent the standard error of the mean (n=3). A student’s t-test was performed to 
calculate the P-value. 
Summary of the CHST11 MSC data 
CHST11 expression peaked at day 7 in MSCs during chondrogenesis, which was then 
reduced by day 14 (Figure 7.1). The wet mass of the cartilage discs increased during 
MSC chondrogenesis, however, CHST11 knockdown resulted in a reduction in the wet 
mass of the discs formed compared to the controls (Figure 7.4). CHST11 knockdown 
also reduced expression of some anabolic marker genes (COL2A1, ACAN and SOX9) and 
increased expression of ADAMTS5, a catabolic marker gene, and RUNX2 and 
COL10A1,hypertrophic marker genes (Figure 7.5, Tables 7.2 and 7.3). My results also 
showed that the amount of sulphated GAGs synthesised by the CHST11 knocked-down 
cells was significantly lower than that produced by the control cells (Figures 7.8 and 
7.9).  
Overall, my results clearly demonstrate a role for CHST11 during chondrogenesis in the 
MSC model that I have used. 
7.2.5 Gene expression changes after CHST11 knockdown in OA and NOF 
chondrocytes 
My MSC data raise the question whether CHST11 is only important during the 
formation of the cartilage or if it also plays a role in mature cartilage. Therefore, I 
knocked-down CHST11 in chondrocytes extracted from four hip and four knee joints of 
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OA patients and from a NOF patient and assessed what effect this had on gene 
expression (Chapter 2.26). Details regarding the 9 patients are listed in Table 7.4.  For 
gene expression I focused on 6 of the 13 genes listed in Table 7.1: COL2A1, ACAN, 
TIMP1, SOX9, MMP1 and MMP13. Knockdown of CHST11 was successful in all 9 
patients (data not shown). However, due to insufficient amounts of protein extracted 
from the chondrocytes, I was not able to test for the concomitant reduction in CHST11 
protein.  
Complimentary DNA was synthesised from the cell lysates 48 hours post transfection 
with anti-CHST11 siRNA (Chapter 2.16). Gene expression was measured in cDNAs 
synthesised from RNAs from the control cells (cells transfected with a non-targeting 
siRNA) and the CHST11 knocked-down cells using real time PCR (Chapter 2.17). A two-
tailed student’s t-test was performed to compare the gene expression in control cells 
and the CHST11 knocked-down cells. Significant (P<0.05) up/down regulation in gene 
expression was plotted for the knee and hip OA patients and for the NOF patient 
(Figure 7.10). The actual values of these significant data are listed in Table 7.5. A 
Wilcoxon signed rank test was not performed for these experiments due to the low 
sample size. 
Of the nine patients, only two OA patients (patients C and F) showed a significant 
down regulation of COL2A1. OA patients D, E and F showed elevated levels of ACAN. 
An upregulation of TIMP1 was seen in the hip OA patients E, F and H, and a down 
regulation of TIMP1 was seen in the NOF patient. None of the 9 patients showed an 
up/down regulation of SOX9 expression. The knee OA patients A, D and I, and the NOF 
patient, showed a decreased expression of MMP1. MMP13 expression was elevated 
only in patient B and was down regulated only in the NOF patient.  
In summary, I observed significant effects on gene expression following CHST11 
knockdown in chondrocytes. However, this was not observed in all patients studied.  
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Patient 
letter 
Age at 
surgery 
Sex Joint type 
A 79 F OA knee 
B 54 M OA knee 
C 63 M OA knee 
D 49 F OA knee 
E 52 F OA hip 
F 67 F OA hip 
G 54 F OA hip 
H 77 M OA hip 
I 80 F NOF hip 
Table 7.4: Details of the nine patients studied. 
 
 
 
 
163 
 
 
                                                                                                                                         
Gene 
Knee OA Hip OA NOF 
A B C D E F G H I 
COL2A1 - 0.68 - - - - - 0.54 - 
ACAN - - - 1.24 - - 1.24 1.30 - 
TIMP1 - - - - 1.50 - 2.12 1.34 0.63 
SOX9 - - - - - - - - - 
MMP1 - 0.67 0.66 0.69 - - - - 0.59 
MMP13 1.26 - - - - - - - 0.59 
Table 7.5: Significant (P<0.05) fold change in gene expression following CHST11 knockdown 
in days 0, 3, 7 and 14 MSC discs, relative to control discs.  
A value greater than 1 denotes a significant upregulation of gene expression and a value less 
than 1 denotes a significant down regulation of gene expression. A dash (-) indicates no 
significant change in gene expression. 
 
Figure 7.10: Effect of CHST11 knockdown in knee OA, hip OA and NOF chondrocytes. Each data 
point represents a significant (p<0.05) up/down regulation of gene expression relative to 
housekeeping genes in response to CHST11 knockdown. 
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7.2.6 Proteoglycan quantification in CHST11 knocked-down OA chondrocytes 
To determine if CHST11 knockdown in adult chondrocytes leads to a reduction in 
extracellular proteoglycan synthesis, I next cultured chondrocytes extracted from one 
knee OA patient (an 83 year old female) in high density micromasses for analysis using 
Alcian blue staining (Chapter 2.30 and 2.31). CHST11 expression was successfully 
knocked-down by 8 fold in these cells, which was assessed by real time PCR (Figure 
7.11). As above, there was insufficient protein to test for the depletion in CHST11 
protein. 
Quantification of Alcian blue staining showed that there was no significant difference 
in the amount of sulphated GAGs synthesised in the control cells compared to the cells 
transfected with the anti-CHST11 siRNA (Figures 7.12 and 7.13).  
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Figure 7.11:CHST11 expression in cells transfected with a non-targeting (NT) siRNA and with 
an anti-CHST11 siRNA. The error bars represent standard error of the mean (n=3). A 
student’s t-test was performed to calculate the P-value.  
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Figure 7.12: Alcian blue staining in micromasses cultured from cells transfected with a non-
targeting (NT) siRNA and with an anti-CHST11 siRNA. 
  
 
Figure 7.13: Absorbance at 600 nm per microgram of protein in micromasses cultured from 
cells transfected with a non-targeting (NT) siRNA and with an anti-CHST11 siRNA. The error 
bars represent the standard error of the mean (n=3). A student’s t-test was performed to 
calculate the P-value. 
 
In summary, CHST11 knockdown in adult chondrocytes from OA and NOF patients led 
to a change in gene expression of various genes, although the effect was not 
consistent among individuals. CHST11 knockdown did not lead to a change in overall 
proteoglycan synthesis in OA chondrocytes. However, since I was not able to test for 
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the concomitant depletion of CHST11 protein, I cannot exclude the possibility that the 
CHST11 protein levels did not decrease following CHST11 knockdown. 
7.3 Discussion 
During MSC differentiation into chondrocytes, CHST11 expression was highest at day 7 
and then decreased by day 14. This suggests that CHST11 expression is regulated to 
maintain the correct sulphation balance during chondrogenesis.  
The Transwell discs increased in wet mass as the cells progressed towards 
chondrogenesis, which has been observed previously by Murdoch et al. (2007). GAG 
assays carried out in the discs by those authors showed a linear increase in 
proteoglycan content, which corresponded to the increase in wet mass that they 
observed. The discs also stained strongly with Safranin O, which shows further 
evidence of the formation of a cartilage matrix during chondrogenesis (Murdoch et al., 
2007). My results showed that the wet mass of the CHST11 knocked-down discs 
increased during differentiation, however the wet mass was lower than that of the 
discs formed by the control cells at all time points. This suggests that the loss of 
CHST11 has resulted in these discs being less hydrated, as a correct sulphation balance 
of GAGs is important for water retention in order to maintain the structural integrity of 
the cartilage (Gama et al., 2006).  
Gene expression analysis on CHST11 knocked-down MSC discs showed a down 
regulation of anabolic marker genes COL2A1, ACAN and SOX9. It is of interest that 
ACAN expression was down regulated in response to CHST11 knockdown, which may 
correspond to the loss of wet mass seen in these discs compared to the controls, as 
aggrecan plays a role in water retention in cartilage. Catabolic marker genes MMP13 
and MMP1 were upregulated in one donor and ADAMTS5 was upregulated in both 
donors after CHST11 knockdown. These results support a role of CHST11 in 
chondrogenesis. CHST11 knockdown resulted in an increase in RUNX2 expression in 
both donors, which may suggest that CHST11 is not involved in driving cells towards 
osteogenesis. COL10A1 expression follows a similar pattern to that of COL2A1 
expression during MSC chondrogenesis (Figure 1A; Appendix 2). However in CHST11 
knocked-down cells, COL10A1 expression was elevated, whereas COL2A1 expression 
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was decreased, suggesting that CHST11 plays a role in chondrogenesis and does not 
promote chondrocyte hypertrophy.  
As CHST11 expression was initially upregulated until day 7 of chondrogenesis and then 
down regulated by day 14, it could be that CHST11 expression is regulated to achieve 
the correct sulphation balance during chondrogenesis. The correct sulphation pattern 
and balance of GAGs is crucial for the interaction of the extracellular matrix with 
growth factors (Klüppel et al., 2005). Different signalling pathways may interact in 
these cells at different time points during chondrogenesis, and the absence of CHST11 
can disrupt the response of these cells to external growth factors, which can alter the 
expression of several genes involved in chondrogenesis. This may lead to the decrease 
in anabolism and increase in catabolism, osteogenesis and hypertrophy as observed. In 
some instances, an inconsistent response was seen, for example, COL2A1 expression 
was down regulated initially in donor B, but was upregulated at day 14. This may be a 
result of other signalling pathways being activated to counteract the loss of CHST11 
during chondrogenesis.   
CHST11 knockdown also led to a significant reduction in the amount of sulphated GAGs 
in MSCs from both donors, which corresponds to the reduction in wet mass observed 
in the Transwell discs after CHST11 knockdown. 
Having seen a role of CHST11 during MSC chondrogenesis, my next aim was to 
determine if CHST11 was important in adult chondrocytes. Hence I assessed the gene 
expression changes in response to CHST11 knockdown in adult OA and NOF 
chondrocytes. The results showed significant changes in gene expression, however, 
there was no consistent effect among patients. Also, there was no change in the 
amount of sulphated GAGs produced in these cells in response to CHST11 knockdown.  
My results show that CHST11 is important during chondrogenesis, the loss of which 
leads to changes in gene expression during MSC differentiation, a reduction in the wet 
mass of cartilage discs and a decrease in the amount of sulphated GAGs produced 
during differentiation. However this effect was not replicated in adult OA and NOF 
cartilage. Therefore, these results may explain the lack of evidence for cis regulation at 
CHST11 in OA tissue that can account for the OA association signal at chromosome 
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12q23.3. Therefore, MSCs can perhaps be used as a more suitable tissue type for 
functional studies of CHST11.  
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Chapter 8: General discussion 
Many epidemiological studies have shown a genetic link to OA, therefore OA is 
recognised as a polygenic and multifactorial disease (Loughlin, 2011). A number of OA 
associated polymorphisms have been identified through candidate gene studies, 
genome-wide linkage studies and genome-wide association scans. 
Functional studies on some OA associated polymorphisms have shown that these 
affect the structure of the protein encoded or affect the expression of the gene 
through cis regulation. An example of a polymorphism that affects protein structure is 
a polymorphism in the aspartic acid (D) repeat sequence in ASPN that showed 
association to OA. Harbouring the D14 allele of the repeat sequence resulted in greater 
inhibition of the TGF-β signalling pathway (Kizawa et al., 2005). A good example of a 
polymorphism that affects gene expression through cis regulation is a 5'UTR SNP in 
GDF5, rs143383. This is a T to C transition and showed compelling association to OA in 
European and Asian cohorts (reviewed in Loughlin, 2011). Functional studies have 
suggested that rs143383 is perhaps the polymorphism influencing OA susceptibility at 
this locus, with the OA associated T allele mediating reduced GDF5 transcription 
relative to the C allele in all joint tissues so far tested (Egli et al., 2009). 
OA chondrocytes respond discordantly to GDF5  
In Chapter 3 I hypothesised that this deficit in GDF5 could be attenuated by the 
application of exogenous GDF5 protein and I assessed what effect such application will 
have on primary OA chondrocyte gene expression.  
Key findings of Chapter 3: 
1. OA cartilage expressed genes that code for the three GDF5 receptors, in 
particular BMPR-II and BMPR-IA. The expression of BMPR-IA, which encodes the 
alternative type I receptor that GDF5 binds to, was significantly higher in OA and 
NOF cartilage compared to BMPR-IB, which encodes the receptor towards which 
GDF5 shows preferential activity. The same receptor expression pattern was 
observed in OA chondrocytes cultured in monolayer.  
2. I chose to use two GDF5 proteins, one that was designed to show increased 
specificity for BMPR-IA compared to BMPR-IB, and another that was insensitive to 
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GDF5 antagonist noggin. I used four different recombinant GDF5 proteins in total; 
wildtype mouse, wildtype human and the two variants (A and B). All four of the 
exogenous GDF5 proteins were able to activate the Smad 1/5/8 signalling pathway 
in SW1353 cells, as demonstrated by a luciferase reporter assay, and in 
chondrocytes, as confirmed by western blot analysis, at a concentration of 100 
ng/ml. 
3. Gene expression analyses of a panel of chondrocyte marker genes revealed 
that OA chondrocytes respond to exogenous GDF5 in an inconsistent manner, 
whereas a consistent response was observed in cells stimulated with exogenous 
TGF-β1 and stimulation with IL-1α and OSM in combination.  
My results show that the inconsistency in response to GDF5 will need to be 
surmounted if treatment with exogenous GDF5 is going to be advanced as a potential 
means of alleviating the genetic deficit mediated by OA susceptibility at the gene 
GDF5. 
Carrying out gene expression analyses in chondrocytes cultured in monolayer has 
several limitations. Inter-patient variability due to genetic and epigenetic factors and 
co-morbidity can be problematic in assessing a trend in response to GDF5. To 
overcome this, a larger sample size is needed, although this is challenging due to the 
limited availability of samples. Monolayer culture of chondrocytes can also add to this 
variability as the chondrocyte phenotype is difficult to maintain in culture. 
Chondrocytes expanded in monolayer have been shown to have a low proliferative 
capacity and undergo dedifferentiation (Harrison et al., 2000; Dell'Accio et al., 2001). 
Therefore, it may be more suitable to carry out these studies using in vitro culture 
techniques that provide a three-dimensional cellular environment and use agarose, 
fibrin or alginate as scaffolds for chondrocytes to adhere to (Buschmann et al., 1992; 
Schultz et al., 1997; Andreas et al., 2008). High density micromass culture is also being 
used as a simple and effective culture model and has been used for anti-rheumatic 
drug screening (Ibold et al., 2007; Andreas et al., 2009) and in regenerative medicine 
to investigate cartilage formation and the influence of environmental and culture 
conditions (Anderer and Libera, 2002; Tallheden et al., 2004; Grogan et al., 2007; 
Dehne et al., 2009). Chondrocyte pellet culture is also another culture technique that is 
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widely used and has been suggested as transplants in cartilage repair (Anderer and 
Libera, 2002). 
Allelic expression analysis of the OA susceptibility locus that maps to 
MICAL3  
As candidate gene studies focused on genes whose protein products play roles in joint 
biology, these required prior knowledge of the disease process. Genome-wide 
association scans have instead yielded more novel loci that show association in OA. 
Recent findings suggest that OA susceptibility appears to be mediated by 
polymorphisms in genes whose protein products are involved in pathways that 
regulate joint maintenance and development, instead of genes encoding structural 
proteins of the ECM (Reynard and Loughlin, 2013).  For example, the arcOGEN GWAS 
produced OA association signals to RUNX2 and PTHLH genes, which encode proteins 
involved in endochondral ossification and to CHST11, whose protein product is 
involved in proteoglycan synthesis (Zeggini et al., 2012).  
Having identified OA susceptibility loci, it is important to further investigate these to 
explore whether the susceptibility is mediated through altered gene expression or 
protein function. Apart from the functional studies that were carried out on the GDF5 
SNP rs143383, as described above and in Chapter 3.1, recent studies have generated 
functional data for the chromosome 7q22 signal from the Rotterdam GWAS and for 
the chromosome 14q31.1 locus that maps to DIO2, that was produced through a 
candidate gene study (reviewed in Reynard and Loughlin, 2013). The chromosome 
7q22 signal contained, amongst other genes, HBP1 and DUS4L, and reduced expression 
of HBP1 was seen in cartilage and synovium tissue, and reduced expression of DUS4L 
was seen in fatpad tissue, in carriers of the OA associated allele (Raine et al., 2012).  
The authors also carried out allelic expression imbalance (AEI) analyses at HBP1 and 
observed that the pattern of AEI demonstrated by carriers of the OA associated allele 
was significantly different from that seen in non-carriers. Functional studies on DIO2 
showed that AEI was present at the OA associated SNP rs225014 in this gene, with a 
significant increase in expression from the C allele relative to the T allele in cartilage 
tissue (Bos et al., 2012).  
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Aside from OA, AEI analyses have commonly been used to identify cis regulatory 
polymorphisms that account for changes in gene expression in a variety of human 
tissue types including blood (Pant et al., 2006), brain (Pinsonneault et al., 2006; Zhang 
et al., 2007), lung (Heighway et al., 2003), liver (Hirota et al., 2004) and adipose tissue 
(Pastinen et al., 2004).  
In chapter 4 I have carried out functional studies on rs2277831, an OA associated SNP 
identified through stage 1 of the arcOGEN GWAS, with a P-value of 2.3x10-5. The SNP 
on chromosome 22q11.21, maps to an intron in MICAL3. The association signal 
encompasses two other genes, BCL2L13 and BID, whose proteins have roles in 
apoptosis. This was of interest as chondrocyte apoptosis is a hallmark of OA (Kim et al., 
2000; Blanco et al., 2004).  
I carried out gene and allelic expression analyses on BCL2L13, BID and MICAL3 in 
cartilage, fatpad, synovium, cancellous bone and osteophyte tissue as it is important to 
conduct such analyses in pathologically relevant tissues. For example, Emilsson et al. 
(2008) showed that there is a significant difference in the gene expression profile in 
blood and adipose tissue in obesity. This suggests that eQTLs can act in a tissue specific 
manner. My hypothesis was that the OA associated locus highlighted by rs2277831 can 
be marking an eQTL, affecting the gene expression of either MICAL3 or its two 
neighbouring genes.  
Key findings of Chapter 4: 
1. BCL2L13, BID and MICAL3 were expressed in all joint tissues that were tested. 
2. There was no correlation between BCL2L13, BID and MICAL3 gene expression 
and genotype at rs2277831. 
3. AEI was observed at BCL2L13, BID and MICAL3 in all tissue types analysed, 
however this did not correlate with genotype at rs2277831. 
Therefore, my results did not support a role for cis-regulation at BCL2L13, BID or 
MICAL3 as accounting for the OA association signal at chromosome 22q11.21. There is 
a possibility that the original discovery of the OA association to rs2277831 was a false 
positive, and may account for the lack of correlation seen between gene expression 
and genotype at this locus.  
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Assessing whether the OA associated locus that maps to chromosome 
12q23.3 mediates its effect by influencing the gene expression of 
CHST11 
I subsequently focused on a second locus that was identified through the arcOGEN 
GWAS. The OA associated SNP is rs835487 and is located at chromosome 12q23.3. The 
association surpassed the genome-wide significance threshold, with a P-value of 1.64 x 
10-8. The SNP is located in intron 2 of CHST11, which encodes an enzyme that catalyses 
the sulphation of glycosaminoglycans, hence making it a highly interesting locus to 
study in the context of OA. Again I hypothesised that the association to rs835487 may 
influence the gene expression of CHST11. I carried out gene expression and AEI 
analyses on tissue types relevant to OA; cartilage, fatpad and synovium, as well as in 
NOF cartilage. 
Key findings of Chapter 5: 
1. The expression of CHST11 was observed in all joint tissues analysed. 
2. The expression of CHST11 was significantly higher in OA cartilage compared to 
NOF cartilage. 
3.  CHST11 expression in OA cartilage, fatpad and synovium tissue and in NOF 
cartilage did not correlate with the genotype at the associated SNP rs835487. 
4. Although AEI at CHST11 was observed in OA cartilage, fatpad and synovium 
tissue and in NOF cartilage, this did not correlate with the genotype at the 
associated SNP, rs835487. Therefore, perhaps there are eQTLs operating in adult 
tissues, but an eQTL, if present, that correlates with rs835487 may not be 
operating in end stage OA tissue. 
 I speculated that since a role for CHST11 during development has been well 
established in mouse (Klüppel et al., 2005) and zebrafish (Mizumoto et al., 2009), 
perhaps tissue from OA patients may not be a suitable tissue type to carry out 
functional studies on CHST11. Therefore, to understand how the OA susceptibility 
marked by rs835487 affects CHST11 expression, it may be necessary to analyse AEI in 
MSCs that are undergoing chondrogenic differentiation, and to follow the pattern of 
AEI during chondrogenesis in these cells. Also, in vitro assays such as luciferase 
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reporter assays and electrophoretic mobility shift assays (EMSAs) could be used to 
study the functionality of a particular allele. However results from these in vitro assays 
need to be interpreted with caution as the variants are assayed outside of their natural 
context. For example, the DNA sequences used in these approaches lack the naturally 
occurring chromatin configuration and also, the function of a SNP may be dependent 
on the naturally occurring haplotypes around the SNP of interest (Knight, 2005).  
Sequence analysis of CHST11 coding exons 
In Chapter 6 I set out to look for rare variants in the CHST11 coding sequence in OA 
patients. The DNA variant databases suggested that there were no common coding 
SNPs in CHST11. These databases are based on population samples, and therefore I 
looked directly at an OA cohort for potentially rare but penetrant risk alleles.  
Key findings of Chapter 6: 
1. One of 192 hip OA patients that were sequenced carried a novel mutation, in 
exon 3 of CHST11. This is a G to C transition resulting in a non conservative amino 
acid change from lysine to asparagine. 
2. The mutation was absent in an additional 599 hip OA patients that were 
subsequently genotyped for this variant. The allele frequency of this mutation is 
estimated therefore to be 0.063%. 
There are therefore no variants in the coding exons of CHST11 that can contribute to 
OA disease susceptibility at a population level.  
Role of CHST11 in chondrocyte differentiation  
In Chapter 7, I aimed to look for the role of CHST11 during chondrogenesis. For this, I 
differentiated iliac crest derived MSCs from two young donors into chondrocytes after 
CHST11 knockdown, and then analysed changes in gene expression of anabolic, 
catabolic and hypertrophic marker genes. 
Key findings of Chapter 7: 
1. During chondrogenesis, the expression of CHST11 was highest at day 7, and 
was down regulated by day 14. 
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2. The wet mass of the CHST11 knocked-down discs increased through 
chondrogenesis, but was lower than the control discs at each time point. This 
suggests a reduction in water retention due to altered sulphation of GAGs in 
the CHST11 knocked-down discs. 
3. Gene expression analysis on CHST11 knocked-down discs showed a down 
regulation of anabolic marker genes COL2A1, ACAN and SOX9 and an 
upregulation of catabolic marker gene ADAMTS5 and the hypertrophic marker 
genes RUNX2 and COL10A1. 
4. CHST11 knockdown also resulted in a significant reduction in the amount of 
sulphated GAGs as measured by Alcian blue staining. 
5. Having seen a role of CHST11 during chondrogenesis, I assessed the gene 
expression changes in response to CHST11 knockdown in adult OA and NOF 
chondrocytes. The results showed significant changes in gene expression, 
however, there was no consistent effect among patients. 
6. There was no change in the amount of sulphated GAGs produced by OA 
chondrocytes as measured by Alcian blue staining. 
My results showed the importance of CHST11 during chondrogenesis, the loss of which 
results in gene expression changes during MSC differentiation, reduction in wet mass 
of cartilage discs and a reduction in sulphated GAGs produced during differentiation.  
As CHST11 expression is increased in knee OA (Karlsson et al., 2010) and in hip OA (Xu 
et al., 2012; Chapter 5.2.2), it will be interesting to assess what effect the 
overexpression of CHST11 will have on gene expression of chondrocyte marker genes 
and the sulphation of GAGs during differentiation of MSCs into chondrocytes.  
CHST11 catalyses the transfer of sulphate groups in chondroitin to the 4-hydroxyl 
group of N-acetylgalactosamine (GalNAc) sugars, to form chondroitin-4- sulphate (CS-
A). CHST11 also shows activity towards dermatan (Mikami et al., 2003), to form 
dermatan sulphate (DS, also known as CS-B). Other enzymes that catalyse the transfer 
of sulphate groups to the 4-hydroxyl position include CHST12, CHST13 and CHST14. In 
addition, CHST3 and CHST7 catalyse the addition of sulphate groups to the 6-hydroxyl 
group of chondroitin disaccharides, to form chondroitin-6-sulphate (CS-C; Caterson, 
2012). As Alcian blue is a global measure of sulphated GAGs, it is not a specific stain to 
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detect CS-A alone. It is possible to use antibodies that recognise different sulphation 
motifs of CS and DS GAG chains (Caterson, 2012). Hence, it will be of interest to assess 
the effect of CHST11 knockdown on the sulphation of specific CSs, and also to 
determine if CHST12, CHST13 or CHST14, which also catalyse the synthesis of CS-A, can 
compensate for the lack of CHST11.  
It is reported that in colon adenocarcinoma, the ratio of 4-hydroxyl sulphated and 6-
hydroxyl sulphated chondroitin changes from 4:1 in normal colon tissue to 1:3 in 
malignant cells (Theocharis, 2002). As the expression of CHST11 is increased in OA 
(Karlsson et al., 2010; Xu et al., 2012), it will also be of interest to assess if there is an 
alteration in the pattern of chondroitin sulphation in OA cartilage compared to normal 
cartilage, which can perhaps be used as a biomarker for the development and 
progression of OA.   
In summary, the aim of my thesis was to explore the functional effects of OA 
susceptibility loci. I have showed that OA chondrocytes respond discordantly to GDF5, 
a protein encoded by an OA susceptibility gene. I have explored the functional effects 
of two OA associated variants residing on MICAL3 and CHST11, but did not see a 
correlation between the genotype of the associated SNP and gene expression. I 
sequenced CHST11 coding exons in hip OA patients to look for rare variants, and did 
not find evidence for any that could account for disease susceptibility. I have then 
assessed the role of CHST11 during MSC differentiation into chondrocytes, and I 
observed that CHST11 knockdown leads to gene expression changes in anabolic, 
catabolic and hypertrophic marker genes, and a reduction in the synthesis of sulphated 
GAGs.  
As OA is a polygenic disorder, risk alleles will only have a very small effect on overall 
disease susceptibility, hence their use as a diagnostic tool is currently limited 
(Rodriguez-Fontenla et al., 2012). However, identifying the key pathways that the 
genes harbouring these OA risk alleles are involved in, may prove to be beneficial in 
the development of new therapies for OA (Reynard and Loughlin, 2013).  
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Appendix  
 
Appendix 1: 
Ethics statement 
The Newcastle and North Tyneside research ethics committees granted ethical 
approval for the collection of cartilage from patients undergoing hip or knee joint 
replacement for primary OA (REC reference number 09/H0906/72). Each donor 
provided informed consent. The project was discussed with the donor verbally by a 
trained research nurse and if the donor agreed to participate written consent was then 
taken. This consent procedure was approved by the ethics committee and the written 
consent was then filed by the consenting nurse.  OA status was confirmed using pre-
operative records. All patients had full-thickness cartilage lesions. 
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Appendix 2: 
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Figure 1A: Gene expression changes that undergo during day 0 to day 14 of MSC chondrogenesis. 
These experiments were performed by Dr Matt Barter (Newcastle University). Error bars represent standard error of the mean. 
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